Circular RNA and preparation method thereof

By using circular RNA precursors and divalent metal cation incubation technology with specific structures, circular RNA is generated and purified, and the problems of low efficiency in circular RNA preparation and high immunogenicity are solved, achieving more efficient circular RNA generation and reducing immune responses .

CN118922539APending Publication Date: 2024-11-08CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202280065213.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-09-27
Filing Date
2022-09-26
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing circular RNA preparation methods are inefficient and the generated circular RNA has high immunogenicity, which limits its application in the field of biomedicine.

Method used

By self-splicing, a circular RNA precursor comprising a 3' self-splicing intron fragment, a first retention loop element, a nucleotide sequence of interest, a second retention loop element and a 5' self-splicing intron fragment, by self-splicing The reaction produces circular RNA and RNA circularization is performed using divalent metal cations at a specific temperature, and the circular RNA is purified in combination with a specific probe.

Benefits of technology

It improves the production efficiency of circular RNA and significantly reduces its immunogenicity, making it more suitable for use as a drug or drug carrier.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004760412920000871
    Figure BDA0004760412920000871
  • Figure BDA0004760412920000881
    Figure BDA0004760412920000881
  • Figure BDA0004760412920000891
    Figure BDA0004760412920000891
Patent Text Reader

Abstract

The present invention relates to the field of biomedicine, in particular to improved circular RNA and a preparation method thereof, and the improved circular RNA is high in production efficiency and has reduced immunogenicity. The invention also relates to a vector for the preparation of said improved circular RNA, as well as to the use of said improved circular RNA.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular, to an improved circular RNA and a preparation method thereof, wherein the improved circular RNA has high generation efficiency and reduced immunogenicity. The present invention also relates to a vector for preparing the improved circular RNA, and the use of the improved circular RNA. Background of the Invention

[0003] Circular RNA is a common type of RNA in eukaryotes. Naturally occurring circular RNA is mainly produced by a molecular mechanism called "back splicing" in cells. It has been found that eukaryotic circular RNA has a variety of molecular cell regulatory functions. For example, circular RNA can regulate the expression of target genes by binding to microRNAs; circular RNA can regulate gene expression by directly binding to target proteins.

[0004] Due to its circular properties, circular RNA has a longer half-life relative to linear mRNA, so it is speculated that circular RNA synthesized in vitro may have better stability. Methods for forming circular RNA in vitro include chemical methods, enzyme catalysis methods, and ribozyme catalysis methods. The chemical method is costly and the size of the available circular RNA molecules is limited. The enzyme catalysis method mainly utilizes T4 RNA ligase to catalyze the cyclization of linear RNA, and the RNA load size that can be cyclized is also limited. The ribozyme catalysis method (e.g., based on class I introns) is a promising method for preparing circular RNA.

[0005] The natural group I intron system can undergo shearing and ligation reactions to form circular intron RNA. The specific shearing site conserved sequence located at the 5' end of exon E1 is broken by the nucleophilic attack of the 3' hydroxyl of free guanosine triphosphate, resulting in a naked 3' hydroxyl, and guanosine acid is bound to the broken 5' exon E1. Afterwards, the naked 3' hydroxyl at the 5' end of the intron attacks the conserved sequence between the 3' end of the intron and exon E2, excises exon E2, and the intron undergoes a circularization reaction to obtain a circular intron RNA. At present, a modified ribozyme catalysis method from the Anabaena tRNA intron has been reported for the formation of circular RNA in vitro, which is called the "Group I permuted intron-exon self-splicing system" (PIE system). This method can excise introns to form circular RNA containing exons, so this method has the potential to form expressible circular RNA. The basic design principle of the PIE system is to connect the exon E1 and E2 sequences end to end through molecular cloning to form a continuous circular plasmid. The intron is cut and broken by restriction endonucleases to obtain a linear plasmid. Then, in vitro transcription is performed through the T7 promoter upstream of the inverted 3' intron to obtain a linear RNA containing a 3' intron-E2-E1-5' intron structure. Similar to the natural class I intron system, the specific splicing site conservative sequence of exon E1 is broken by the nucleophilic attack of the free guanosine 3' hydroxyl, exon E1 produces a naked 3' hydroxyl, and guanosine binds to the broken 5' intron. Afterwards, the naked 3' hydroxyl of exon E1 attacks the conservative sequence between the 3' intron and exon E2, excises the 3' intron, and exon E2 and E1 undergo a circular reaction to obtain a circular E1-E2 RNA.

[0006] However, there is still a need in the art for improved circular RNA and methods for preparing the same.

[0007] Brief description of the invention

[0008] In one aspect, the invention provides a circular RNA precursor comprising the following elements arranged in the following order from 5' to 3' direction:

[0009] a) 3' self-splicing intron fragment;

[0010] b) a first retention loop element;

[0011] c) a nucleotide sequence of interest;

[0012] d) a second retention loop-forming element; and

[0013] e) 5' self-splicing intron fragment;

[0014] Wherein the circular RNA precursor is capable of generating a circular RNA comprising the first retention loop element, the nucleotide sequence of interest and the second retention loop element by self-splicing. In some preferred embodiments, the total length of the first retention loop element and the second retention loop element is about 5 to about 100 nucleotides.

[0015] In one aspect, the present invention provides a nucleic acid vector for producing a circular RNA molecule, wherein the vector comprises the circular RNA precursor coding sequence described in the present invention.

[0016] In another aspect, the present invention provides circular RNA, which is prepared from the circular RNA precursor or nucleic acid vector described in the present invention.

[0017] In another aspect, the present invention provides a circular RNA comprising a first retention loop-forming element, a nucleotide sequence of interest and a second retention loop-forming element. In some preferred embodiments, the first retention loop-forming element and the second retention loop-forming element have a total length of about 5 to about 100 nucleotides.

[0018] In another aspect, the present invention also provides use of the circular RNA precursor and / or circular RNA of the present invention as an expression vector.

[0019] In another aspect, the present invention provides a pharmaceutical composition comprising the nucleic acid vector of the present invention and / or the circular RNA precursor and / or circular RNA of the present invention, and a pharmaceutically acceptable carrier.

[0020] In another aspect, the present invention provides a method for preparing a circular RNA, the method comprising:

[0021] 1) Providing the circular RNA precursor of the present invention or obtaining the circular RNA precursor by transcription from the nucleic acid vector of the present invention;

[0022] 2) incubating the circular RNA precursor in the presence of a divalent metal cation at a temperature at which RNA circularization occurs; and

[0023] 3) Harvesting the circular RNA obtained in step 2).

[0024] In another aspect, the present invention provides a method for preparing a circular RNA, the method comprising:

[0025] a) providing a nucleic acid vector comprising a self-splicing intron-based RNA circularization element as a transcription template; and

[0026] b) incubating the nucleic acid vector in an in vitro transcription system comprising a divalent metal cation and an RNA polymerase for a first period of time, during which the linear RNA produced by in vitro transcription self-circularizes under the action of the RNA cyclization element to produce a circular RNA.

[0027] In one aspect, the present invention provides a method for purifying circular RNA, the method comprising:

[0028] a) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a circular RNA-specific probe under conditions that allow the circular RNA-specific probe to specifically bind to the circular RNA and form a complex;

[0029] b) separating the complex from one or more components in the mixture that are not bound to the circular RNA-specific probe; and

[0030] c) releasing the circular RNA from the complex.

[0031] In one aspect, the present invention provides a method for purifying circular RNA, the method comprising:

[0032] i) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a linear circular RNA precursor-specific probe under conditions that allow the linear circular RNA precursor-specific probe to specifically bind to the linear circular RNA precursor and form a complex; and

[0033] ii) removing the complex formed by the linear circular RNA precursor-specific probe and the linear circular RNA precursor from the mixture,

[0034] iii) collecting the mixture containing circular RNA obtained in step ii), and

[0035] Optionally, steps i)-iii) are performed multiple times, such as 2 times, 3 times, 4 times or more.

[0036] In one aspect, the present invention provides a method for purifying circular RNA, the method comprising:

[0037] i) adding a linear RNA-specific tag to the linear RNA in a mixture comprising circular RNA and linear RNA;

[0038] ii) contacting the mixture comprising circular RNA and linear RNA with a linear RNA probe that specifically binds to the tag under conditions that allow the probe to specifically bind to the linear RNA and form a complex; and

[0039] iii) removing the complex formed by the linear RNA probe and the linear RNA from the mixture,

[0040] iv) collecting the mixture containing circular RNA obtained in step ii),

[0041] Optionally, steps ii)-iv) are performed multiple times, such as 2 times, 3 times, 4 times or more.

[0042] In one aspect, the invention provides circular RNA produced or purified by the method described herein.

[0043] In one aspect, the present invention provides an in vitro transcription method, the method comprising:

[0044] a) providing a nucleic acid vector as a template for in vitro transcription;

[0045] b) incubating the nucleic acid vector in an in vitro transcription system comprising a divalent metal cation and an RNA polymerase for a first period of time; and

[0046] c) i) adding an additional amount of metal cation to the system, or ii) changing the buffer of the system and adding metal cation to the system, and incubating the system to react for a second period of time.

[0047] In one aspect, the invention provides RNA produced by the in vitro transcription method of the invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 , different methods of RNA circularization.

[0050] Figure 2 , RNA circularization by T4 ligase.

[0051] Figure 3 , RNA circularization with the splint via T4 ligase.

[0052] Figure 4 , through RNA circularization of Td class I introns.

[0053] Figure 5 , RNA circularization through Ana class I introns.

[0054] Figure 6 , RNA circularization through the Tornado system.

[0055] Figure 7 , AnaX system, and schematic diagram of the components of RNA circularization.

[0056] Figure 8 , circular POLR2A generated by class I intron splicing stimulates immune responses.

[0057] Fig. 9, the secondary structures of circular POLR2A_Lig, circular POLR2A_TD and circular POLR2A_Ana were predicted using circSHAPE-MaP in vitro.

[0058] Fig.10 , shorten the foreign sequence in circular RNA to reduce immunogenicity.

[0059] Fig.11 , the translation efficiency of AnaX-circRNA is higher than that of mRNA.

[0060] Fig.12 , the immunogenicity of AnaX-circRNA is lower than that of mRNA.

[0061] Fig.13 , AnaX circularizes RNAs of different lengths.

[0062] Fig.14 , AnaX-catalyzed circular RNA has lower immunogenicity.

[0063] Fig.15 Compared with the corresponding mRNA, the circular RBD and luciferase RNA catalyzed by AnaX have higher translation efficiency.

[0064] Figure 16. Modification of base pairs in the stem-loop of the retention sequence.

[0065] Fig.17 Increasing the number of base pairs in the stem-loop can improve the efficiency of RNA circularization.

[0066] Fig.18 , replace the base pairs in the stem-loop of the retained sequence with AU pairs or GC pairs.

[0067] Fig.19 , the strong pairing ability in the stem-loop structure improves the RNA circularization efficiency (different circularization time periods).

[0068] Fig. 20 , the strong pairing ability in the stem-loop structure improves the RNA circularization efficiency (encoding mCheery and Luciferase).

[0069] Fig.21 , modifying the base pairs in the stem-loop of the retained sequence does not affect the immunogenicity.

[0070] Fig. 22 Replacing the base pairs in the stem-loop of the retention sequence with GC pairs can improve the translation efficiency of circular RNA.

[0071] Fig.23 , the effect of the loop in the retention sequence stem-loop on RNA circularization.

[0072] Fig.24 , shortened foreign sequences in circular RNA maintain high circularization efficiency.

[0073] Fig.25 , transform the homology arm of AnaX class I intron.

[0074] Fig.26 , increasing the length of the homology arm of AnaX class I intron can improve the efficiency of RNA circularization.

[0075] Fig. 27 , improvement of Azoarcus class I introns and their stem-loop structures.

[0076] Fig.28 , IRES has no effect on protein translation whether it is upstream or downstream of the protein coding region.

[0077] Fig.29 , simplify and optimize methods for RNA circularization.

[0078] Fig.30 , adding Mg2+ can improve IVT and cyclization efficiency.

[0079] Fig.31 Adding a large amount of Mg2+ after 3 hours of IVT can significantly improve the efficiency of IVT.

[0080] Fig.32 , adding NaOAc can improve the efficiency of in vitro transcription.

[0081] Fig.33 , Adding KCl can improve the efficiency of in vitro transcription.

[0082] Fig.34 , Mg(OAc)2 can improve the efficiency of in vitro transcription.

[0083] Fig.35 , high temperature affects the efficiency of in vitro transcription and does not promote circularization.

[0084] Fig.36 , Prolonging the in vitro transcription time can increase RNA yield and promote RNA circularization.

[0085] Fig.37 , effects of buffer on in vitro transcription and RNA circularization efficiency.

[0086] Fig.38 , the effect of different MnCl2 concentrations on RNA circularization efficiency.

[0087] Fig.39 , the effects of circularization temperature and time on RNA circularization efficiency.

[0088] Fig.40, the effects of different buffers and different pH on RNA circularization efficiency.

[0089] Fig.41 , by purifying AnaX-circRNA using ligand.

[0090] Fig.42 , compare the enrichment of circular RNA by ligands of different lengths.

[0091] Fig.43 , compare the specificity of ligand binding to circular RNA by shortening the ligand length.

[0092] Fig.44 , translation efficiency of circular mCherry RNA purified by affinity oligomeric ligand magnetic beads.

[0093] Fig.45 , low immunogenicity of circular mCherry purified by affinity oligomeric ligand magnetic beads.

[0094] Fig.46 , affinity oligomeric ligand purified circular Luciferase RNA.

[0095] Fig.47 , affinity oligomeric ligand purification of circular POLR2A cyclized by T4 ligase.

[0096] Fig.48 , affinity oligomeric ligand purification of Td class I intron circularized circular POLR2A.

[0097] Fig.49 , L The purification efficiency of circular RNA by igand Intron and Ligand Feature columns.

[0098] Fig.50 , double-column affinity chromatography to purify circRNA.

[0099] Fig.51 , tailing linear RNA to purify circular RNA.

[0100] Fig.52 , circular RNA is more stable in cells than linear RNA.

[0101] Fig.53 , naked circular RNA is stable at RT or 4°C.

[0102] Fig.54 , compare the expression and stability of luciferase mRNA and cyclic luciferase RNA in cells.

[0103] Fig.55, compare the immunogenicity of luciferase mRNA and cyclic luciferase RNA in cells.

[0104] Fig.56 , delivering naked circular RNA via intradermal injection.

[0105] Fig.57 , delivery of circular RNA via liposomes.

[0106] Fig.58 , m5C modification affects RNA circularization.

[0107] Fig.59 , Ψ modification affects RNA circularization.

[0108] Fig.60 , m1Ψ modification affects RNA circularization.

[0109] Fig.61 , m6A modification affects RNA circularization.

[0110] Fig.62 , nucleotide modification affects circular RNA expression.

[0111] Fig.63 , detect the efficiency of IRES of different types of viruses through fluorescence.

[0112] Fig.64 , Detect the efficiency of IRES of different types of viruses by Western Blot.

[0113] Fig.65 , BRAV1_L, and PV1_L showed translation efficiency comparable to that of CVB3.

[0114] Fig.66 , detect the activity of different IRES in different cells. DETAILED DESCRIPTION OF THE INVENTION

[0116] In the present invention, unless otherwise specified, the scientific and technical terms used refer to the meanings generally understood by those skilled in the art. In addition, the terms and experimental methods used in this article regarding protein and nucleotide chemistry, molecular biology, cell and tissue culture, microbiology, and immunology are all terms and conventional methods commonly used in the art. For example, standard DNA recombination and molecular cloning techniques used herein are well known to those skilled in the art and are described in detail in the following references: Sambrook, J., Fritsch, Efland Maniatis, T., Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989. At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.

[0117] As used herein, the term "and / or" encompasses all combinations of items connected by the term, and each combination should be considered to have been listed separately herein. For example, "A and / or B" encompasses "A," "A and B," and "B." For example, "A, B, and / or C" encompasses "A," "B," "C," "A and B," "A and C," "B and C," and "A and B and C."

[0118] "Polynucleotide", "nucleic acid sequence", "nucleotide sequence" or "nucleic acid fragment" are used interchangeably and refer to single-stranded or double-stranded RNA or DNA polymers, optionally containing synthetic, non-natural or altered nucleotide bases. Nucleotides (usually present in 5'-monophosphate form) are referred to by their single letter names as follows: "A" is adenosine or deoxyadenosine (RNA or DNA, respectively), "C" represents cytidine or deoxycytidine, "G" represents guanosine or deoxyguanosine, "U" represents uridine, "T" represents deoxythymidine, "R" represents purine (A or G), "Y" represents pyrimidine (C or T), "K" represents G or T, "H" represents A or C or T, "I" represents inosine, and "N" represents any nucleotide. Although the nucleotide sequences herein may be represented as DNA sequences (including T), when RNA is referred to, the corresponding RNA sequence can be easily determined by a skilled artisan (i.e., replacing T with U).

[0119] Sequence "identity" has a meaning recognized in the art, and the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the full length of a polynucleotide or polypeptide or along a region of the molecule. (See, for example: Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Many methods can be used to determine sequence identity. An example of an algorithm suitable for determining a percentage of sequence identity is the algorithm used in the Basic Local Alignment Search Tool (hereinafter "BLAST"), see, for example, Altschul et al., J. Mol. Biol. 215: 403-410, 1990 and Altschul et al., Nucleic Acids Res., 15: 3389-3402, 1997. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information (hereinafter "NCBI"). The default parameters used in determining sequence identity using software available from NCBI (such as BLASTN for nucleic acid sequences) are described in McGinnis et al. Nucleic Acids Res., 32: W20-W25, 2004.

[0120] I. Circular RNA, Precursors, and Vectors

[0121] In one aspect, the invention provides a circular RNA precursor comprising the following elements arranged in the following order from 5' to 3' direction:

[0122] a) 3' self-splicing intron fragment;

[0123] b) a first retention loop element;

[0124] c) a nucleotide sequence of interest;

[0125] d) a second retention loop-forming element; and

[0126] e) 5' self-splicing intron fragment;

[0127] The circular RNA precursor is capable of generating a circular RNA comprising the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element by self-splicing.

[0128] "Circular RNA precursor" herein refers to a linear RNA molecule capable of forming a covalently linked closed circular RNA molecule, such as by self-splicing. The circular RNA precursor can be transcribed from a nucleic acid vector comprising a circular RNA precursor encoding sequence. Alternatively, the circular RNA precursor can also be obtained by chemical synthesis.

[0129] In some embodiments, the circular RNA precursor can form a covalently linked closed circular RNA molecule by self-splicing under the action of the self-splicing intron fragment and the retained loop-forming element.

[0130] As used herein, the term "self-splicing intron" refers to an intron that has self-splicing ribozyme activity, capable of excising itself and connecting two flanking exons. In some embodiments, the splicing is autocatalytic splicing.

[0131] "Self-splicing introns" include, but are not limited to, class I introns and class II introns. Class I introns include 14 subclasses, and most class I introns belong to the IC3 subclass. For example, the class I introns may be class I introns of the cyanobacteria Anabaena belonging to the IC3 subclass, or class I introns from T4 phage belonging to the IA2 subclass, or class I introns from Azoarcus sp. BH72 belonging to the IC3 subclass. Additional examples of self-splicing introns useful in the present invention include, but are not limited to, those derived from the following organisms: Enterobacteriophage T4, Bacteriophage Twort, Bacteriophage SPO1, Bacteriophage S3b, Bacillus anthracis, Clostridium botulinum, Tetrahymena thermophila, Dunaliella parva, Pneumocystis carinii, Physarum polycephalum, Anabaena sp. PCC7120, Scytonema hofmanni, Agrobacterium tumefaciens, Synechocystis PCC 6803, Synechococcus elongatus PCC 6301, Neurospora crassa, Candida albicans, Scytalidium dimidiatum, Saccharomyces cerevisiae, Pediastrum biradiatum, Chlamydomonas nivalis, Chlorella vulgaris, Amoebidium parasiticum,Neurospora crassa,Emericella nidulans,Saccharomyces cerevisiae,Schizosaccharomyces pombe,Neochloris aquatica,Dunaliella parva,Symkania negevensis,Emericella nidulans.See, for example, Vicens, Q., et al., (2008). Toward predicting self-splicing and protein-facilitated splicing of group I introns. RNA 14:2013-2029; Tanner, AM, et al., (1996). Activity and thermostability of thr small self-splicing group I intron in the pre-tRNAIIeof the purple bacterium Azoarcus.RNA 2:74-83.

[0132] In some embodiments, the 3' self-splicing intron fragment and the 5' self-splicing intron fragment are derived from the same self-splicing intron. In some embodiments, the 3' self-splicing intron fragment is derived from or comprises the 3' end portion of the self-splicing intron (natural self-splicing intron), and correspondingly the 5' self-splicing intron fragment is derived from or comprises the 5' end portion of the self-splicing intron (natural self-splicing intron). In some embodiments, the 3' self-splicing intron fragment and the 5' self-splicing intron fragment combination retain the self-splicing activity of the self-splicing intron (natural self-splicing intron).

[0133] In some embodiments, the 3' self-splicing intron fragment is derived from the 3' end portion of the natural self-splicing intron, i.e., the portion from the internal split site to the 3' end of the natural self-splicing intron, and correspondingly the 5' self-splicing intron fragment is derived from the 5' end portion of the natural self-splicing intron, i.e., the portion from the internal split site to the 5' end of the natural self-splicing intron, and the combination of the 3' self-splicing intron fragment and the 5' self-splicing intron fragment retains the self-splicing activity of the natural self-splicing intron.

[0134] In some embodiments, the self-splicing intron is a class I intron. In some embodiments, the self-splicing intron is a class I intron of the IA2 or IC3 subclass, preferably the IC3 subclass.

[0135] In some embodiments, the 3' self-splicing intron fragment is a 3' class I intron fragment. In some embodiments, the 5' self-splicing intron fragment is a 5' class I intron fragment.

[0136] As used herein, a 3' self-splicing intron fragment (e.g., a 3' class I intron fragment) is a sequence that is at least 75%, e.g., at least 80%, at least 85%, at least 90%, at least 95%, 100% identical to the 3' end portion of a natural self-splicing intron (e.g., class I intron). A 5' self-splicing intron fragment (e.g., a 5' class I intron fragment) is a sequence that is at least 75%, e.g., at least 80%, at least 85%, at least 90%, at least 95%, 100% identical to the 5' end portion of a natural self-splicing intron (e.g., class I intron).

[0137] It is generally believed that in order to achieve cyclization, the natural class I intron needs to be split from the internal site to form the so-called "inverted class I intron-exon self-splicing system" (Group I permuted intron-exon self-splicing system, PIE system). The internal split site is selected to produce two independent parts of the natural class I intron (3' end part and 5' end part), which together can maintain the ribozyme activity required for self-splicing, even after inversion. It is believed that the two independent parts of the natural class I intron that maintain the overall conformation of the natural class I intron can maintain the ribozyme activity required for self-splicing. In some embodiments, the 3' end part of the natural class I intron is the part from the internal split site to the 3' end of the natural class I intron, and accordingly, the 5' end part of the natural class I intron is the part from the internal split site to the 5' end of the natural class I intron.

[0138] The internal splitting site of the class I intron can be determined by those skilled in the art, for example, it can be determined by referring to the following literature: Puttaraju M., et al., (1992). Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons; Puttaraju M., et al., (1996). Cirularribozymes generated in Escherichia coli using group I self-splicing permuted intron-exson sequences. For example, for class I introns, especially for Anabaena class I introns, they can usually be split at a specific site in their P6 region to form a PIE system. Therefore, in some embodiments, the 3' end portion of a natural class I intron (e.g., Anabaena class I intron) is the portion from a specific site in the P6 region of a natural class I intron (e.g., Anabaena class I intron) to the 3' end. In some embodiments, the 5' end portion of the natural class I intron (e.g., Anabaena class I intron) is a portion from a specific site in the P6 region of the natural class I intron (e.g., Anabaena class I intron) to the 5' end. For class I introns, in particular for Anabaena class I introns, the split site can also be located in its P2, P5, P8 or P9 region to form a PIE system, as shown in WO2021236855A1. For class II introns, the split site can be located in its D4 region, see, for example: Roth A. et al., Natural circularly permuted group II introns I bacteria produce RNA circles, 2021; Pyle MA et al., Group II intron self-splicing, 2016.

[0139] The length of the 3' portion of a natural class I intron may be about 5%-95%, such as about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% of the full length of the natural class I intron. Accordingly, the length of the 5' portion of a natural class I intron may be about 5%-90%, such as about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% of the full length of the natural class I intron.

[0140] In some embodiments, the combination of the 3' group I intron fragment and the 5' group I intron fragment has substantially the self-splicing activity of the corresponding native group I intron.

[0141] In some embodiments, the self-splicing intron is a class I intron of the cyanobacteria Anabaena, for example, a class I intron of a pre-tRNA-Leu gene of the cyanobacteria Anabaena. Accordingly, in some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) and the 5' self-splicing intron fragment (5' class I intron fragment) are derived from a class I intron of the cyanobacteria Anabaena, for example, a class I intron of a pre-tRNA-Leu gene of the cyanobacteria Anabaena. In some embodiments, the natural class I intron of the pre-tRNA-Leu gene of the cyanobacteria Anabaena has the nucleotide sequence of SEQ ID NO: 136. The P6 region corresponds to positions 98 to 157 of SEQ ID NO: 136. The split site can be any position between positions 122 to 138 of SEQ ID NO: 136.

[0142] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from the class I intron of the cyanobacterium Anabaena pre-tRNA-Leu gene, and comprises or consists of the nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence having at least 75%, for example, at least 80%, at least 85%, at least 90%, at least 95%, 100% identity to SEQ ID NO: 1. In some embodiments, the 5' self-splicing intron fragment (5' class I intron fragment) is derived from the class I intron of the cyanobacterium Anabaena pre-tRNA-Leu gene, and comprises or consists of the nucleotide sequence of SEQ ID NO: 2, or a nucleotide sequence having at least 75%, for example, at least 80%, at least 85%, at least 90%, at least 95%, 100% identity to SEQ ID NO: 2.

[0143] In some embodiments, the self-splicing intron is a class I intron of T4 phage, for example, a class I intron of a T4 phage td gene. Accordingly, in some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) and the 5' self-splicing intron fragment (5' class I intron fragment) are derived from a class I intron of T4 phage, for example, a class I intron of a T4 phage td gene. In some embodiments, the natural class I intron of the T4 phage td gene has the nucleotide sequence of SEQ ID NO:149. The P6 region corresponds to the 100th to the 246th position of SEQ ID NO:149. The split site can be any position between the 109th to the 125th position of SEQ ID NO:149.

[0144] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from the class I intron of the T4 phage td gene, and comprises or consists of the nucleotide sequence of SEQ ID NO: 5 or a nucleotide sequence having at least 75%, for example, at least 80%, at least 85%, at least 90%, at least 95%, 100% identity to SEQ ID NO: 5. In some embodiments, the 5' self-splicing intron fragment (5' class I intron fragment) is derived from the class I intron of the T4 phage td gene, and comprises or consists of the nucleotide sequence of SEQ ID NO: 6 or a nucleotide sequence having at least 75%, for example, at least 80%, at least 85%, at least 90%, at least 95%, 100% identity to SEQ ID NO: 6.

[0145] In some embodiments, the self-splicing intron can be a class I intron of Azoarcus sp.BH72, for example, a class I intron of Azoarcus sp.BH72 pre-tRNA-Ile gene. Accordingly, in some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) and the 5' self-splicing intron fragment (5' class I intron fragment) are derived from a class I intron of Azoarcus sp.BH72, for example, a class I intron of Azoarcus sp.BH72 pre-tRNA-Ile gene. In some embodiments, the natural class I intron of the Azoarcus sp.BH72 pre-tRNA-Ile gene has the nucleotide sequence of SEQ ID NO:137. The P6 region corresponds to positions 108 to 138 of SEQ ID NO:137. The split site can be any position between positions 121 to 125 of SEQ ID NO:137.

[0146] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from the class I intron of the Azoarcus sp. BH72 pre-tRNA-Ile gene, and comprises the nucleotide sequence of SEQ ID NO: 3 or a nucleotide sequence having at least 75%, for example, at least 80%, at least 85%, at least 90%, at least 95%, 100% identity to SEQ ID NO: 3, or consists thereof. In some embodiments, the 5' self-splicing intron fragment (5' class I intron fragment) is derived from the class I intron of the Azoarcus sp. BH72 pre-tRNA-Ile gene, and comprises the nucleotide sequence of SEQ ID NO: 4 or a nucleotide sequence having at least 75%, for example, at least 80%, at least 85%, at least 90%, at least 95%, 100% identity to SEQ ID NO: 4, or consists thereof.

[0147] As used herein, "retained circularizing element" refers to a sequence that participates in circularization or is required for circularization by a self-splicing intron and participates in circularization together with a self-splicing intron but is retained in the final circular RNA. The "retained circularizing element" herein may also be referred to as an "intra-circular circularizing element".

[0148] The inventors surprisingly found that when RNA cyclization is performed using self-splicing introns, the additional cyclizing elements introduced into the circular RNA will increase the immunogenicity of the circular RNA molecule, while after truncating and mutating the elements retained in the circular RNA (retained cyclizing elements), the cyclization efficiency can be retained or even improved, and the immunogenicity of the circular RNA can be significantly reduced, which is of great significance for the potential application of circular RNA as a drug or drug carrier.

[0149] In some embodiments, the total length of the first retention loop-forming element and the second retention loop-forming element is no greater than about 500 nucleotides, for example, no greater than about 500, about 400, about 300, about 200, about 100, about 90, about 80, about 70, about 60, about 50, about 40, about 30, about 20, about 15, about 10, or about 5 nucleotides.

[0150] In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 500 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 400 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 300 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 200 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 100 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 90 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 80 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 70 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 60 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 50 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 40 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 30 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 20 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 15 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 10 nucleotides, or any integer number of nucleotides therebetween.

[0151] In some embodiments, the first retention loop-forming element and the second retention loop-forming element have a total length of at least 5 nucleotides. In some embodiments, the first retention loop-forming element and the second retention loop-forming element have a total length of at least 10 nucleotides. In some embodiments, the first retention loop-forming element and the second retention loop-forming element have a total length of at least 15 nucleotides.

[0152] In some embodiments, the first retention loop element and the second retention loop element have a total length of about 5 to about 100 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 10 to about 100 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 15 to about 100 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 15 to about 30 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 20 to about 35 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 25 to about 40 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 30 to about 45 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 35 to about 50 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 40 to about 55 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 45 to about 60 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 50 to about 65 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 55 to about 70 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 60 to about 75 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 65 to about 80 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 70 to about 85 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 75 to about 90 nucleotides, or any integer number of nucleotides therebetween.In some embodiments, the first retention loop element and the second retention loop element have a total length of about 80 to about 95 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 85 to about 100 nucleotides, or any integer number of nucleotides therebetween.

[0153] In some embodiments, the total length of the first retention loop element and the second retention loop element is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 , 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500 nucleotides.

[0154] In some embodiments, the first and second retention loop-forming elements cause the circular RNA comprising them to have reduced immunogenicity relative to a control circular RNA comprising the retention loop-forming elements of SEQ ID NO:29 and SEQ ID NO:64 (Ana3.0, the total length of the retention loop-forming element is 176 nucleotides).

[0155] In some embodiments, the first retention loop-forming element and the second retention loop-forming element cause the circular RNA comprising the same to have reduced immunogenicity relative to a control linear RNA, e.g., a corresponding linear RNA comprising the same nucleotide sequence of interest but without the chemically modified nucleotides.

[0156] As used herein, "reduced immunogenicity" may refer to a reduced immune response caused by contact of the circular RNA with a cell, i.e., a lower level of immune response than a control circular RNA or a control linear RNA. For example, a reduced immune response refers to reduced cytokine expression. The cytokines include, but are not limited to, IFNβ, TNFα, IL6 and / or RIG-I. In some embodiments, the immunogenicity of the circular RNA is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or more. Reduced immunogenicity can be determined by methods well known in the art, such as those described in Example 10 of the present invention.

[0157] In some embodiments, the first retention loop-forming element and the second retention loop-forming element cause the circular RNA or circular RNA precursor containing them to have a comparable or increased loop-forming efficiency relative to the circular RNA or circular RNA precursor containing the retention loop-forming element (Ana3.0) of SEQ ID NO:29 and SEQ ID NO:64.

[0158] As used herein, "circularization efficiency" may refer to the ratio of output circular RNA to input precursor within a given time period. Alternatively, "circularization efficiency" as used herein may refer to the ratio of desired circular RNA to linear RNA in the final product within a given time period. Circularization efficiency can be determined by methods well known in the art, such as the methods described in Examples 17, 19, and 20 of the present invention.

[0159] In some embodiments, the circular RNA has an increased circularization efficiency of at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more.

[0160] In some embodiments, the first retention loop-forming element comprises, or consists of, a 3' exon region and an optional first spacer in the 5' to 3' direction. In the circular RNA precursor, the 5' end of the 3' exon region is directly connected to the 3' end of the 3' self-splicing intron fragment.

[0161] As used herein, the "exon region" in the retention looping element is a sequence derived from a natural exon of a self-splicing intron (an exon flanking a self-splicing intron), and can be recognized and / or spliced ​​by a self-splicing intron (or a combination of a first self-splicing intron fragment and a second self-splicing intron fragment), and is therefore required for circularization. The "exon region" herein may also be referred to as a "splicing site sequence".

[0162] In some embodiments, the 3' exon region is derived from the natural 3' exon of the self-splicing intron (the exon flanking (downstream) the 3' end of the self-splicing intron) or a continuous fragment thereof starting from the 5' end nucleotide.

[0163] In some embodiments, the 3' exon region is the entire native 3' exon of the self-splicing intron, or has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 99% or at least 99% sequence identity with all the native 3' exons of the self-splicing intron, or has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleotide substitutions, deletions or additions compared to all the native 3' exons of the self-splicing intron.

[0164] In some embodiments, the 3' exon region is a continuous segment starting from the 5' terminal nucleotide of the natural 3' exon. In some embodiments, the 3' exon region has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the continuous segment starting from the 5' terminal nucleotide of the natural 3' exon. In some embodiments, the 3' exon region has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleotide substitutions, deletions or additions compared to the continuous segment starting from the 5' terminal nucleotide of the natural 3' exon.

[0165] In some embodiments, the continuous segment starting from the 5' terminal nucleotide of the natural 3' exon comprises or consists of at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the nucleotides of the natural 3' exon. In some embodiments, the length of the continuous segment starting from the 5' terminal nucleotide of the natural 3' exon is at least 1 nucleotide, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 50 or more nucleotides. In some embodiments, the length of the continuous fragment starting from the 5'-terminal nucleotide of the native 3' exon is 1 nucleotide or at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 50 nucleotides, or at most the full length of the native 3' exon.

[0166] In some embodiments, wherein the self-splicing intron is a class I intron, the 3' exon region comprises a sequence (e.g., a sequence of about 1 to about 20 nucleotides) at least at its 5' end that can pair with the P1 region of the corresponding class I intron to form a P10 double-stranded region.

[0167] It is believed that for the self-splicing of group I introns, the continuous one or more nucleotides (e.g., at least about 1 to about 7 nucleotides) from the 5' end of the natural 3' exon can be paired with the P1 region to form a P10 double-stranded region, thus playing an important role in self-splicing. The definitions of the P1 region and the P10 region of group I introns are known in the art, for example, can be determined by referring to the following documents: Burke, JM, et al., (1987). Structural conventions for group I introns; Stahley, RM, et al (2006). RNA splicing: group I intron crystal structures reveal the basis of splice site selection and metal ion catalysis; Woodson, AS, (2005). Structure and assembly of group I introns.

[0168] In some embodiments, the second retention loop-forming element comprises, or consists of, a 5' exon region and an optional second spacer in the 3' to 5' direction. In the circular RNA precursor, the 3' end of the 5' exon region is directly connected to the 5' end of the second self-splicing intron fragment.

[0169] In some embodiments, the 5' exon region is derived from the natural 5' exon of the self-splicing intron (the exon flanking (downstream) the 5' end of the self-splicing intron) or a continuous fragment thereof starting from the 3' end nucleotide.

[0170] In some embodiments, the 5' exonic region is the entire native 5' exon of the self-splicing intron, or has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 99% or at least 99% sequence identity with all the native 5' exons of the class I intron, or has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleotide substitutions, deletions or additions compared to all the native 5' exons of the self-splicing intron.

[0171] In some embodiments, the 5' exon region is a continuous segment starting from the 3' terminal nucleotide of the natural 5' exon. In some embodiments, the 5' exon region has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the continuous segment starting from the 3' terminal nucleotide of the natural 5' exon. In some embodiments, the 5' exon region has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleotide substitutions, deletions or additions compared to the continuous segment starting from the 3' terminal nucleotide of the natural 5' exon.

[0172] In some embodiments, the continuous segment starting from the 3' terminal nucleotide of the natural 5' exon comprises or consists of at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the nucleotides of the natural 5' exon. In some embodiments, the length of the continuous segment starting from the 3' terminal nucleotide of the natural 5' exon is at least 1 nucleotide, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 50 or more nucleotides. In some embodiments, the length of the continuous fragment starting from the 3' terminal nucleotide of the native 5' exon is 1 nucleotide or at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 50 nucleotides, or at most the full length of the native 5' exon.

[0173] In some embodiments, wherein the self-splicing intron is a class I intron, the 5' exon region comprises a sequence (e.g., a sequence of about 3 to about 8 consecutive nucleotides) at its 3' end that can pair with the internal guide sequence (IGS) of the corresponding class I intron to form a P1 double-stranded region.

[0174] It is believed that for the self-splicing of group I introns, the continuous about 3 to about 8 nucleotides from the 3' end of the natural 5' exon can be paired with the internal guide sequence (IGS) to form a P1 double-stranded region, thus playing an important role in self-splicing. The definition of the IGS and / or P1 region of group I introns is known in the art, for example, it can be determined by referring to the following documents: Burke, JM, et al., (1987). Structural conventions for group I introns; Stahley, RM, et al (2006). RNA splicing: group I intron crystal structures reveal the basis of splice site selection and metal ion catalysis; Woodson, AS, (2005). Structure and assembly of group I introns.

[0175] In some embodiments, the 3' exon region is derived from the 3' native exon of the class I intron of the Anabaena pre-tRNA-Leu gene. The 3' native exon of the class I intron of the Anabaena pre-tRNA-Leu gene comprises the nucleotide sequence of SEQ ID NO: 7. In some embodiments, the 5' exon region is derived from the 5' native exon of the class I intron of the Anabaena pre-tRNA-Leu gene. The 5' native exon of the class I intron of the Anabaena pre-tRNA-Leu gene comprises the nucleotide sequence of SEQ ID NO: 8.

[0176] In some embodiments, the 3' exon region is derived from the 3' native exon of the class I intron of the T4 phage td gene. The 3' native exon of the class I intron of the T4 phage td gene comprises the nucleotide sequence of SEQ ID NO: 11. In some embodiments, the 5' exon region is derived from the 5' native exon of the class I intron of the T4 phage td gene. The 5' native exon of the class I intron of the T4 phage td gene comprises the nucleotide sequence of SEQ ID NO: 12.

[0177] In some embodiments, the 3' exon region is derived from the 3' native exon of the class I intron of the Azoarcus sp. BH72 pre-tRNA-Ile gene. The 3' native exon of the class I intron of the Azoarcus sp. BH72 pre-tRNA-Ile gene comprises the nucleotide sequence of SEQ ID NO: 9. In some embodiments, the 5' exon region is derived from the 5' native exon of the class I intron of the Azoarcus sp. BH72 pre-tRNA-Ile gene. The 5' native exon of the class I intron of the Azoarcus sp. BH72 pre-tRNA-Ile gene comprises the nucleotide sequence of SEQ ID NO: 10.

[0178] During the circularization process of the circular RNA precursor, the 3' self-splicing intron fragment (e.g., 3' class I intron fragment) and the sequence upstream of its 5' end (if present), and the 5' self-splicing intron fragment (e.g., 5' class I intron fragment) and the sequence downstream of its 3' end (if present) are both removed, and the 5' end of the first retained loop-forming element and the 3' end of the second retained loop-forming element are covalently linked to achieve RNA circularization.

[0179] In some embodiments, the first retention loop-forming element and the second retention loop-forming element comprise different spacer sequences, or one of them comprises a spacer sequence and the other does not comprise a spacer sequence.

[0180] As used herein, "spacer" refers to any continuous nucleotide sequence that at least does not negatively interfere with the function of a connected element. Generally, if it is necessary to avoid the mutual influence of two close or adjacent elements, a spacer can be inserted between the two elements. The spacer sequence described herein may have two functions: (1) promoting cyclization and (2) promoting functionality by allowing the retention of loop elements and the correct folding of the nucleotide sequence of interest (such as IRES). In some embodiments, the spacer length is no more than 150, no more than 100, no more than 50, no more than 30, no more than 10, no more than 5 or no more than 3 nucleotides. In some embodiments, the spacer length is 5 nucleotides. In some embodiments, the spacer length is 4 nucleotides. In some embodiments, the spacer length is 3 nucleotides. In some embodiments, the first spacer may not exist. In some embodiments, the second spacer may not exist. In some embodiments, both the first spacer and the second spacer may not exist.

[0181] In some embodiments, the first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure. In some embodiments, a splicing junction is contained in the loop of the stem-loop structure.

[0182] In some embodiments, the presence of the stem-loop structure is predicted and / or determined by the nucleotide sequence of the 3' self-splicing intron fragment (e.g., 3' class I intron fragment), the first retention looping element, the second retention looping element, and the 5' self-splicing intron fragment (e.g., 5' class I intron fragment) involved in the cyclization. In some embodiments, the presence of the stem-loop structure is predicted and / or determined based on the nucleotide sequence by RNA structure prediction tools such as RNAfold (http: / / rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi) or RNAstructure (https: / / rna.urmc.rochester.edu / RNAstructureWeb / index.html). By referring to Example 3 and Fig.10 The methods described herein can predict and / or determine the presence of a stem-loop structure.

[0183] In some embodiments, the first retention loop-forming element comprises a sequence structure of the following formula: 5'-first loop sequence-first paired sequence-first non-paired sequence-3'; and the second retention loop-forming element comprises a sequence structure of the following formula: 5'-second non-paired sequence-second paired sequence-second loop sequence-3',

[0184] wherein the first non-pairing sequence or the second non-pairing sequence may be present or absent independently,

[0185] The first pairing sequence and the second pairing sequence can complementarily pair to form a stem of the stem-loop structure, and the first loop sequence and the second loop sequence can form a loop of the stem-loop structure, for example, by self-splicing to perform circularization.

[0186] Typically, the sequence forming the loop of the stem-loop structure is derived from the 3' exon region or the 5' exon region.

[0187] In some embodiments, wherein the self-splicing intron is a class I intron, the first loop sequence comprises or consists of one or more nucleotides (e.g., about 1 to about 20 nucleotides), which can pair with the P1 region of the corresponding class I intron (or a structure consisting of a 3' self-splicing intron fragment and a 5' self-splicing intron fragment) to form a P10 double-stranded region during the circularization process.

[0188] In some embodiments, the first loop sequence may comprise or consist of a (N)n nucleotide sequence, wherein N represents any nucleotide (A, G, U or C), and n represents an integer between 1-20, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In some specific embodiments, n is 2, 4 or 5.

[0189] In some embodiments, the first loop sequence comprises or consists of about 1 to about 7 consecutive nucleotides starting from the 5'-terminal nucleotide of the native 3' exon of a class I intron.

[0190] In some embodiments, the first loop sequence comprises or consists of, for example, AAAA, AA, UUUU, CAAA, or GAAA.

[0191] In some embodiments, wherein the self-splicing intron is a class I intron, the second loop sequence comprises or consists of one or more nucleotides (e.g., about 3 to about 8 nucleotides), which can be paired with the internal guide sequence (IGS) of the corresponding class I intron (or a structure consisting of a 3' self-splicing intron fragment and a 5' self-splicing intron fragment) to form a P1 double-stranded region during the circularization process.

[0192] In some embodiments, the second loop sequence comprises or consists of about 3 to about 8 consecutive nucleotides starting from the 3'-terminal nucleotide of the native 5' exon of the class I intron.

[0193] In some embodiments, the second loop sequence comprises or consists of, for example, CUU or CUC.

[0194] In some specific embodiments, a ring having a sequence of CUUAAAA, CUUUUUU, CUUAA, CUUGAAA, CUUUAAA, CUUCAAA or CUCAAAA may be formed after cyclization.

[0195] In some embodiments, the first loop sequence comprises AAAA or consists of it, and the second loop sequence comprises CUU or consists of it. In some specific embodiments, a loop with a CUUAAAA sequence can be formed after cyclization.

[0196] The pairing sequence forming the stem of the stem-loop structure may be from the exon region, however, it may also be from the spacer sequence. Alternatively, the pairing sequence may be from the exon region and the spacer sequence, i.e., the pairing sequence comprises at least a portion of the exon region and at least a portion of the spacer.

[0197] Without being limited by any theory, the RNA cyclization efficiency based on intron self-splicing (e.g., class I intron self-splicing) is related to the number of base pairs or base pair type or composition of the stem portion in the stem-loop structure formed by the retained loop element. The stability of the stem-loop structure (e.g., as can be predicted by calculated free energy) may affect the cyclization efficiency.

[0198] In some embodiments, the stem portion in the stem-loop structure comprises at least 2 base pairs, such as at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or more base pairs, preferably continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 2-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 3-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 4-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 5-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 6-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 7-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 8-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 9-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 10-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 11-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 12-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 13-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 14-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 base pairs, preferably continuous base pairs. In some embodiments, the stem portion of the stem-loop structure comprises 5 base pairs, preferably continuous base pairs. In some embodiments, the stem portion of the stem-loop structure comprises 6 base pairs, preferably continuous base pairs. In some embodiments, the stem portion of the stem-loop structure comprises 7 base pairs, preferably continuous base pairs.

[0199] In some embodiments, the stem portion in the stem-loop structure contains at most 2 base mismatches, or at most 1 base mismatch. Preferably, the stem portion does not contain a base mismatch.

[0200] In some embodiments, the predicted free energy of the stem-loop structure is less than about -1 kal / mol, less than about -2 kal / mol, less than about -3 kal / mol, less than about -4 kal / mol, less than about -5 kal / mol, less than about -6 kal / mol, less than about -7 kal / mol, less than about -8 kal / mol, less than about -9 kal / mol, less than about -10 kal / mol, or less. In some embodiments, the predicted free energy of the stem-loop structure is about -1 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -2 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -3 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -4 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -5 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -6 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -7 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -8 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -9 kal / mol to about -10 kal / mol. The free energy can be determined, for example, by RNAfold (http: / / rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi) or RNAstructure (https: / / rna.urmc.rochester.edu / RNAstructureWeb / index.html) structure prediction tools.

[0201] In some embodiments, the first mate sequence comprises only G and the second mate sequence comprises only C. In some embodiments, the first mate sequence comprises only C and the second mate sequence comprises only G. In some embodiments, the first mate sequence comprises only A and the second mate sequence comprises only U.

[0202] In some embodiments, the first mate sequence comprises or consists of any one of SEQ ID NOs: 42-55.

[0203] In some embodiments, the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% sequence identity to a nucleotide sequence selected from one of SEQ ID NOs: 13-55. In some embodiments, the first retention loop-forming element comprises or consists of a nucleotide sequence selected from one of SEQ ID NOs: 13-55.

[0204] In some embodiments, the second paired sequence comprises or consists of any one of SEQ ID NOs: 78-93.

[0205] In some embodiments, the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% sequence identity to a nucleotide sequence selected from one of SEQ ID NOs: 56-93. In some embodiments, the second retention loop-forming element comprises or consists of a nucleotide sequence selected from one of SEQ ID NOs: 56-93.

[0206] In some embodiments, the first retention loop-forming element comprises or consists of any one of the nucleotide sequences of SEQ ID NOs: 13-55, and the second retention loop-forming element comprises or consists of any one of the nucleotide sequences of SEQ ID NOs: 56-93.

[0207] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:57.

[0208] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:58.

[0209] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:59.

[0210] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60.

[0211] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:61.

[0212] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:62.

[0213] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0214] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0215] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0216] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0217] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0218] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67.

[0219] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:59.

[0220] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0221] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:59.

[0222] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:63.

[0223] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from a class I intron of an Anabaena pre-tRNA-Leu gene, and comprises or consists of a nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence having at least 75%, e.g., at least 80%, at least 85%, at least 90%, at least 95%, 100% sequence identity to SEQ ID NO: 1;

[0224] The 5' self-splicing intron fragment (5' class I intron fragment) is derived from a class I intron of a pre-tRNA-Leu gene of Anabaena, and comprises or consists of a nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence having at least 75%, e.g., at least 80%, at least 85%, at least 90%, at least 95%, 100% sequence identity with SEQ ID NO: 2;

[0225] The total length of the first retention loop-forming element and the second retention loop-forming element is about 5 to about 100 nucleotides, or any integer number of nucleotides therebetween;

[0226] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, wherein the first retention loop-forming element comprises a sequence structure of the following formula: 5'-first loop sequence-first paired sequence-first non-paired sequence-3'; and the second retention loop-forming element comprises a sequence structure of the following formula: 5'-second non-paired sequence-second paired sequence-second loop sequence-3',

[0227] wherein the first non-pairing sequence or the second non-pairing sequence may be present or absent independently, the first pairing sequence and the second pairing sequence may complementarily pair to form a stem of the stem-loop structure, wherein the first loop sequence and the second loop sequence may form a loop of the stem-loop structure, for example, by self-splicing for cyclization,

[0228] wherein the first loop sequence comprises or consists of AAAA, AA, UUUU, CAAA or GAAA, and the second loop sequence comprises or consists of CUU or CUC; and

[0229] The first paired sequence comprises or consists of any one of SEQ ID NOs: 42-55; and the second paired sequence comprises or consists of any one of SEQ ID NOs: 78-93.

[0230] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from a class I intron of an Anabaena pre-tRNA-Leu gene, and comprises or consists of a nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence having at least 75%, e.g., at least 80%, at least 85%, at least 90%, at least 95%, 100% sequence identity to SEQ ID NO: 1;

[0231] The 5' self-splicing intron fragment (5' class I intron fragment) is derived from a class I intron of a pre-tRNA-Leu gene of Anabaena, and comprises or consists of a nucleotide sequence of SEQ ID NO: 2 or a nucleotide sequence having at least 75%, e.g., at least 80%, at least 85%, at least 90%, at least 95%, 100% sequence identity with SEQ ID NO: 2;

[0232] The total length of the first retention loop-forming element and the second retention loop-forming element is about 5 to about 100 nucleotides, or any integer number of nucleotides therebetween;

[0233] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity with a nucleotide sequence selected from one of SEQ ID NOs: 13-55, and the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity with a nucleotide sequence selected from one of SEQ ID NOs: 56-93.

[0234] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from a class I intron of an Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 1;

[0235] The 5' self-splicing intron fragment (5' class I intron fragment) is derived from the class I intron of the Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 2;

[0236] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, wherein

[0237] 1) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 57;

[0238] 2) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 58;

[0239] 3) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0240] 4) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60;

[0241] 5) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 61;

[0242] 6) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 62;

[0243] 7) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0244] 8) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0245] 9) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0246] 10) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0247] 11) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0248] 12) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67;

[0249] 13) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0250] 14) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0251] 15) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0252] 16) The first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:63.

[0253] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from a class I intron of an Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 1;

[0254] The 5' self-splicing intron fragment (5' class I intron fragment) is derived from the class I intron of the Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 2;

[0255] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, wherein the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59.

[0256] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from a class I intron of an Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 1;

[0257] The 5' self-splicing intron fragment (5' class I intron fragment) is derived from the class I intron of the Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 2;

[0258] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, wherein the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59.

[0259] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from a class I intron of an Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 1;

[0260] The 5' self-splicing intron fragment (5' class I intron fragment) is derived from the class I intron of the Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 2;

[0261] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, wherein the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 63.

[0262] In some embodiments, the 3' self-splicing intron fragment (3' class I intron fragment) is derived from a class I intron of an Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 1;

[0263] The 5' self-splicing intron fragment (5' class I intron fragment) is derived from the class I intron of the Anabaena pre-tRNA-Leu gene and comprises or consists of the nucleotide sequence of SEQ ID NO: 2;

[0264] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, wherein the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56.

[0265] In some embodiments, the circular RNA precursor further comprises a 5' homology arm sequence and a 3' homology arm sequence that can complementarily pair to form a homology arm double-stranded region. In some embodiments, the 5' homology arm sequence is upstream of the 5' end of the 3' self-splicing intron fragment, and the 3' homology arm sequence is downstream of the 3' end of the 5' self-splicing intron fragment.

[0266] The length of the homology arm can be, for example, about 5-50 nucleotides, for example, about 5-50, about 10-50, about 20-50, about 30-50 or about 40-50 nucleotides. In some embodiments, the length of the homology arm can be 20 nucleotides. In some embodiments, the length of the homology arm can be 40 nucleotides. In certain embodiments, the length of the homology arm is at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides. In certain embodiments, the length of the homology arm is no more than 50, 45, 40, 35, 30, 25 or 20 nucleotides. In certain embodiments, the length of the homology arms is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 nucleotides. The two homology arm sequences can be polyA and polyT, respectively, or polyG and polyC, respectively.

[0267] In some embodiments, one of the homology arm sequences may have any of the nucleotide sequences in SEQ ID NOs: 151-162 or a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% sequence identity with any of SEQ ID NOs: 151-162, and the other homology arm sequence may have a corresponding complementary sequence. In some preferred embodiments, the 5' homology arm sequence is the nucleotide sequence of SEQ ID NO: 152, and the 3' homology arm sequence is the nucleotide sequence of SEQ ID NO: 162.

[0268] In some embodiments, the nucleotide sequence of interest comprises at least one protein coding sequence and a translation initiation element such as an internal ribosome entry site (IRES) operably linked thereto. Here, "operably linked" refers to that a translation initiation element such as an IRES is capable of directing the translation of the encoded protein. In some embodiments, in the circular RNA precursor, the translation initiation element such as an IRES is located upstream of the 5' end of at least one protein coding sequence, or the translation initiation element such as an IRES is located downstream of the 3' end of at least one protein coding sequence.

[0269] The protein coding sequence may encode a protein of eukaryotic, prokaryotic or viral origin. In certain embodiments, the protein may be any protein for therapeutic or diagnostic purposes. For example, the protein coding region may encode a human protein, an antigen, an antibody, a gene editing enzyme such as a CRISPR nuclease, etc. For example, the encoded protein may be a chimeric antigen receptor, an immunomodulatory protein and / or a transcription factor, etc. Some specific examples include, but are not limited to, EGF, FGF1, RBD, G6PC, PAH, HGF, etc.

[0270] The IRES sequence can be selected from, but is not limited to, the following IRES sequences: Taura syndrome virus, blood-sucking assassin bug virus, Theile's encephalomyelitis virus, simian virus 40, fire ant virus 1, cereal aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immunodeficiency virus type 1, glass leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea looper-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FGF2, human SFTPA1, human AML l / RUNX1, Drosophila antennae, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip crepe virus, aptamer of eIF4G, Coxsackievirus B3 (CVB3) or Coxsackievirus A (CVA1 / 2). Wild-type IRES sequences can also be modified and used in the present invention. Preferably, the IRES is CVB3, BRAV-1_L, PV1_L, CAV2_L, BRAV-1, PV1 or CAV2.

[0271] An exemplary IRES comprises the nucleotide sequence set forth in one of SEQ ID NOs: 105-135, or comprises a nucleotide sequence having at least 75%, e.g., at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to one of SEQ ID NOs: 105-135.

[0272] In some embodiments, the nucleotide sequence of interest is a non-protein coding sequence. For example, the non-protein coding sequence can be an antisense RNA, an aptamer, a guide RNA, or any non-protein coding RNA present in an organism, etc. The non-protein coding sequence may or may not contain a specific secondary structure.

[0273] In some embodiments, the nucleotide sequence of interest is at least 10, 20, 40, 60, 80, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 10000, 20000 nucleotides in length. In some embodiments, the nucleotide sequence of interest is about 10 to about 20,000 nucleotides in length.

[0274] The circular RNA precursor may be (e.g., chemically) unmodified, partially modified, or completely modified. In some embodiments, the circular RNA precursor comprises at least one nucleotide modification. In some embodiments, up to 100% of the nucleosides of the circular RNA precursor are modified. In some embodiments, at least one nucleotide modification is a cytidine modification, a uridine modification, or an adenosine modification. In some embodiments, at least one nucleoside modification is selected from 5-methylcytosine (m5C), N6-methyladenosine (m6A), pseudouridine (ψ), N1-methylpseudouridine (m1ψ), and 5-methoxyuridine (5moU). In some embodiments, the circular RNA precursor comprises less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 15%, less than 10%, less than 5%, less than 1% of a specific nucleotide modification. The percentage of a specific nucleotide modification herein refers to the ratio of nucleotides in a sequence that have undergone the specific modification to nucleotides that can undergo the specific modification.

[0275] In some preferred embodiments, the circular RNA precursor is unmodified. In some embodiments, the circular RNA precursor does not contain nucleotide chemical modifications.

[0276] In one aspect, the present invention provides a nucleic acid vector for producing a circular RNA molecule, the vector comprising a circular RNA precursor encoding sequence of the present invention.

[0277] As used herein, "vector" refers to a section of DNA extracted from a virus, plasmid or cell of a higher organism, into which a foreign DNA fragment can be inserted or has been inserted for cloning and / or expression purposes. In certain embodiments, the vector can be stably maintained in an organism. The vector may include, for example, an origin of replication, a selective marker or a reporter gene, such as antibiotic resistance or GFP, and / or a multiple cloning site (MCS). The term includes linear DNA fragments (e.g., PCR products, linear plasmid fragments), plasmid vectors, viral vectors, cosmids, bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs), etc.

[0278] In some embodiments, the nucleic acid vector further comprises an RNA polymerase promoter sequence operably connected to the circular RNA precursor coding sequence. The operably connected promoter allows in vivo and / or in vitro transcription of the circular RNA precursor. The promoter is, for example, a T7 RNA polymerase promoter, a T6 viral RNA polymerase promoter, an SP6 viral RNA polymerase promoter, a T3 viral RNA polymerase promoter, or a T4 viral RNA polymerase promoter.

[0279] In another aspect, the present invention provides circular RNA, which is prepared from the circular RNA precursor or nucleic acid vector described in the present invention.

[0280] In another aspect, the present invention provides a circular RNA comprising a first retention loop-forming element, a nucleotide sequence of interest, and a second retention loop-forming element.

[0281] In some embodiments, the first retention loop-forming element, the nucleotide sequence of interest, and the second retention loop-forming element may be as defined above.

[0282] In some embodiments, the first retention loop element and the second retention loop element participate in RNA looping or are required for RNA looping through a self-splicing intron (e.g., a class I intron). The first retention loop element and the second retention loop element participate in looping with the self-splicing intron (e.g., a class I intron) but are retained in the final circular RNA.

[0283] In some embodiments, the first retention loop-forming element and the second retention loop-forming element are covalently linked. In some embodiments, the 5' end of the first retention loop-forming element and the 3' end of the second retention loop-forming element are covalently linked.

[0284] As used herein, "retained looping element" refers to a sequence that participates in looping or is required for looping by a self-splicing intron. The retained looping element participates in looping together with the self-splicing intron but is retained in the final circular RNA.

[0285] The inventors surprisingly found that when RNA cyclization is performed using self-splicing introns, the additional cyclizing elements introduced into the circular RNA will increase the immunogenicity of the circular RNA molecule, while after truncating and mutating the elements retained in the circular RNA (retained cyclizing elements), the cyclization efficiency can be retained or even improved, and the immunogenicity of the circular RNA can be significantly reduced, which is of great significance for the potential application of circular RNA as a drug or drug carrier.

[0286] In some embodiments, the total length of the first retention loop-forming element and the second retention loop-forming element is no greater than about 500 nucleotides, for example, no greater than about 500, about 400, about 300, about 200, about 100, about 90, about 80, about 70, about 60, about 50, about 40, about 30, about 20, about 15, about 10, or about 5 nucleotides.

[0287] In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 500 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 400 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 300 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 200 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 100 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 90 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 80 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 70 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 60 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 50 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 40 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 30 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 20 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 15 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 2 to about 10 nucleotides, or any integer number of nucleotides therebetween.

[0288] In some embodiments, the first retention loop-forming element and the second retention loop-forming element have a total length of at least 5 nucleotides. In some embodiments, the first retention loop-forming element and the second retention loop-forming element have a total length of at least 10 nucleotides. In some embodiments, the first retention loop-forming element and the second retention loop-forming element have a total length of at least 15 nucleotides.

[0289] In some embodiments, the first retention loop element and the second retention loop element have a total length of about 5 to about 100 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 10 to about 100 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 15 to about 100 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 15 to about 30 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 20 to about 35 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 25 to about 40 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 30 to about 45 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 35 to about 50 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 40 to about 55 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 45 to about 60 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 50 to about 65 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 55 to about 70 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 60 to about 75 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 65 to about 80 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 70 to about 85 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 75 to about 90 nucleotides, or any integer number of nucleotides therebetween.In some embodiments, the first retention loop element and the second retention loop element have a total length of about 80 to about 95 nucleotides, or any integer number of nucleotides therebetween. In some embodiments, the first retention loop element and the second retention loop element have a total length of about 85 to about 100 nucleotides, or any integer number of nucleotides therebetween.

[0290] In some embodiments, the total length of the first retention loop element and the second retention loop element is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 , 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500 nucleotides.

[0291] In some embodiments, the first and second retention loop-forming elements cause the circular RNA comprising them to have reduced immunogenicity relative to a control circular RNA comprising the retention loop-forming elements of SEQ ID NO:29 and SEQ ID NO:64 (Ana3.0, the total length of the retention loop-forming element is 176 nucleotides).

[0292] In some embodiments, the circular RNA has reduced immunogenicity relative to a control circular RNA comprising the retention loop elements of SEQ ID NO: 29 and SEQ ID NO: 64 (Ana3.0, the total length of the retention loop element is 176 nucleotides).

[0293] In some embodiments, the first retention loop-forming element and the second retention loop-forming element cause the circular RNA comprising them to have reduced immunogenicity relative to a control linear RNA, e.g., a corresponding linear RNA without chemically modified nucleotides.

[0294] In some embodiments, the circular RNA has reduced immunogenicity relative to a control linear RNA, e.g., a corresponding linear RNA without chemically modified nucleotides.

[0295] As used herein, "reduced immunogenicity" may refer to a reduced immune response caused by contact of the circular RNA with a cell, i.e., a lower level of immune response than a control circular RNA or a control linear RNA. For example, a reduced immune response refers to reduced cytokine expression. The cytokines include, but are not limited to, IFNβ, TNFα, IL6 and / or RIG-I. In some embodiments, the immunogenicity of the circular RNA is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or more. Reduced immunogenicity can be determined by methods well known in the art, such as those described in Example 10 of the present invention.

[0296] In some embodiments, the first and second retention loop-forming elements allow the circular RNA comprising them to have comparable or increased loop-forming efficiency relative to the circular RNA comprising the retention loop-forming elements of SEQ ID NO: 29 and SEQ ID NO: 64 (Ana3.0).

[0297] As used herein, "circularization efficiency" may refer to the ratio of output circular RNA to input precursor in a given time period. Alternatively, as used herein, "circularization efficiency" may refer to the ratio of desired circular RNA to linear RNA in the final product in a given time period. Circularization efficiency can be determined by methods well known in the art, such as the methods described in Examples 17, 19, and 20 of the present invention.

[0298] In some embodiments, the circular RNA has an increased circularization efficiency of at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 100%, at least about 200%, at least about 300%, at least about 400%, at least about 500%, or more.

[0299] In some embodiments, the first retention loop-forming element comprises or consists of a 3' exon region and an optional spacer from the 5' to 3' direction. In the circular RNA precursor, the 5' end of the 3' exon region is directly connected to the 3' end of the 3' self-splicing intron fragment.

[0300] As used herein, the "exon region" in the retention looping element is a sequence derived from a natural exon of a self-splicing intron (an exon flanking the self-splicing intron) and is capable of being recognized and / or spliced ​​by the self-splicing intron (or a combination of a first self-splicing intron fragment and a second self-splicing intron fragment), and is therefore required for circularization.

[0301] In some embodiments, the 3' exon region is derived from the natural 3' exon of the self-splicing intron (the exon flanking (downstream) the 3' end of the self-splicing intron) or a continuous fragment thereof starting from the 5' end nucleotide.

[0302] In some embodiments, the 3' exon region is the entire native 3' exon of the self-splicing intron, or has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 99% or at least 99% sequence identity with all the native 3' exons of the self-splicing intron, or has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleotide substitutions, deletions or additions compared to all the native 3' exons of the self-splicing intron.

[0303] In some embodiments, the 3' exon region is a continuous segment starting from the 5' terminal nucleotide of the natural 3' exon. In some embodiments, the 3' exon region has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the continuous segment starting from the 5' terminal nucleotide of the natural 3' exon. In some embodiments, the 3' exon region has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleotide substitutions, deletions or additions compared to the continuous segment starting from the 5' terminal nucleotide of the natural 3' exon.

[0304] In some embodiments, the continuous segment starting from the 5' terminal nucleotide of the natural 3' exon comprises or consists of at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the nucleotides of the natural 3' exon. In some embodiments, the length of the continuous segment starting from the 5' terminal nucleotide of the natural 3' exon is at least 1 nucleotide, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 50 or more nucleotides. In some embodiments, the length of the continuous fragment starting from the 5'-terminal nucleotide of the native 3' exon is 1 nucleotide or at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 50 nucleotides, or at most the full length of the native 3' exon.

[0305] In some embodiments, wherein the self-splicing intron is a class I intron, the 3' exon region comprises a sequence (e.g., a sequence of about 1 to about 20 nucleotides) at least at its 5' end that can pair with the P1 region of the corresponding class I intron to form a P10 double-stranded region.

[0306] It is believed that for the self-splicing of group I introns, the continuous one or more nucleotides (e.g., at least about 1 to about 7 nucleotides) from the 5' end of the natural 3' exon can be paired with the P1 region to form a P10 double-stranded region, thus playing an important role in self-splicing. The definitions of the P1 region and the P10 region of group I introns are known in the art, for example, can be determined by referring to the following documents: Burke, JM, et al., (1987). Structural conventions for group I introns; Stahley, RM, et al (2006). RNA splicing: group I intron crystal structures reveal the basis of splice site selection and metal ion catalysis; Woodson, AS, (2005). Structure and assembly of group I introns.

[0307] In some embodiments, the second retention loop-forming element comprises or consists of a 5' exon region and an optional spacer from the 3' to 5' direction. In the circular RNA precursor, the 3' end of the 5' exon region is directly connected to the 5' end of the second self-splicing intron fragment.

[0308] In some embodiments, the 5' exon region is derived from the natural 5' exon of the self-splicing intron (the exon flanking (downstream) the 5' end of the self-splicing intron) or a continuous fragment thereof starting from the 3' end nucleotide.

[0309] In some embodiments, the 5' exonic region is the entire native 5' exon of the self-splicing intron, or has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 99% or at least 99% sequence identity with all the native 5' exons of the class I intron, or has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleotide substitutions, deletions or additions compared to all the native 5' exons of the self-splicing intron.

[0310] In some embodiments, the 5' exon region is a continuous segment starting from the 3' terminal nucleotide of the natural 5' exon. In some embodiments, the 5' exon region has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the continuous segment starting from the 3' terminal nucleotide of the natural 5' exon. In some embodiments, the 5' exon region has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleotide substitutions, deletions or additions compared to the continuous segment starting from the 3' terminal nucleotide of the natural 5' exon.

[0311] In some embodiments, the continuous segment starting from the 3' terminal nucleotide of the natural 5' exon comprises or consists of at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the nucleotides of the natural 5' exon. In some embodiments, the length of the continuous segment starting from the 3' terminal nucleotide of the natural 5' exon is at least 1 nucleotide, such as at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 50 or more nucleotides. In some embodiments, the length of the continuous fragment starting from the 3' terminal nucleotide of the native 5' exon is 1 nucleotide or at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 50 nucleotides, or at most the full length of the native 5' exon.

[0312] In some embodiments, wherein the self-splicing intron is a class I intron, the 5' exon region comprises a sequence (e.g., a sequence of about 3 to about 8 consecutive nucleotides) at its 3' end that can pair with the internal guide sequence (IGS) of the corresponding class I intron to form a P1 double-stranded region.

[0313] It is believed that for the self-splicing of group I introns, the continuous about 3 to about 8 nucleotides from the 3' end of the natural 5' exon can be paired with the internal guide sequence (IGS) to form a P1 double-stranded region, thus playing an important role in self-splicing. The definition of the IGS and / or P1 region of group I introns is known in the art, for example, it can be determined by referring to the following documents: Burke, JM, et al., (1987). Structural conventions for group I introns; Stahley, RM, et al (2006). RNA splicing: group I intron crystal structures reveal the basis of splice site selection and metal ion catalysis; Woodson, AS, (2005). Structure and assembly of group I introns.

[0314] In some embodiments, the 3' exon region is derived from the 3' native exon of the class I intron of the Anabaena pre-tRNA-Leu gene. The 3' native exon of the class I intron of the Anabaena pre-tRNA-Leu gene comprises the nucleotide sequence of SEQ ID NO: 7. In some embodiments, the 5' exon region is derived from the 5' native exon of the class I intron of the Anabaena pre-tRNA-Leu gene. The 5' native exon of the class I intron of the Anabaena pre-tRNA-Leu gene comprises the nucleotide sequence of SEQ ID NO: 8.

[0315] In some embodiments, the 3' exon region is derived from the 3' native exon of the class I intron of the T4 phage td gene. The 3' native exon of the T4 phage td gene comprises the nucleotide sequence of SEQ ID NO: 11. In some embodiments, the 5' exon region is derived from the 5' native exon of the class I intron of the T4 phage td gene. The 5' native exon of the T4 phage td gene comprises the nucleotide sequence of SEQ ID NO: 12.

[0316] In some embodiments, the 3' exon region is derived from the 3' native exon of the class I intron of the Azoarcus sp. BH72 pre-tRNA-Ile gene. The 3' native exon of the Azoarcus sp. BH72 pre-tRNA-Ile gene comprises the nucleotide sequence of SEQ ID NO: 9. In some embodiments, the 5' exon region is derived from the 5' native exon of the class I intron of the Azoarcus sp. BH72 pre-tRNA-Ile gene. The 5' native exon of the Azoarcus sp. BH72 pre-tRNA-Ile gene comprises the nucleotide sequence of SEQ ID NO: 10.

[0317] During the circularization process of the circular RNA precursor, the 3' self-splicing intron fragment (e.g., 3' class I intron fragment) and the sequence upstream of its 5' end (if present), and the 5' self-splicing intron fragment (e.g., 5' class I intron fragment) and the sequence downstream of its 3' end (if present) are both removed, and the 5' end of the first retained loop-forming element and the 3' end of the second retained loop-forming element are covalently linked to achieve RNA circularization.

[0318] In some embodiments, the first retention loop-forming element and the second retention loop-forming element comprise different spacer sequences, or one of them comprises a spacer sequence and the other does not comprise a spacer sequence.

[0319] As used herein, "spacer" refers to any continuous nucleotide sequence that at least does not negatively interfere with the function of a connected element. Generally, if it is necessary to avoid the mutual influence of two close or adjacent elements, a spacer can be inserted between the two elements. The spacer sequence described herein can have two functions: (1) promoting cyclization and (2) promoting functionality by allowing the correct folding of the retained loop element and the nucleotide sequence of interest (such as IRES). In some embodiments, the spacer length is no more than 150, no more than 100, no more than 50, no more than 30, no more than 10, no more than 5 or no more than 3 nucleotides. In some embodiments, the spacer length is 5 nucleotides. In some embodiments, the spacer length is 4 nucleotides. In some embodiments, the spacer length is 3 nucleotides. In some embodiments, the spacer may not exist.

[0320] In some embodiments, the first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure. In some embodiments, a splicing junction is contained in the loop of the stem-loop structure.

[0321] In some embodiments, the presence of the stem-loop structure is predicted and / or determined by the nucleotide sequence of the 3' self-splicing intron fragment (e.g., 3' class I intron fragment), the first retention looping element, the second retention looping element, and the 5' self-splicing intron fragment (e.g., 5' class I intron fragment) involved in the cyclization. In some embodiments, the presence of the stem-loop structure is predicted and / or determined based on the nucleotide sequence by RNA structure prediction tools such as RNAfold (http: / / rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi) or RNAstructure (https: / / rna.urmc.rochester.edu / RNAstructureWeb / index.html). By referring to Example 3 and Fig.10 The methods described herein can predict and / or determine the presence of a stem-loop structure.

[0322] In some embodiments, the first retention loop-forming element comprises a sequence structure of the following formula: 5'-first loop sequence-first paired sequence-first non-paired sequence-3'; and the second retention loop-forming element comprises a sequence structure of the following formula: 5'-second non-paired sequence-second paired sequence-second loop sequence-3',

[0323] wherein the first non-pairing sequence or the second non-pairing sequence may be present or absent independently,

[0324] The first mate sequence and the second mate sequence can complementarily pair to form a stem of the stem-loop structure, wherein the first loop sequence and the second loop sequence can form a loop of the stem-loop structure, for example, by self-splicing.

[0325] Typically, the sequence forming the loop of the stem-loop structure is derived from the 3' exon region and / or the 5' exon region.

[0326] In some embodiments, wherein the self-splicing intron is a class I intron, the first loop sequence comprises or consists of one or more nucleotides (e.g., about 1 to about 20 nucleotides) that can pair with the P1 region of the corresponding class I intron to form a P10 double-stranded region during the cyclization process.

[0327] In some embodiments, the first loop sequence may comprise or consist of an (N)n nucleotide sequence, wherein N represents any nucleotide (A, G, U or C) and n represents an integer between 1-20, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0328] In some embodiments, the first loop sequence comprises or consists of about 1 to about 7 consecutive nucleotides starting from the 5'-terminal nucleotide of the native 3' exon of a class I intron.

[0329] In some embodiments, the first loop sequence comprises or consists of, for example, AAAA, AA, UUUU, CAAA, or GAAA.

[0330] In some embodiments, wherein the self-splicing intron is a class I intron, the second loop sequence comprises or consists of one or more nucleotides (e.g., about 3 to about 8 nucleotides), which can pair with the internal guide sequence (IGS) of the class I intron to form the P1 double-stranded region during the cyclization process.

[0331] In some embodiments, the second loop sequence comprises or consists of about 3 to about 8 consecutive nucleotides starting from the 3'-terminal nucleotide of the native 5' exon of the class I intron.

[0332] In some embodiments, the second loop sequence comprises or consists of, for example, CUU or CUC.

[0333] In some specific embodiments, a ring having a sequence of CUUAAAA, CUUUUUU, CUUAA, CUUGAAA, CUUUAAA, CUUCAAA or CUCAAAA may be formed after cyclization.

[0334] In some embodiments, the first loop sequence comprises AAAA or consists of it, and the second loop sequence comprises CUU or consists of it. In some specific embodiments, a loop with a CUUAAAA sequence can be formed after cyclization.

[0335] The pairing sequence forming the stem of the stem-loop structure may be from the exon region, however, it may also be from the spacer sequence. Alternatively, the pairing sequence may be from the exon region and the spacer sequence, i.e., the pairing sequence comprises at least a portion of the exon region and at least a portion of the spacer.

[0336] Without being limited by any theory, the RNA cyclization efficiency based on intron self-splicing (e.g., class I intron self-splicing) is related to the number of base pairs or base pair type or composition of the stem portion in the stem-loop structure formed by the retained loop element. The stability of the stem-loop structure (e.g., as can be predicted by calculated free energy) may affect the cyclization efficiency.

[0337] In some embodiments, the stem portion in the stem-loop structure comprises at least 2 base pairs, such as at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15 or more base pairs, preferably continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 2-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 3-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 4-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 5-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 6-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 7-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 8-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 9-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 10-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 11-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 12-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 13-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 14-15 or more continuous base pairs. In some embodiments, the stem portion in the stem-loop structure comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 base pairs, preferably continuous base pairs. In some embodiments, the stem portion of the stem-loop structure comprises 5 base pairs, preferably continuous base pairs. In some embodiments, the stem portion of the stem-loop structure comprises 6 base pairs, preferably continuous base pairs. In some embodiments, the stem portion of the stem-loop structure comprises 7 base pairs, preferably continuous base pairs.

[0338] In some embodiments, the stem portion in the stem-loop structure contains at most 2 base mismatches, or at most 1 base mismatch. Preferably, the stem portion does not contain a base mismatch.

[0339] In some embodiments, the predicted free energy of the stem-loop structure is less than about -1 kal / mol, less than about -2 kal / mol, less than about -3 kal / mol, less than about -4 kal / mol, less than about -5 kal / mol, less than about -6 kal / mol, less than about -7 kal / mol, less than about -8 kal / mol, less than about -9 kal / mol, less than about -10 kal / mol, or less. In some embodiments, the predicted free energy of the stem-loop structure is about -1 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -2 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -3 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -4 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -5 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -6 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -7 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -8 kal / mol to about -10 kal / mol. In some embodiments, the predicted free energy of the stem-loop structure is about -9 kal / mol to about -10 kal / mol. The free energy can be determined, for example, by RNAfold (http: / / rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi) or RNAstructure (https: / / rna.urmc.rochester.edu / RNAstructureWeb / index.html) structure prediction tools.

[0340] In some embodiments, the first mate sequence comprises only G and the second mate sequence comprises only C. In some embodiments, the first mate sequence comprises only C and the second mate sequence comprises only G. In some embodiments, the first mate sequence comprises only A and the second mate sequence comprises only U.

[0341] In some embodiments, the first mate sequence comprises or consists of any one of SEQ ID NOs: 42-55. In some embodiments, the second mate sequence comprises or consists of any one of SEQ ID NOs: 78-93.

[0342] In some embodiments, the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% sequence identity to a nucleotide sequence selected from one of SEQ ID NOs: 13-55. In some embodiments, the first retention loop-forming element comprises or consists of a nucleotide sequence selected from one of SEQ ID NOs: 13-55.

[0343] In some embodiments, the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% sequence identity to a nucleotide sequence selected from one of SEQ ID NOs: 56-93. In some embodiments, the second retention loop-forming element comprises or consists of a nucleotide sequence selected from one of SEQ ID NOs: 56-93.

[0344] In some embodiments, the first retention loop-forming element comprises or consists of any one of the nucleotide sequences of SEQ ID NOs: 13-55, and the second retention loop-forming element comprises or consists of any one of the nucleotide sequences of SEQ ID NOs: 56-93.

[0345] In some embodiments, the total length of the first retention loop-forming element and the second retention loop-forming element is from about 5 to about 100 nucleotides, or any integer number of nucleotides therebetween;

[0346] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, wherein the first retention loop-forming element comprises a sequence structure of the following formula: 5'-first loop sequence-first paired sequence-first non-paired sequence-3'; and the second retention loop-forming element comprises a sequence structure of the following formula: 5'-second non-paired sequence-second paired sequence-second loop sequence-3',

[0347] wherein the first non-pairing sequence or the second non-pairing sequence may be present or absent independently, the first pairing sequence and the second pairing sequence may complement each other to form a stem of the stem-loop structure, wherein the first loop sequence and the second loop sequence may form a loop of the stem-loop structure, for example, by self-splicing for cyclization,

[0348] wherein the first loop sequence comprises or consists of AAAA, AA, UUUU, CAAA or GAAA, and the second loop sequence comprises or consists of CUU or CUC; and

[0349] The first paired sequence comprises or consists of any one of SEQ ID NOs: 42-55; and the second paired sequence comprises or consists of any one of SEQ ID NOs: 78-93.

[0350] In some embodiments, the total length of the first retention loop-forming element and the second retention loop-forming element is from about 5 to about 100 nucleotides, or any integer number of nucleotides therebetween;

[0351] The first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for cyclization after self-splicing, the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity with a nucleotide sequence selected from one of SEQ ID NOs: 13-55, and the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity with a nucleotide sequence selected from one of SEQ ID NOs: 56-93.

[0352] In some embodiments, the first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure for circularization after self-splicing, wherein

[0353] 1) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 57;

[0354] 2) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 58;

[0355] 3) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0356] 4) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60;

[0357] 5) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 61;

[0358] 6) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 62;

[0359] 7) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0360] 8) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0361] 9) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0362] 10) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0363] 11) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0364] 12) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67;

[0365] 13) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0366] 14) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0367] 15) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0368] 16) The first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:63.

[0369] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:57.

[0370] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:58.

[0371] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:59.

[0372] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60.

[0373] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:61.

[0374] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:62.

[0375] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0376] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0377] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0378] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0379] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0380] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67.

[0381] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:59.

[0382] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:56.

[0383] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:59.

[0384] In some embodiments, the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:63.

[0385] In some embodiments, the nucleotide sequence of interest comprises at least one protein coding sequence and a translation initiation element such as an IRES operably linked thereto (a translation initiation element such as an IRES is defined above). Here, "operably linked" refers to a translation initiation element such as an IRES that is capable of directing the translation of the encoded protein.

[0386] In some embodiments, the circular RNA comprises, in order, a first retention loop element, a translation initiation element such as an IRES, at least one protein coding sequence, and a second retention loop element. In some embodiments, the circular RNA comprises, in order, a first retention loop element, at least one protein coding sequence, a translation initiation element such as an IRES, and a second retention loop element.

[0387] The protein coding sequence may encode a protein of eukaryotic, prokaryotic or viral origin. In certain embodiments, the protein may be any protein for therapeutic or diagnostic purposes. For example, the protein coding region may encode a human protein, an antigen, an antibody, a gene editing enzyme such as a CRISPR nuclease, etc. For example, the encoded protein may be a chimeric antigen receptor, an immunomodulatory protein and / or a transcription factor, etc. Some specific examples include, but are not limited to, EGF, FGF1, RBD, G6PC, PAH, HGF, etc.

[0388] The IRES sequence can be selected from, but is not limited to, the following IRES sequences: Taura syndrome virus, blood-sucking assassin bug virus, Theile's encephalomyelitis virus, simian virus 40, fire ant virus 1, cereal aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immunodeficiency virus type 1, glass leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea looper-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FGF2, human SFTPA1, human AML l / RUNX1, Drosophila antennae, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip crepe virus, aptamer of eIF4G, Coxsackievirus B3 (CVB3) or Coxsackievirus A (CVA1 / 2). Wild-type IRES sequences can also be modified and used in the present invention. Preferably, the IRES is CVB3, BRAV-1_L, PV1_L, CAV2_L, BRAV-1, PV1 or CAV2.

[0389] An exemplary IRES comprises the nucleotide sequence set forth in one of SEQ ID NOs: 105-135, or comprises a nucleotide sequence having at least 75%, e.g., at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to one of SEQ ID NOs: 105-135.

[0390] In some embodiments, the nucleotide sequence of interest is a non-protein coding sequence. For example, the non-protein coding sequence can be an antisense RNA, an aptamer, a guide RNA, or any non-protein coding RNA present in an organism, etc. The non-protein coding sequence may or may not contain a specific secondary structure.

[0391] In some embodiments, the nucleotide sequence of interest is at least 10, 20, 40, 60, 80, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 10000, 20000 nucleotides in length.

[0392] In some embodiments, the circular RNA is at least 10, 20, 40, 60, 80, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 10000, 20000 nucleotides in length. In some embodiments, the circular RNA is at least about 10 nucleotides in length. In some embodiments, the circular RNA is about 500nt or less. In some embodiments, the circular RNA is at least about 1k nt.

[0393] The circular RNA may be unmodified, partially modified or fully modified. In some embodiments, the circular RNA comprises at least one nucleotide modification. In some embodiments, up to 100% of the nucleosides of the circular RNA are modified. In some embodiments, at least one nucleotide modification is a cytidine modification, a uridine modification or an adenosine modification. In some embodiments, at least one nucleotide modification is selected from 5-methylcytosine (m5C), N6-methyladenosine (m6A), pseudouridine (ψ), N1-methylpseudouridine (m1ψ) and 5-methoxyuridine (5moU). In some embodiments, the circular RNA comprises less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 15%, less than 10%, less than 5%, less than 1% of a specific nucleotide modification. The percentage of a specific nucleotide modification herein refers to the ratio of nucleotides in a sequence that have undergone the specific modification to nucleotides that can undergo the specific modification.

[0394] In some preferred embodiments, the circular RNA is unmodified.In some embodiments, the circular RNA does not comprise nucleotide modifications.

[0395] In another aspect, the present invention also provides use of the circular RNA precursor and / or circular RNA of the present invention as an expression vector.

[0396] In another aspect, the present invention provides a pharmaceutical composition comprising the nucleic acid vector of the present invention and / or the circular RNA precursor and / or circular RNA of the present invention, and a pharmaceutically acceptable carrier. The specific use of the composition depends on the nucleotide sequence of interest.

[0397] In some embodiments, the pharmaceutical composition is used to treat a disease in an individual. The specific disease to be treated depends on the nucleotide sequence of interest.

[0398] Pharmaceutically acceptable carriers may include, but are not limited to, buffers, excipients, stabilizers or preservatives. Examples of pharmaceutically acceptable carriers are physiologically compatible solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delay agents, such as salts, buffers, sugars, antioxidants, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants or emulsifiers or combinations thereof. The amount of a pharmaceutically acceptable carrier in a pharmaceutical composition can be determined experimentally based on the activity of the carrier and the desired properties of the formulation, such as stability and / or minimal oxidation.

[0399] II. Methods for preparing circular RNA

[0400] In another aspect, the present invention provides a method for preparing a circular RNA, the method comprising:

[0401] 1) Providing the circular RNA precursor of the present invention or obtaining the circular RNA precursor by transcription from the nucleic acid vector of the present invention;

[0402] 2) incubating the circular RNA precursor in the presence of a divalent metal cation at a temperature at which RNA circularization occurs; and

[0403] 3) Harvesting the circular RNA obtained in step 2).

[0404] In some embodiments, the divalent metal cation is Mg 2+ and / or Mn 2+ .

[0405] In some embodiments, the concentration of the divalent metal cation is at least about 5 mM, e.g., about 5 mM to about 550 mM, e.g., at least about 5 mM, about 10 mM, about 15 mM, at least about 20 mM, at least about 30 mM, at least about 40 mM, at least about 50 mM, at least about 60 mM, at least about 70 mM, at least about 80 mM, at least about 90 mM, at least about 100 mM, at least about 125 mM, at least about 150 mM, at least about 175 mM, at least about 200 mM, at least about 250 mM, at least about 300 mM, at least about 350 mM, at least about 400 mM, at least about 450 mM, at least about 500 mM, at least about 550 mM, or more.

[0406] In another aspect, the present invention provides a method for preparing circular RNA, the method comprising

[0407] a) providing a nucleic acid vector comprising a self-splicing intron-based RNA circularization element as a transcription template; and

[0408] b) incubating the nucleic acid vector in an in vitro transcription system comprising a divalent metal cation and an RNA polymerase for a first period of time, during which the linear RNA produced by in vitro transcription self-circularizes under the action of the RNA circularization element to produce a circular RNA.

[0409] In some embodiments, the nucleic acid vector is a nucleic acid vector described in Section I of the present invention.

[0410] In some embodiments, the divalent metal cation in the in vitro transcription system is Mg2 + .

[0411] In some embodiments, the in vitro transcription system further comprises a monovalent metal cation and / or a monovalent anion.

[0412] In some embodiments, the monovalent metal cation is Na + or K + .

[0413] In some embodiments, the monovalent metal anion is Cl - or CH3COO - (OAc).

[0414] In some embodiments, the concentration of the divalent metal cation in the system during the first time period is about 5 mM-about 50 mM, such as about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM. In some embodiments, the concentration of the divalent metal cation in the system during the first time period is 30 mM.

[0415] In some embodiments, the concentration of the monovalent metal cation in the system during the first time period is about 5 mM to about 50 mM, such as about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM. In some embodiments, the monovalent metal cation is Na + , the concentration in the system during the first time period is 15 mM. In some embodiments, the monovalent metal cation is K + , the concentration in the system during the first time period is 90mM.

[0416] In some embodiments, the concentration of the monovalent anion in the system during the first time period is about 5 mM to about 50 mM, such as about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 100 mM, about 150 mM. In some embodiments, the monovalent anion is Cl - , the concentration in the system during the first time period is 90 mM. In some embodiments, the monovalent anion is CH3COO - , the concentration in the system during the first time period is 125mM.

[0417] In some embodiments, the in vitro transcription and self-circularization are performed in the same reaction system.

[0418] In some embodiments, the method does not include the step of isolating and / or purifying the linear RNA produced by in vitro transcription.

[0419] Those skilled in the art know that the in vitro transcription system also includes various components required for transcription, such as buffer, rATP, rCTP, rUTP, rGTP, etc.

[0420] In some embodiments, the buffer of the in vitro transcription system is Tris hydrochloric acid buffer, or HEPES buffer, or MES buffer, or citrate buffer, or phosphate buffer. In some embodiments, the buffer of the in vitro transcription system is HEPES buffer.

[0421] In some embodiments, the pH of the in vitro transcription system is in the range of about 5 to about 8, for example, a pH of about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, or about 8. In some embodiments, the pH of the in vitro transcription system is 7.5.

[0422] The RNA polymerase depends on the promoter used on the nucleic acid vector to drive transcription. The RNA polymerase may include but is not limited to T7 RNA polymerase, T6 viral RNA polymerase, SP6 viral RNA polymerase, T3 viral RNA polymerase or T4 viral RNA polymerase. In some embodiments, the RNA polymerase is T7 RNA polymerase.

[0423] In some embodiments, the first time period is at least 0.5 hours, such as about 0.5 hours to about 24 hours, such as about 0.5 hours, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 5 hours, about 10 hours or about 24 hours. In some embodiments, the first time period is 3 hours.

[0424] In some embodiments, the first period of time is carried out at about 16°C to about 60°C, for example, at about 16°C, about 17°C, about 18°C, about 19°C, about 20°C, about 21°C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31°C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41°C, about 42°C, about 43°C, about 44°C, about 45°C, about 46°C, about 47°C, In some embodiments, the first period of time is carried out at about 37° C., about 36° C., about 37° C., about 38° C., about 39° C., about 40° C., about 41° C., about 42° C., about 43° C., about 44° C., about 45° C., about 46° C., about 47° C., about 48° C., about 49° C., about 50° C., about 51° C., about 52° C., about 53° C., about 54° C., about 55° C., about 56° C., about 57° C., about 58° C., about 59° C., or about 60° C. In some embodiments, the first period of time is carried out at about 37° C.

[0425] In some embodiments, after the first period of reaction in step b), the method further comprises step c):

[0426] adding an additional amount of metal cations to the in vitro transcription system and reacting for a second period of time; or

[0427] The system's buffer is changed, metal cations are added and reacted for a second period of time.

[0428] In some embodiments, the metal cation added for the second period of time is a divalent metal cation, such as Mg. 2+ or Mn 2+ .

[0429] In some embodiments, the metal cation is added to a final concentration of at least about 5 mM, such as about 5 mM to about 550 mM, such as at least about 5 mM, at least about 10 mM, at least about 15 mM, at least about 20 mM, at least about 30 mM, at least about 40 mM, at least about 50 mM, at least about 60 mM, at least about 70 mM, at least about 80 mM, at least about 90 mM, at least about 100 mM, at least about 125 mM, at least about 150 mM, at least about 175 mM, at least about 200 mM, at least about 250 mM, at least about 300 mM, at least about 350 mM, at least about 400 mM, at least about 450 mM, at least about 500 mM, at least about 550 mM, or more during the second period of reaction.

[0430] In some embodiments, during the reaction in the second time period, the buffer of the system is Tris hydrochloric acid buffer, or HEPES buffer, or MES buffer, or citric acid buffer, or phosphate buffer.

[0431] In some embodiments, the pH range of the reaction system in the second time period is 5-8, for example, pH 5, pH 5.5, pH 6, pH 6.5, pH 7, pH 7.5 or pH 8.

[0432] In some embodiments, the second time period is at least 5 minutes, e.g., about 5 minutes to about 2 hours, e.g., about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 120 minutes or more.

[0433] In some embodiments, the reaction in the second time period is carried out at about 25°C to about 75°C, for example, at about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31°C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41°C, about 42°C, about 43°C, about 44°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, about 70°C or about 75°C.

[0434] In some embodiments, the method further comprises a step of recovering or purifying the produced circular RNA.

[0435] In one aspect, the invention provides a circular RNA produced by the method described herein.

[0436] In one aspect, the present invention provides an in vitro transcription method, the method comprising:

[0437] a) providing a nucleic acid vector as a template for in vitro transcription;

[0438] b) incubating the nucleic acid vector in an in vitro transcription system comprising a divalent metal cation and an RNA polymerase for a first period of time; and

[0439] c) i) adding an additional amount of metal cation to the system, or ii) changing the buffer of the system and adding metal cation to the system, and incubating the system to react for a second period of time.

[0440] In some embodiments, the in vitro transcription system in the reaction during the first period of time further comprises a monovalent metal cation and / or a monovalent anion.

[0441] In some embodiments, the divalent metal cation in the in vitro transcription system during the first period of time is Mg 2+ .

[0442] In some embodiments, the monovalent metal cation in the reaction in the first time period is Na + , or K + .

[0443] In some embodiments, the monovalent anion in the reaction in the first time period is Cl - , or CH3COO - .

[0444] The RNA polymerase depends on the promoter used on the nucleic acid vector to drive transcription. The RNA polymerase may include but is not limited to T7 RNA polymerase, T6 viral RNA polymerase, SP6 viral RNA polymerase, T3 viral RNA polymerase or T4 viral RNA polymerase. In some embodiments, the RNA polymerase is T7 RNA polymerase.

[0445] In some embodiments, the concentration of the divalent metal cation in the reaction during the first time period is about 5 mM to about 50 mM, such as about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM.

[0446] In some embodiments, the concentration of the monovalent metal cation in the reaction in the first time period is about 5 mM to about 100 mM, for example, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 60 mM, about 70 mM, about 80 mM, about 90 mM, about 100 mM.

[0447] In some embodiments, the concentration of the monovalent anion in the reaction in the first time period is about 5 mM to about 150 mM, for example, about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM, about 50 mM, about 100 mM, about 150 mM.

[0448] In some embodiments, the buffer of the in vitro transcription system in the reaction of the first time period is Tris hydrochloric acid buffer, or HEPES buffer, or MES buffer, or citrate buffer, or phosphate buffer.

[0449] In some embodiments, the pH range of the in vitro transcription system in the reaction in the first time period is 5-8, for example, pH 5, pH 5.5, pH 6, pH 6.5, pH 7, pH 7.5 or pH 8.

[0450] In some embodiments, the first time period is at least 0.5 hours, such as about 0.5 hours to about 24 hours, such as about 0.5 hours, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 5 hours, about 10 hours or about 24 hours.

[0451] In some embodiments, the first period of time is carried out at about 16°C to about 60°C, for example, at about 16°C, about 17°C, about 18°C, about 19°C, about 20°C, about 21°C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31°C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41°C, about 42°C, about 43°C, about 44°C, about 45°C, about 46°C, about 47°C, ℃, about 50 ℃, about 51 ℃, about 52 ℃, about 53 ℃, about 54 ℃, about 55 ℃, about 56 ℃, about 57 ℃, about 58 ℃, about 59 ℃ or about 60 ℃.

[0452] In some embodiments, the metal cation added to the system for the second time period reaction is a divalent metal cation, such as Mg 2+ or Mn 2+ .

[0453] In some embodiments, the metal cation is added to the reaction in the second time period to a final concentration of at least about 5 mM, such as about 5 mM to about 550 mM, such as at least about 5 mM, about 10 mM, about 15 mM, at least about 20 mM, at least about 30 mM, at least about 40 mM, at least about 50 mM, at least about 60 mM, at least about 70 mM, at least about 80 mM, at least about 90 mM, at least about 100 mM, at least about 125 mM, at least about 150 mM, at least about 175 mM, at least about 200 mM, at least about 250 mM, at least about 300 mM, at least about 350 mM, at least about 400 mM, at least about 450 mM, at least about 500 mM, at least about 550 mM, or more.

[0454] In some embodiments, the second time period is at least 5 minutes, e.g., about 5 minutes to about 2 hours, e.g., about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 120 minutes or more.

[0455] In some embodiments, the reaction in the second time period is carried out at about 25°C to about 75°C, for example, at about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C, about 31°C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41°C, about 42°C, about 43°C, about 44°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, about 70°C or about 75°C.

[0456] In some embodiments, the method further comprises the step of recovering and / or purifying the RNA obtained in step c).

[0457] In one aspect, the invention provides RNA produced by the method described herein.

[0458] III. Circular RNA Purification Method

[0459] In one aspect, the present invention provides a method for purifying circular RNA, the method comprising:

[0460] a) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a circular RNA-specific probe under conditions that allow the circular RNA-specific probe to specifically bind to the circular RNA and form a complex;

[0461] b) separating the complex from one or more components in the mixture that are not bound to the circular RNA-specific probe; and

[0462] c) releasing the circular RNA from the complex.

[0463] In some embodiments, the circular RNA is prepared by cyclizing a linear circular RNA precursor. In some embodiments, the circular RNA is prepared by connecting the two ends of a linear circular RNA precursor with an RNA ligase, such as T4 RNA ligase. In some embodiments, the circular RNA is prepared by the self-splicing ribozyme activity of a class I intron-based cyclizing element contained in a linear circular RNA precursor, for example, the circular RNA is a circular RNA described in Section I or any of the following clauses and / or is prepared by the method described in Section II or any of the following clauses.

[0464] In some embodiments, the circular RNA-specific probe is a single-stranded DNA probe.

[0465] In some embodiments, the circular RNA-specific probe is a single-stranded RNA probe.

[0466] In some embodiments, the circular RNA-specific probe specifically hybridizes to regions on both sides of the circularization junction of the circular RNA.

[0467] In some embodiments, the circular RNA-specific probe is at least 10 nucleotides, at least 12 nucleotides, at least 14 nucleotides, at least 16 nucleotides, at least 18 nucleotides, at least 20 nucleotides, at least 25 nucleotides, at least 30 nucleotides, at least 35 nucleotides or longer in length, for example, the circular RNA-specific probe is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 25, 27, 28, 29 or 30 nucleotides in length.

[0468] In some embodiments, the circular RNA-specific probe is immobilized on a support such as a solid support. For example, the circular RNA-specific probe is immobilized on the support after binding to the circular RNA, or the circular RNA-specific probe is pre-immobilized on the support.

[0469] In some embodiments, the conditions in step a) include denaturing the RNA at about 60°C to about 95°C (e.g., about 60°C, about 62°C, about 64°C, about 66°C, about 68°C, about 70°C, about 75°C, about 80°C, about 85°C, about 90°C, about 95°C) for about 2 minutes to about 10 minutes (e.g., about 2, 3, 4, 5, 6, 7, 8, 9 or 10 minutes), and then gradually reducing the temperature to below about 40°C (e.g., below about 35°C, below about 30°C, below about 25°C, below about 20°C or less) to anneal the circular RNA to the circular RNA-specific probe.

[0470] In some embodiments, the conditions in step a) include high salt in a concentration range of 0.25 M-2 M, for example, 0.25 M, 0.5 M, 0.75 M, 1 M, 1.25 M, 1.5 M, 1.75 M or 2 M. In some embodiments, the salt is NaCl or a guanidine salt (e.g., guanidine hydrochloride).

[0471] In some embodiments, step b) removes the one or more components by washing the complex with a wash buffer.

[0472] In some embodiments, step c) releases the circular RNA by increasing the temperature to about 60°C to about 95°C (e.g., about 60°C, about 62°C, about 64°C, about 66°C, about 68°C, about 70°C, about 75°C, about 80°C, about 85°C, about 90°C, about 95°C).

[0473] In some embodiments, wherein step c) releases the circular RNA by eluting with an elution buffer. In some embodiments, the elution buffer is a low salt buffer, for example, a buffer having a salt concentration of less than 0.5 M. In some embodiments, the elution buffer is a Tris-EDTA buffer (TE buffer) or water.

[0474] In some embodiments, the method further comprises the following steps:

[0475] i) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a linear circular RNA precursor-specific probe under conditions that allow the linear circular RNA precursor-specific probe to specifically bind to the linear circular RNA precursor and form a complex;

[0476] ii) removing the complex formed by the linear circular RNA precursor-specific probe and the linear circular RNA precursor from the mixture, and

[0477] iii) collecting the mixture containing circular RNA obtained in step ii).

[0478] In some embodiments, the steps i)-iii) are performed before step a), for example, multiple steps i)-iii) are performed before step a), for example, 2, 3, 4 or more times. In some embodiments, the steps i)-iii) are performed simultaneously with steps a)-c).

[0479] In one aspect, the present invention provides a method for purifying circular RNA, the method comprising:

[0480] i) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a linear circular RNA precursor-specific probe under conditions that allow the linear circular RNA precursor-specific probe to specifically bind to the linear circular RNA precursor and form a complex; and

[0481] ii) removing the complex formed by the linear circular RNA precursor-specific probe and the linear circular RNA precursor from the mixture,

[0482] iii) collecting the mixture containing circular RNA obtained in step ii), and

[0483] Optionally, steps i)-iii) are performed multiple times, such as 2 times, 3 times, 4 times or more.

[0484] In some embodiments, the linear circular RNA precursor-specific probe specifically binds to the linear circular RNA precursor and does not substantially bind to the circular RNA.

[0485] In some embodiments, the linear circular RNA precursor-specific probe is immobilized on a support, such as a solid support. For example, the linear circular RNA precursor-specific probe is immobilized on the support after binding to the linear circular RNA precursor, or the linear circular RNA precursor-specific probe is pre-immobilized on the support.

[0486] In some embodiments of the method for purifying circular RNA of the present invention, the linear circular RNA precursor comprises the following elements arranged in the following order from 5' to 3' direction:

[0487] a) 3' self-splicing intron fragment;

[0488] b) a first retention loop element;

[0489] c) a nucleotide sequence of interest;

[0490] d) a second retention loop-forming element; and

[0491] e) 5' self-splicing intron fragment;

[0492] Wherein the linear circular RNA precursor can remove the 3' self-splicing intron fragment and the 5' self-splicing intron fragment by self-splicing to generate a circular RNA comprising the first retention loop element, the nucleotide sequence of interest and the second retention loop element. In some embodiments, the elements of the linear circular RNA precursor are as defined in Section 1 or any of the following clauses herein.

[0493] In some embodiments, the circular RNA-specific probe specifically hybridizes to at least a portion of the first retention loop-forming element and a portion of the second retention loop-forming element.

[0494] In some embodiments, the linear circular RNA precursor-specific probe hybridizes to a portion of the linear circular RNA precursor excluding the first retention loop-forming element, the nucleotide sequence of interest, and the second retention loop-forming element.

[0495] In some embodiments, the linear circular RNA precursor-specific probe hybridizes to the 3' self-splicing intron fragment or a portion thereof or its 5' flanking sequence, or the 5' self-splicing intron fragment or a portion thereof or its 3' flanking sequence.

[0496] In some embodiments, the linear circular RNA precursor comprises a sequence selected from SEQ ID NO: 96-101 or a complementary sequence thereof, preferably SEQ ID NO: 100 or a complementary sequence thereof, which is outside the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element, and the linear circular RNA precursor-specific probe specifically hybridizes to it.

[0497] In some embodiments of the method of purifying circular RNA described herein, the molar ratio of the probe to the RNA molecule in the mixture is about 1:1 to about 100,000:1.

[0498] In some embodiments, the linear circular RNA precursor-specific probe hybridizes with a 3' homology arm sequence or a portion thereof on a linear circular RNA precursor, or a 5' homology arm sequence or a portion thereof on a linear circular RNA precursor. In some embodiments, the homology arm sequence comprises polyA, polyU, polyG or polyC. In some embodiments, the length of the homology arm sequence is about 10-about 200nt. Accordingly, in some embodiments, the linear circular RNA precursor-specific probe comprises polyT, polyA, polyC or polyG. In some embodiments, the linear circular RNA precursor-specific probe is about 10-about 200nt in length.

[0499] In one aspect, the present invention provides a method for purifying circular RNA, the method comprising:

[0500] i) adding a linear RNA-specific tag to the linear RNA in a mixture comprising circular RNA and linear RNA;

[0501] ii) contacting the mixture comprising circular RNA and linear RNA with a linear RNA probe that specifically binds to the tag under conditions that allow the probe to specifically bind to the linear RNA and form a complex; and

[0502] iii) removing the complex formed by the linear RNA probe and the linear RNA from the mixture,

[0503] iv) collecting the mixture containing circular RNA obtained in step ii),

[0504] Optionally, steps ii)-iv) are performed multiple times, such as 2 times, 3 times, 4 times or more.

[0505] In some embodiments, the tag comprises a polyA, polyG, polyU or polyC sequence. Accordingly, the probe comprises a polyT / polyU, polyC, polyA or polyG sequence. Alternatively, the tag may be a random sequence, and the probe comprises a sequence complementary to the random sequence.

[0506] In some embodiments, the tag may be about 10-200 nt in length. In some embodiments, the probe may be about 10-200 nt in length.

[0507] In some embodiments, the tag is added to the end of the linear RNA by adding PolyA / T / C / G polymerase or ligase to the mixture. In some embodiments, rATP, rGTP, rUTP, rCTP or rNTP, or a 10-200nt random tag sequence is also added to the mixture.

[0508] In some embodiments, the linear RNA probe specifically binds to the added tag and does not substantially bind to the circular RNA. In some embodiments, the linear RNA probe is a single-stranded DNA probe, or a single-stranded RNA probe.

[0509] In some embodiments, the linear RNA probe is immobilized on a support such as a solid support, for example, the linear RNA probe is immobilized on the support after binding to the linear RNA, or the linear RNA probe is pre-immobilized on the support.

[0510] Terms

[0511] The following clauses are part of the disclosure of the present invention and will further illustrate the present invention.

[0512] Item 1 A circular RNA precursor comprising the following elements arranged in the following order from 5' to 3' direction:

[0513] a) 3' self-splicing intron fragment;

[0514] b) a first retention loop element;

[0515] c) a nucleotide sequence of interest;

[0516] d) a second retention loop-forming element; and

[0517] e) 5' self-splicing intron fragment;

[0518] wherein the circular RNA precursor is capable of generating a circular RNA comprising the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element by self-splicing thereof,

[0519] The total length of the first retention loop-forming element and the second retention loop-forming element is about 5 to about 100 nucleotides.

[0520] Item 2 The circular RNA precursor of Item 1, wherein the self-splicing intron is selected from a class I intron and a class II intron, for example, the self-splicing intron is a class I intron.

[0521] Item 3 The circular RNA precursor of Item 1 or 2, wherein the self-splicing intron is selected from the IC3 subclass of class I introns.

[0522] Clause 4 The circular RNA precursor of any one of clauses 1 to 3, wherein the self-splicing intron is selected from the group consisting of the class I introns of the cyanobacteria Anabaena, the class I introns of the T4 phage, or the class I introns of Azoarcus sp. BH72, for example, the self-splicing intron is the class I intron of the cyanobacteria Anabaena.

[0523] Clause 5 The circular RNA precursor of any one of clauses 1 to 4, wherein the self-splicing intron is selected from the group consisting of the class I intron of the Anabaena pre-tRNA-Leu gene, the class I intron of the T4 phage td gene, or the class I intron of the Azoarcus sp. BH72 pre-tRNA-Leu gene, for example, the self-splicing intron is the class I intron of the Anabaena pre-tRNA-Leu gene.

[0524] Clause 6 A circular RNA precursor according to any one of clauses 1 to 5, wherein the 3' self-splicing intron fragment is derived from the 3' end portion of a natural self-splicing intron, i.e., the portion from the internal division site to the 3' end of the natural self-splicing intron, and wherein the 5' self-splicing intron fragment is derived from the 5' end portion of a natural self-splicing intron, i.e., the portion from the internal division site to the 5' end of the natural self-splicing intron, and the combination of the 3' self-splicing intron fragment and the 5' self-splicing intron fragment retains the self-splicing activity of the natural self-splicing intron.

[0525] Item 7 The circular RNA precursor described in Item 6, wherein the internal split site is located in the P6, P2, P5, P8 or P9 region of a class I intron, or the D4 region of a class II intron, preferably, the internal split site is located in the P6 region of a class I intron.

[0526] Clause 8 The circular RNA precursor of Clause 6 or 7, wherein the 3' self-splicing intron fragment has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity with the 3' end portion of a natural self-splicing intron, and the 5' self-splicing intron fragment has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity with the 5' end portion of a natural self-splicing intron.

[0527] Clause 9 The circular RNA precursor of any one of clauses 1 to 8, wherein the self-splicing intron is a class I intron of the Anabaena pre-tRNA-Leu gene, and the 3' self-splicing intron fragment comprises, or consists of, the nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 100% identical to SEQ ID NO: 1; and the 5' self-splicing intron fragment comprises, or consists of the nucleotide sequence of SEQ ID NO: 2, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 100% identical to SEQ ID NO: 2.

[0528] Clause 10 The circular RNA precursor of any one of clauses 1 to 8, wherein the self-splicing intron is a class I intron of the T4 phage td gene, and the 3' self-splicing intron fragment comprises, or consists of, the nucleotide sequence of SEQ ID NO: 5, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 5; and the 5' self-splicing intron fragment comprises, or consists of the nucleotide sequence of SEQ ID NO: 6, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 6.

[0529] Clause 11 The circular RNA precursor of any one of clauses 1 to 8, wherein the self-splicing intron is a class I intron of the Azoarcus sp. BH72 pre-tRNA-Leu gene, and the 3' self-splicing intron fragment comprises, or consists of, the nucleotide sequence of SEQ ID NO: 3, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 3; and the 5' self-splicing intron fragment comprises, or consists of the nucleotide sequence of SEQ ID NO: 4, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 4.

[0530] Clause 12 The circular RNA precursor of any one of clauses 1 to 11, wherein the first retention loop-forming element and the second retention loop-forming element cause the circular RNA comprising them to have reduced immunogenicity relative to a control RNA, such as a control circular RNA comprising loop-forming elements of SEQ ID NO: 29 and SEQ ID NO: 64, or a control linear RNA comprising the same nucleotide sequence of interest.

[0531] Clause 13 The circular RNA precursor of any one of clauses 1 to 12, wherein the first retention loop-forming element and the second retention loop-forming element cause the circular RNA or circular RNA precursor comprising it to have a comparable or increased loop-forming efficiency relative to a control circular RNA or circular RNA precursor, such as a control circular RNA or circular RNA precursor comprising the first retention loop-forming element and the second retention loop-forming element of SEQ ID NO: 29 and SEQ ID NO: 64 (Ana3.0), respectively.

[0532] Clause 14 The circular RNA precursor of any of Clauses 1-13, wherein the first retention loop-forming element and the second retention loop-forming element have a total length of about 20 to about 35 nucleotides.

[0533] Clause 15 The circular RNA precursor of any one of clauses 1 to 14, wherein the first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure, for example, after self-splicing circularization.

[0534] Item 16 The circular RNA precursor of Item 15, wherein the loop of the stem-loop structure comprises a splicing junction.

[0535] Clause 17 The circular RNA precursor of any one of clauses 15-16, wherein the first retention loop-forming element comprises a sequence structure described in the following formula: 5'-first loop sequence-first paired sequence-first non-paired sequence-3'; and the second retention loop-forming element comprises a sequence structure described in the following formula: 5'-second non-paired sequence-second paired sequence-second loop sequence-3',

[0536] wherein the first non-pairing sequence or the second non-pairing sequence may be present or absent independently,

[0537] The first pairing sequence and the second pairing sequence can complementarily pair to form a stem of the stem-loop structure, wherein the first loop sequence and the second loop sequence can form a loop of the stem-loop structure, for example, by self-splicing circularization.

[0538] Item 18 The circular RNA precursor of Item 17, wherein the first loop sequence comprises or consists of one or more nucleotides that can pair with the P1 region corresponding to the self-splicing intron to form the P10 double-stranded region during circularization.

[0539] Item 19 The circular RNA precursor of Item 17 or 18, wherein the first loop sequence consists of an (N)n nucleotide sequence, wherein N represents any nucleotide (A, G, U or C) and n represents an integer between 1-20, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0540] Clause 20 The circular RNA precursor of any one of clauses 17 to 19, wherein the first loop sequence comprises or consists of AAAA, AA, UUUU, CAAA or GAAA, preferably AAAA.

[0541] Item 21 The circular RNA precursor of any one of Items 17-20, wherein the second loop sequence comprises or consists of one or more nucleotides that can pair with the internal guide sequence (IGS) corresponding to the self-splicing intron to form the P1 double-stranded region during the circularization process.

[0542] Clause 22 The circular RNA precursor of any of Clauses 17-21, wherein the second loop sequence comprises CUU or CUC, preferably CUU.

[0543] Clause 23 The circular RNA precursor of any of clauses 17 to 22, wherein the loop of the stem-loop structure has a sequence of CUUAAAA, CUUUUUU, CUUAA, CUUGAAA, CUUUAAA, CUUCAAA or CUCAAAA, preferably CUUAAAA.

[0544] Clause 24 The circular RNA precursor of any one of clauses 17-23, wherein the stem portion in the stem-loop structure comprises 2-15 or more consecutive base pairs. Preferably, the stem portion in the stem-loop structure comprises 5, 6 or 7 consecutive base pairs.

[0545] Clause 25 The circular RNA precursor of any one of Clauses 17-24, wherein the stem portion in the stem-loop structure contains at most 2 base mismatches, or the stem portion contains only 1 base mismatch, preferably, the stem portion does not contain a base mismatch.

[0546] Clause 26 The circular RNA precursor of any one of Clauses 17-25, wherein the first pairing sequence comprises only G and the second pairing sequence comprises only C.

[0547] Clause 27 The circular RNA precursor of any of Clauses 17-25, wherein the first pairing sequence comprises only C and the second pairing sequence comprises only G.

[0548] Clause 28 The circular RNA precursor of any of Clauses 17-25, wherein the first pairing sequence comprises only A and the second pairing sequence comprises only U.

[0549] Clause 29 The circular RNA precursor of any one of Clauses 17-25, wherein the first paired sequence comprises or consists of any one of SEQ ID NOs: 42-55, and the second paired sequence comprises or consists of any one of SEQ ID NOs: 78-93.

[0550] Clause 30 The circular RNA precursor of any of clauses 15-29, wherein the predicted free energy of the stem-loop structure is less than about -1 kal / mol, less than about -2 kal / mol, less than about -3 kal / mol, less than about -4 kal / mol, less than about -5 kal / mol, less than about -6 kal / mol, less than about -7 kal / mol, less than about -8 kal / mol, less than about -9 kal / mol, less than about -10 kal / mol, or less.

[0551] Clause 31 The circular RNA precursor of any one of clauses 1 to 30, wherein the first retention loop-forming element comprises, or consists of, a 3' exon region from the 5' to 3' direction and an optional first spacer; and the second retention loop-forming element comprises, or consists of, a 5' exon region from the 3' to 5' direction and an optional second spacer.

[0552] Item 32 The circular RNA precursor of Item 31, wherein the 3' exon region is derived from the natural 3' exon of the self-splicing intron, the 5' exon region is derived from the natural 5' exon of the self-splicing intron, and the 3' exon region and the 5' exon region can be recognized and / or spliced ​​by the self-splicing intron or the combination of the 3' self-splicing intron fragment and the 5' self-splicing intron fragment.

[0553] Clause 33 The circular RNA precursor of Clause 32, wherein the 3' exon region is a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to a native 3' exon or a contiguous stretch of about 1 to about 50 nucleotides starting from the 5'-terminal nucleotide of a native 3' exon,

[0554] The 5' exon region is a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with a native 5' exon or a continuous stretch of about 1 to about 50 nucleotides starting from the 3' terminal nucleotide of a native 5' exon.

[0555] Clause 34 The circular RNA precursor of any of clauses 1 to 33, wherein the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 13-55.

[0556] Clause 35 The circular RNA precursor of any of clauses 1 to 34, wherein the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 56-93.

[0557] Clause 36 The circular RNA precursor of any one of clauses 1 to 35, wherein the first retention loop-forming element comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 13 to 55, and the second retention loop-forming element comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 56 to 93.

[0558] Clause 37 The circular RNA precursor of any one of clauses 1 to 36, wherein

[0559] 1) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 57;

[0560] 2) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 58;

[0561] 3) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0562] 4) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60;

[0563] 5) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 61;

[0564] 6) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 62;

[0565] 7) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0566] 8) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0567] 9) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0568] 10) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0569] 11) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0570] 12) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67;

[0571] 13) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0572] 14) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0573] 15) The first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:63.

[0574] Item 38 A circular RNA precursor comprising the following elements arranged in the following order from 5' to 3' direction:

[0575] a) 3' self-splicing intron fragment;

[0576] b) a first retention loop element;

[0577] c) a nucleotide sequence of interest;

[0578] d) a second retention loop-forming element; and

[0579] e) 5' self-splicing intron fragment;

[0580] wherein the circular RNA precursor is capable of generating a circular RNA comprising the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element by self-splicing thereof,

[0581] wherein the total length of the first retention loop-forming element and the second retention loop-forming element is about 5 to about 100 nucleotides,

[0582] wherein the self-splicing intron is selected from the class I intron of the Anabaena pre-tRNA-Leu gene,

[0583] wherein the 3' self-splicing intron fragment comprises the nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 1, or consists thereof; and the 5' self-splicing intron fragment comprises the nucleotide sequence of SEQ ID NO: 2, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 2, or consists thereof,

[0584] wherein the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 13-55, and the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 56-93.

[0585] Clause 39 The circular RNA precursor of Clause 38, wherein the 3' self-splicing intron fragment comprises or consists of the nucleotide sequence of SEQ ID NO: 1, and the 5' self-splicing intron fragment comprises or consists of the nucleotide sequence of SEQ ID NO: 2.

[0586] Clause 40 The circular RNA precursor of clause 38 or 39, wherein

[0587] 1) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 57;

[0588] 2) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 58;

[0589] 3) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0590] 4) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60;

[0591] 5) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 61;

[0592] 6) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 62;

[0593] 7) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0594] 8) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0595] 9) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0596] 10) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0597] 11) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0598] 12) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67;

[0599] 13) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0600] 14) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0601] 15) The first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:63.

[0602] Clause 41 The circular RNA precursor of any one of Clauses 1 to 40, wherein the circular RNA precursor further comprises a 5' homology arm sequence and a 3' homology arm sequence that are capable of complementary pairing to form a homology arm double-stranded region.

[0603] Item 42 The circular RNA precursor of Item 41, wherein the 5' homology arm sequence is upstream of the 3' self-splicing intron fragment, and the 3' homology arm sequence is downstream of the 5' self-splicing intron fragment.

[0604] Clause 43 The circular RNA precursor of any of Clauses 1 to 42, wherein the homology arms are about 5-50 nucleotides in length, preferably about 40 nucleotides in length.

[0605] Clause 44 The circular RNA precursor of any of Clauses 41 to 43, wherein the two homology arm sequences may be polyA and polyT, respectively, or polyG and polyC, respectively.

[0606] Clause 45 The circular RNA precursor of any one of clauses 41-44, wherein one of the homology arm sequences may have any nucleotide sequence in SEQ ID NO: 151-162 or a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% sequence identity with any one of SEQ ID NO: 151-162, and the other homology arm sequence may have a corresponding complementary sequence.

[0607] Clause 46 The circular RNA precursor of any one of clauses 1 to 45, wherein the nucleotide sequence of interest comprises at least one protein coding sequence and a translation initiation element such as an internal ribosome entry site (IRES) operably linked thereto.

[0608] Item 47 The circular RNA precursor of Item 46, wherein the translation initiation element, such as an IRES, is located upstream of the 5' end of at least one protein coding sequence.

[0609] Item 48 The circular RNA precursor of Item 46, wherein the translation initiation element, such as IRES, is located downstream of the 3' end of the at least one protein coding sequence.

[0610] Clause 49 A circular RNA precursor as described in any of Clauses 46 to 48, wherein the protein coding sequence encodes a protein of eukaryotic, prokaryotic or viral origin, for example, any protein for therapeutic or diagnostic use.

[0611] Clause 50 The circular RNA precursor of any one of clauses 46-49, wherein the translation initiation element is an internal ribosome entry site (IRES), and the IRES sequence can be selected from but not limited to the following IRES sequences: Taura syndrome virus, blood-sucking assassin bug virus, Theilerian encephalomyelitis virus, simian virus 40, red fire ant virus 1, cereal aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immune Defective virus type 1, glass leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea geometrid-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FGF2, human SFTPA1, human AML l / RUNXl, Drosophila antennae, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip shrivelled disease virus, aptamer of eIF4G, Coxsackievirus B3 (CVB3) or Coxsackievirus A (CVA1 / 2), preferably, the IRES is CVB3, BRAV-1_L, PV1_L, CAV2_L, BRAV-1, PV1 or CAV2.

[0612] Clause 51 The circular RNA precursor of any of clauses 46-50, wherein the IRES comprises the nucleotide sequence shown in one of SEQ ID NOs: 105-135, or comprises a nucleotide sequence having at least 75%, for example, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to one of SEQ ID NOs: 105-135.

[0613] Item 52 The circular RNA precursor of any one of Items 1-45, wherein the nucleotide sequence of interest is a non-protein coding sequence, for example, the non-protein coding sequence is selected from antisense RNA, aptamer, guide RNA or non-protein coding RNA naturally present in an organism.

[0614] Clause 53 The circular RNA precursor of any of Clauses 1-52, wherein the nucleotide sequence of interest is about 10 to about 20,000 nucleotides in length.

[0615] Clause 54 The circular RNA precursor of any of Clauses 1-53, wherein the circular RNA precursor does not comprise a nucleotide chemical modification.

[0616] Item 55. A nucleic acid vector for producing a circular RNA molecule, the vector comprising a coding sequence for a circular RNA precursor according to any one of Items 1-54.

[0617] Clause 56 The nucleic acid vector of Clause 55, further comprising an RNA polymerase promoter sequence operably linked to the circular RNA precursor coding sequence.

[0618] Clause 57 The nucleic acid vector of Clause 56, wherein the promoter is a T7 RNA polymerase promoter, a T6 viral RNA polymerase promoter, an SP6 viral RNA polymerase promoter, a T3 viral RNA polymerase promoter or a T4 viral RNA polymerase promoter, preferably a T7 RNA polymerase promoter.

[0619] Item 58. Circular RNA, which is prepared from the circular RNA precursor of any one of Items 1 to 54 or prepared from the nucleic acid vector of any one of Items 55 to 57.

[0620] Item 59. A circular RNA comprising a first retention loop-forming element, a nucleotide sequence of interest, and a second retention loop-forming element, wherein the first retention loop-forming element, the nucleotide sequence of interest, and the second retention loop-forming element are defined as in any one of items 1-54.

[0621] Item 60 A circular RNA comprising a first retention loop-forming element, a nucleotide sequence of interest, and a second retention loop-forming element,

[0622] The total length of the first retention loop-forming element and the second retention loop-forming element is about 5 to about 100 nucleotides.

[0623] Item 61 The circular RNA of Item 60, wherein the first and second retention loop-forming elements participate in RNA circularization via a self-splicing intron, such as a class I intron, preferably a class I intron of an Anabaena pre-tRNA-Leu gene.

[0624] Clause 62 The circular RNA of Clause 60 or 61, wherein the first retention loop-forming element and the second retention loop-forming element are covalently linked, for example, the 5' end of the first retention loop-forming element and the 3' end of the second retention loop-forming element are covalently linked

[0625] Clause 63 The circular RNA of any one of clauses 60 to 62, wherein the first retention loop-forming element and the second retention loop-forming element cause the circular RNA comprising them to have reduced immunogenicity relative to a control RNA, such as a control circular RNA comprising the retention loop-forming elements of SEQ ID NO: 29 and SEQ ID NO: 64, or a control linear RNA comprising the same nucleotide sequence of interest.

[0626] Clause 64 The circular RNA of any one of clauses 60 to 63, wherein the first retention loop-forming element and the second retention loop-forming element cause the circular RNA comprising them to have a comparable or increased loop-forming efficiency relative to a control circular RNA, such as a control circular RNA comprising the retention loop-forming elements of SEQ ID NO: 29 and SEQ ID NO: 64 (Ana3.0).

[0627] Clause 65 The circular RNA of any of Clauses 60 to 64, wherein the total length of the first retention loop-forming element and the second retention loop-forming element is about 20 to about 35 nucleotides.

[0628] Clause 66 The circular RNA of any of Clauses 60-65, wherein the first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure.

[0629] Clause 67 The circular RNA of Clause 66, wherein the loop of the stem-loop structure comprises a splice site between the first retention loop-forming element and the second retention loop-forming element.

[0630] Clause 68 The circular RNA of any one of clauses 60 to 67, wherein the first retention loop-forming element comprises a sequence structure described in the following formula: 5'-first loop sequence-first paired sequence-first non-paired sequence-3'; and the second retention loop-forming element comprises a sequence structure described in the following formula: 5'-second non-paired sequence-second paired sequence-second loop sequence-3',

[0631] wherein the first non-pairing sequence or the second non-pairing sequence may be present or absent independently,

[0632] The first pairing sequence and the second pairing sequence can complementarily pair to form a stem of the stem-loop structure, wherein the first loop sequence and the second loop sequence can form a loop of the stem-loop structure.

[0633] Item 69 The circular RNA of Item 68, wherein the first loop sequence comprises or consists of one or more nucleotides that can pair with the P1 region corresponding to the self-splicing intron during circularization to form a P10 double-stranded region.

[0634] Clause 70 The circular RNA of clause 68 or 69, wherein the first loop sequence comprises or consists of an (N)n nucleotide sequence, wherein N represents any nucleotide (A, G, U or C) and n represents an integer between 1-20, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

[0635] Clause 71 The circular RNA of any of clauses 68 to 70, wherein the first loop sequence comprises or consists of AAAA, AA, UUUU, CAAA or GAAA, preferably AAAA.

[0636] Clause 72 The circular RNA of any one of clauses 68 to 71, wherein the second loop sequence comprises or consists of one or more nucleotides that can pair with an internal guide sequence (IGS) corresponding to a self-splicing intron to form a P1 double-stranded region during circularization.

[0637] Clause 73 The circular RNA of any of Clauses 68 to 72, wherein the second loop sequence comprises CUU or CUC, preferably CUU.

[0638] Clause 74 The circular RNA of any of clauses 68 to 73, wherein the loop of the stem-loop structure has a sequence of CUUAAAA, CUUUUUU, CUUAA, CUUGAAA, CUUUAAA, CUUCAAA or CUCAAAA, preferably CUUAAAA.

[0639] Clause 75 The circular RNA of any one of clauses 68 to 74, wherein the stem portion in the stem-loop structure comprises 2 to 15 or more consecutive base pairs, preferably, the stem portion in the stem-loop structure comprises 5, 6 or 7 consecutive base pairs.

[0640] Clause 76 The circular RNA of any one of clauses 68 to 75, wherein the stem portion in the stem-loop structure comprises at most 2 base mismatches, or the stem portion comprises only 1 base mismatch, preferably, the stem portion comprises no base mismatch.

[0641] Clause 77 The circular RNA of any of clauses 68 to 76, wherein the first mate sequence comprises only G and the second mate sequence comprises only C.

[0642] Clause 78 The circular RNA of any of clauses 68 to 76, wherein the first mate sequence comprises only C and the second mate sequence comprises only G.

[0643] Clause 79 The circular RNA of any of clauses 68 to 76, wherein the first pairing sequence comprises only A and the second pairing sequence comprises only U.

[0644] Clause 80 The circular RNA of any one of clauses 68 to 76, wherein the first paired sequence comprises or consists of any one of SEQ ID NOs: 42 to 55, and the second paired sequence comprises or consists of any one of SEQ ID NOs: 78 to 93.

[0645] Clause 81 The circular RNA of any of Clauses 67-80, wherein the predicted free energy of the stem-loop structure is less than about -1 kal / mol, less than about -2 kal / mol, less than about -3 kal / mol, less than about -4 kal / mol, less than about -5 kal / mol, less than about -6 kal / mol, less than about -7 kal / mol, less than about -8 kal / mol, less than about -9 kal / mol, less than about -10 kal / mol, or less.

[0646] Clause 82 The circular RNA of any one of Clauses 60 to 81, wherein the first retention loop-forming element comprises, or consists of, a 3' exon region from the 5' to 3' direction and an optional first spacer; and the second retention loop-forming element comprises, or consists of a 5' exon region from the 3' to 5' direction and an optional second spacer.

[0647] Item 83 The circular RNA of Item 82, wherein the 3' exon region is derived from the natural 3' exon of a self-splicing intron, the 5' exon region is derived from the natural 5' exon of a self-splicing intron, and the 3' exon region and the 5' exon region can be recognized and / or spliced ​​by the self-splicing intron or the combination of the 3' self-splicing intron fragment and the 5' self-splicing intron fragment.

[0648] Clause 84 The circular RNA of clause 83, wherein the 3' exon region is a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to a native 3' exon or a contiguous stretch of about 1 to about 50 nucleotides starting from the 5'-terminal nucleotide of a native 3' exon,

[0649] The 5' exon region is a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with a native 5' exon or a continuous stretch of about 1 to about 50 nucleotides starting from the 3' terminal nucleotide of a native 5' exon.

[0650] Clause 85 The circular RNA of any of clauses 60 to 84, wherein the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 13-55.

[0651] Clause 86 The circular RNA of any of clauses 60 to 85, wherein the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 56 to 93.

[0652] Clause 87 The circular RNA of any one of clauses 60 to 86, wherein the first retention loop-forming element comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 13 to 55, and the second retention loop-forming element comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 56 to 93.

[0653] Clause 88 The circular RNA of any one of clauses 60 to 87, wherein

[0654] 1) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 57;

[0655] 2) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 58;

[0656] 3) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0657] 4) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60;

[0658] 5) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 61;

[0659] 6) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 62;

[0660] 7) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0661] 8) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0662] 9) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0663] 10) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0664] 11) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56;

[0665] 12) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67;

[0666] 13) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0667] 14) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59;

[0668] 15) The first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:63.

[0669] Clause 89 The circular RNA of any one of clauses 60 to 88, wherein the nucleotide sequence of interest comprises at least one protein coding sequence and a translation initiation element such as an internal ribosome entry site (IRES) operably linked thereto.

[0670] Clause 90 The circular RNA of Clause 89, wherein the translation initiation element, such as an IRES, is located upstream of the 5' end of the at least one protein coding sequence.

[0671] Item 91 The circular RNA of Item 89, wherein the translation initiation element, such as an IRES, is located downstream of the 3' end of the at least one protein coding sequence.

[0672] Clause 92 The circular RNA of any of clauses 89 to 91, wherein the protein coding sequence encodes a protein of eukaryotic, prokaryotic or viral origin, for example, a protein for therapeutic or diagnostic use.

[0673] Clause 93 The circular RNA of any one of clauses 89-92, wherein the translation initiation element is an internal ribosome entry site (IRES), and the IRES sequence can be selected from but not limited to the following IRES sequences: Taura syndrome virus, blood-sucking assassin bug virus, Theilerian encephalomyelitis virus, simian virus 40, fire ant virus 1, aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immunodeficiency virus 2, Trapped virus type 1, glass leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea geometrid-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FGF2, human SFTPA1, human AML1 / RUNXl, Drosophila antennae, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, human U NR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip shrivell disease virus, aptamer of eIF4G, Coxsackievirus B3 (CVB3) or Coxsackievirus A (CVA1 / 2), preferably, the IRES is CVB3, BRAV-1_L, PV1_L, CAV2_L, BRAV-1, PV1 or CAV2.

[0674] Clause 94 The circular RNA of any one of clauses 89-93, wherein the IRES comprises the nucleotide sequence shown in one of SEQ ID NOs: 105-135, or comprises a nucleotide sequence having at least 75%, for example, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to one of SEQ ID NOs: 105-135.

[0675] Clause 95 The circular RNA of any one of Clauses 60-88, wherein the nucleotide sequence of interest is a non-protein coding sequence, for example, the non-protein coding sequence is selected from antisense RNA, aptamer, guide RNA or non-protein coding RNA naturally present in an organism.

[0676] Clause 96 The circular RNA of any of clauses 60 to 95, wherein the nucleotide sequence of interest is about 10 to about 20,000 nucleotides in length.

[0677] Clause 97 The circular RNA of any of clauses 60 to 96, wherein the circular RNA does not comprise a nucleotide chemical modification.

[0678] Clause 98 Use of the circular RNA precursor of any one of clauses 1 to 54 and / or the circular RNA of any one of clauses 58 to 97 as an expression vector.

[0679] Clause 99. A pharmaceutical composition comprising the circular RNA precursor of any one of Clauses 1 to 54 and / or the nucleic acid vector of any one of Clauses 55 to 57 and / or the circular RNA of any one of Clauses 58 to 97, and a pharmaceutically acceptable carrier.

[0680] Clause 100. The pharmaceutical composition of Clause 99, for use in treating a disease in an individual.

[0681] Item 101. A method for preparing a circular RNA, the method comprising:

[0682] 1) Providing a circular RNA precursor according to any one of clauses 1 to 54 or obtaining a circular RNA precursor by transcription from a nucleic acid vector according to any one of clauses 55 to 57;

[0683] 2) incubating the circular RNA precursor in the presence of a divalent metal cation at a temperature at which RNA circularization occurs; and

[0684] 3) Harvesting the circular RNA obtained in step 2).

[0685] Clause 102 The method of clause 101, wherein the divalent metal cation is Mg 2+ and / or Mn 2+ .

[0686] Clause 103 The method of Clause 101 or 102, wherein the concentration of the divalent metal cation is about 5 mM to about 550 mM.

[0687] Item 104: A method for preparing a circular RNA, the method comprising

[0688] a) providing a nucleic acid vector comprising a self-splicing intron-based RNA circularization element as a transcription template; and

[0689] b) incubating the nucleic acid vector in an in vitro transcription system comprising a divalent metal cation and an RNA polymerase for a first period of time, during which the linear RNA produced by in vitro transcription self-circularizes under the action of the RNA cyclization element to produce a circular RNA.

[0690] Clause 105 The method of clause 104, wherein the nucleic acid vector is the nucleic acid vector of any one of clauses 55-57.

[0691] Clause 106 The method of clause 104 or 105, wherein the divalent metal cation in the in vitro transcription system is Mg2 + .

[0692] Clause 107 The method of any one of Clauses 104-106, wherein the in vitro transcription system further comprises a monovalent metal cation and / or a monovalent anion.

[0693] Clause 108 The method of clause 107, wherein the monovalent metal cation is Na + or K + .

[0694] Clause 109 The method of clause 107, wherein the monovalent metal anion is Cl - or CH3COO - (OAc).

[0695] Clause 110 The method of any of Clauses 104-109, wherein the concentration of the divalent metal cation in the system during the first period of time is about 5 mM to about 50 mM.

[0696] Clause 111 The method of any of Clauses 107-110, wherein the concentration of the monovalent metal cation in the system during the first period of time is about 5 mM to about 100 mM.

[0697] Clause 112 The method of any of Clauses 107-111, wherein the concentration of the monovalent anion in the system during the first period of time is about 5 mM to about 150 mM.

[0698] Clause 113 The method of any of Clauses 107-112, wherein the method does not include a step of isolating and / or purifying linear RNA produced by in vitro transcription.

[0699] Clause 114 The method described in any one of Clauses 107-113, wherein the buffer of the in vitro transcription system is selected from Tris hydrochloric acid buffer, or HEPES buffer, or MES buffer, or citric acid buffer, or phosphate buffer, preferably, the buffer of the in vitro transcription system is HEPES buffer.

[0700] Clause 115 The method of any one of Clauses 107-114, wherein the pH range of the in vitro transcription system is about 5 to about 8, preferably, the pH of the in vitro transcription system is about 7.5.

[0701] Clause 116 The method of any one of Clauses 107-115, wherein the RNA polymerase is selected from T7 RNA polymerase, T6 viral RNA polymerase, SP6 viral RNA polymerase, T3 viral RNA polymerase or T4 viral RNA polymerase, preferably, the RNA polymerase is T7 RNA polymerase.

[0702] Clause 117 The method of any of Clauses 107-116, wherein the first time period is approximately 0.5 hours to approximately 24 hours, preferably, the first time period is 3 hours.

[0703] Clause 118 The method of any of Clauses 107-117, wherein the first period of reaction is carried out at about 16°C to about 60°C, preferably, the first period of reaction is carried out at about 37°C.

[0704] Clause 119 The method of any one of clauses 107-118, wherein after the first period of time of reaction in step b), the method further comprises step c):

[0705] adding an additional amount of metal cations to the in vitro transcription system and reacting for a second period of time; or

[0706] The system's buffer is changed, metal cations are added and reacted for a second period of time.

[0707] Clause 120: The method of clause 119, wherein the metal cation added for the second time period reaction is a divalent metal cation, such as Mg 2+ or Mn 2+ .

[0708] Item 121 The method of Item 119 or 120, wherein during the second period of reaction, the metal cation is added to a final concentration of about 5 mM to about 550 mM.

[0709] Item 122 The method described in Item 119 or 121, wherein during the second time period, the buffer of the system is changed to Tris hydrochloric acid buffer, or HEPES buffer, or MES buffer, or citric acid buffer, or phosphate buffer.

[0710] Item 123 The method of Item 119 or 122, wherein the pH range of the reaction system during the second time period is 5-8.

[0711] Clause 124 The method of clause 119 or 123, wherein the second time period is from about 5 minutes to about 2 hours.

[0712] Clause 125 The method of Clause 119 or 124, wherein the second period of reacting is carried out at about 25°C to about 75°C.

[0713] Clause 126 The method of clause 104 or 125, wherein the method further comprises a step of recovering or purifying the produced circular RNA.

[0714] Item 127. A method for purifying circular RNA, the method comprising:

[0715] a) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a circular RNA-specific probe under conditions that allow the circular RNA-specific probe to specifically bind to the circular RNA and form a complex;

[0716] b) separating the complex from one or more components in the mixture that are not bound to the circular RNA-specific probe; and

[0717] c) releasing the circular RNA from the complex.

[0718] Item 128 The method of Item 127, wherein the circular RNA is prepared by circularizing a linear circular RNA precursor.

[0719] Item 129 The method of Item 127 or 128, wherein the circular RNA is prepared by ligating both ends of a linear circular RNA precursor using an RNA ligase, or by the self-splicing ribozyme activity of a self-splicing intron-based circularization element contained in the linear circular RNA precursor.

[0720] Clause 130 The method of any of Clauses 127-129, wherein the circular RNA-specific probe is a single-stranded DNA or RNA probe.

[0721] Clause 131 The method of any of Clauses 127-130, wherein the circular RNA-specific probe specifically hybridizes to regions on both sides of the circularization junction of the circular RNA.

[0722] Clause 132 The method of any of Clauses 127-131, wherein the circular RNA-specific probe is about 10 nucleotides to about 35 nucleotides in length or longer.

[0723] Item 133 The method of any one of Items 127-132, wherein the circular RNA-specific probe is immobilized on a support such as a solid support, for example, the circular RNA-specific probe is immobilized on the support after binding to the circular RNA, or the circular RNA-specific probe is pre-immobilized on the support.

[0724] Clause 134 The method of any one of clauses 127-133, wherein the conditions in step a) comprise denaturing the RNA at about 60°C to about 95°C for about 2 minutes to about 10 minutes, and then gradually reducing the temperature to below about 40°C to anneal the circular RNA to the circular RNA-specific probe.

[0725] Item 135 The method of Item 134, wherein step c) releases the circular RNA by raising the temperature to about 60°C-about 95°C (e.g., about 60°C, about 62°C, about 64°C, about 66°C, about 68°C, about 70°C, about 75°C, about 80°C, about 85°C, about 90°C, about 95°C).

[0726] Clause 136 The method of any one of clauses 127-133, wherein the conditions in step a) comprise high salt at a concentration ranging from 0.25M to 2M.

[0727] Clause 137 The method of Clause 136, wherein the salt is NaCl or a guanidine salt.

[0728] Item 138 The method of Item 136 or 137, wherein step c) releases the circular RNA by eluting with an elution buffer, such as a low salt buffer.

[0729] Item 139 The method of Item 138, wherein the elution buffer is Tris-EDTA buffer (TE buffer) or water.

[0730] Clause 140 The method of any of clauses 127-139, wherein step b) removes the one or more components by washing the complex with a wash buffer.

[0731] Clause 141 A method according to any one of clauses 127 to 140, wherein the method further comprises the following steps:

[0732] i) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a linear circular RNA precursor-specific probe under conditions that allow the linear circular RNA precursor-specific probe to specifically bind to the linear circular RNA precursor and form a complex;

[0733] ii) removing the complex formed by the linear circular RNA precursor-specific probe and the linear circular RNA precursor from the mixture, and

[0734] iii) collecting the mixture containing circular RNA obtained in step ii).

[0735] Clause 142 The method of Clause 141, wherein steps i)-iii) are performed before step a), for example, steps i)-iii) are performed multiple times before step a), for example, 2 times, 3 times, 4 times or more.

[0736] Clause 143 The method of Clause 141, wherein steps i)-iii) are performed simultaneously with steps a)-c).

[0737] Item 144. A method for purifying circular RNA, the method comprising:

[0738] i) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a linear circular RNA precursor-specific probe under conditions that allow the linear circular RNA precursor-specific probe to specifically bind to the linear circular RNA precursor and form a complex; and

[0739] ii) removing the complex formed by the linear circular RNA precursor-specific probe and the linear circular RNA precursor from the mixture,

[0740] iii) collecting the mixture containing circular RNA obtained in step ii), and

[0741] Optionally, steps i)-iii) are performed multiple times, such as 2 times, 3 times, 4 times or more.

[0742] Clause 145 The method of Clause 144, wherein the linear circular RNA precursor-specific probe specifically binds to the linear circular RNA precursor and does not substantially bind to the circular RNA.

[0743] Item 146 The method described in Item 144 or 145, wherein the linear circular RNA precursor-specific probe is immobilized on a support, such as a solid support, for example, the linear circular RNA precursor-specific probe is immobilized on the support after binding to the linear circular RNA precursor, or the linear circular RNA precursor-specific probe is pre-immobilized on the support.

[0744] Clause 147 The method of any of clauses 127-146, wherein the linear circular RNA precursor comprises the following elements arranged in the following order from 5' to 3' direction:

[0745] a) 3' self-splicing intron fragment;

[0746] b) a first retention loop element;

[0747] c) a nucleotide sequence of interest;

[0748] d) a second retention loop-forming element; and

[0749] e) 5' self-splicing intron fragment;

[0750] The linear circular RNA precursor is capable of removing the 3' self-splicing intron fragment and the 5' self-splicing intron fragment by self-splicing to generate a circular RNA comprising the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element.

[0751] Clause 148 The method of clause 147, wherein the circular RNA-specific probe specifically hybridizes to at least a portion of the first retention loop-forming element and a portion of the second retention loop-forming element.

[0752] Clause 149 The method of clause 147 or 148, wherein the linear precursor RNA-specific probe hybridizes to a portion of the linear circular RNA precursor excluding the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element.

[0753] Clause 150 The method of any one of Clauses 147-149, wherein the linear precursor RNA-specific probe hybridizes to the 3' self-splicing intron fragment or a portion thereof or its 5' flanking sequence, or the 5' self-splicing intron fragment or a portion thereof or its 3' flanking sequence.

[0754] Clause 151 The method of any one of clauses 147-150, wherein the linear circular RNA precursor comprises a sequence selected from SEQ ID NO: 96-101 or a complementary sequence thereof, preferably SEQ ID NO: 100 or a complementary sequence thereof, which is outside the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element, and the linear precursor RNA-specific probe specifically hybridizes to it.

[0755] Clause 152 The method of any of Clauses 147-151, wherein the molar ratio of the probe to the RNA molecules in the mixture is about 1:1 to about 100,000:1.

[0756] Item 153. A method for purifying circular RNA, the method comprising:

[0757] i) adding a linear RNA-specific tag to the linear RNA in a mixture comprising circular RNA and linear RNA;

[0758] ii) contacting the mixture comprising circular RNA and linear RNA with a linear RNA probe that specifically binds to the tag under conditions that allow the probe to specifically bind to the linear RNA and form a complex; and

[0759] iii) removing the complex formed by the linear RNA probe and the linear RNA from the mixture,

[0760] iv) collecting the mixture containing circular RNA obtained in step ii),

[0761] Optionally, steps ii)-iv) are performed multiple times, such as 2 times, 3 times, 4 times or more.

[0762] Clause 154 The method of clause 153, wherein the tag comprises a polyA, polyG, polyU or polyC sequence.

[0763] Clause 155 The method of clause 153 or 154, wherein the tag is about 10-200 nt in length or the probe is about 10-200 nt in length.

[0764] Clause 156 The method of any of Clauses 153-155, wherein the tag is added to the linear RNA by adding Poly A / T / C / G polymerase or ligase to the mixture.

[0765] Clause 157 The method of any of Clauses 153-156, wherein the linear RNA probe specifically binds to the added tag and does not substantially bind to the circular RNA.

[0766] Clause 158 The method of any of Clauses 153-157, wherein the linear RNA probe is a single-stranded DNA probe, or a single-stranded RNA probe.

[0767] Item 159 The method of any one of Items 153-158, wherein the linear RNA probe is immobilized on a support such as a solid support, for example, the linear RNA probe is immobilized on the support after binding to the linear RNA, or the linear RNA probe is pre-immobilized on the support.

[0768] Item 160 A nucleic acid vector for producing a circular RNA molecule, comprising a coding sequence for a circular RNA precursor, the circular RNA precursor comprising the following elements arranged in the following order from 5' to 3' direction:

[0769] a) 3' class I intron fragment;

[0770] b) a first retention loop element;

[0771] c) a nucleotide sequence of interest;

[0772] d) a second retention loop-forming element; and

[0773] e) 5' class I intron fragment;

[0774] Wherein, when a circular RNA precursor is produced by transcription of the nucleic acid vector, the circular RNA precursor is capable of generating a circular RNA comprising the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element;

[0775] The total length of the first retention loop-forming element and the second retention loop-forming element is at least 15 nucleotides, and the first retention loop-forming element and the second retention loop-forming element form a stem-loop structure in the circular RNA.

[0776] Clause 161 The nucleic acid vector of Clause 160, wherein the first retention loop-forming element comprises, from the 5' to the 3' direction: b1) a 3' exon region; and / or b2) a 5' spacer.

[0777] Clause 162 The nucleic acid vector of Clause 160 or 161, wherein the second retention loop-forming element comprises, from the 5' to 3' direction: d1) a 3' spacer; and / or d2) a 5' exon region.

[0778] Clause 163 The nucleic acid vector of any of Clauses 160 to 162, wherein the 3' class I intron fragment and the 5' class I intron fragment are derived from the class I intron of the cyanobacterium Anabaena or from the class I intron of bacteriophage T4.

[0779] Clause 164 The nucleic acid vector of any one of Clauses 160 to 163, wherein the stem portion of the stem-loop structure comprises at least 3 base pairs, or at least 5 base pairs, or at least 7 base pairs.

[0780] Clause 165 The nucleic acid vector of any one of Clauses 160 to 164, wherein the stem portion in the stem-loop structure comprises at most 2 base mismatches, or at most 1 base mismatch, or comprises no base mismatches.

[0781] Clause 166 The nucleic acid vector of any of clauses 160-165, wherein the first retention loop-forming element comprises a nucleotide sequence having at least 80%, at least 90%, at least 95% or 100% sequence identity with a nucleotide sequence selected from SEQ ID NO: 13, 16, 30 and 31.

[0782] Clause 167 The nucleic acid vector of any of clauses 160-166, wherein the second retention loop-forming element comprises a nucleotide sequence having at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NO:56, 57, 59 and 65.

[0783] Clause 168 The nucleic acid vector of any one of clauses 160-167, wherein the first retention loop-forming element and the second retention loop-forming element each comprise

[0784] SEQ ID NO: 13 and SEQ ID NO: 56; or

[0785] SEQ ID NO:31 and SEQ ID NO:65; or

[0786] SEQ ID NO:30 and SEQ ID NO:65; or

[0787] SEQ ID NO: 13 and SEQ ID NO: 59; or

[0788] SEQ ID NO: 16 and SEQ ID NO: 56; or

[0789] SEQ ID NO:13 and SEQ ID NO:57.

[0790] Clause 169 The nucleic acid vector of any one of Clauses 160 to 168, wherein the 3' class I intron fragment comprises the nucleotide sequence shown in SEQ ID NO: 1, and the 5' class I intron fragment comprises the nucleotide sequence shown in SEQ ID NO: 2.

[0791] Clause 170 The nucleic acid vector of any of Clauses 160-169, further comprising a 5' homology arm and a 3' homology arm.

[0792] Clause 171 The nucleic acid vector of Clause 170, wherein the 5' homology arm is at the 5' end of the 3' class I intron fragment, and the 3' homology arm is at the 3' end of the 5' class I intron fragment.

[0793] Clause 172 The nucleic acid vector of any of clauses 160 to 171, wherein the nucleotide sequence of interest comprises a protein coding sequence and an IRES (eg, CVB3 IRES) operably linked thereto.

[0794] Clause 173 The nucleic acid vector of any of clauses 160 to 171, wherein the nucleotide sequence of interest is a non-protein coding sequence.

[0795] Clause 174 The nucleic acid vector of any of Clauses 160-173, further comprising a promoter sequence, such as a T7 promoter, operably linked to the coding sequence of the circular RNA precursor.

[0796] Item 175 Circular RNA,

[0797] 1) prepared from the nucleic acid vector according to any one of the above claims; and / or

[0798] 2) comprising a first retention loop-forming element, a nucleotide sequence of interest, and a second retention loop-forming element, wherein the first and second retention loop-forming elements have a total length of at least 15 nucleotides, and the first retention loop-forming element and the second retention loop-forming element form a stem-loop structure in the circular RNA.

[0799] Clause 176 The circular RNA of Clause 175, wherein the first retention loop-forming element comprises, from 5' to 3' direction: b1) a 3' exonic region; and / or b2) a 5' spacer.

[0800] Clause 177 The circular RNA of Clause 176, wherein the second retention loop-forming element comprises, from the 5' to 3' direction: d1) a 3' spacer; and / or d2) a 5' exonic region.

[0801] Clause 178 The circular RNA of any of Clauses 175 to 177, wherein the stem portion of the stem-loop structure comprises at least 3 base pairs, or at least 5 base pairs, or at least 7 base pairs.

[0802] Clause 179 The circular RNA of any one of clauses 175 to 178, wherein the stem portion in the stem-loop structure comprises at most 2 base mismatches, or at most 1 base mismatch, or comprises no base mismatches.

[0803] Clause 180 The circular RNA of any of clauses 175 to 179, wherein the first retention loop-forming element comprises a nucleotide sequence having at least 80%, at least 90%, at least 95% or 100% sequence identity with a nucleotide sequence selected from SEQ ID NOs: 13, 16, 30 and 31.

[0804] Clause 181 The circular RNA of any of clauses 175 to 180, wherein the second retention loop-forming element comprises a nucleotide sequence having at least 80%, at least 90%, at least 95% or 100% sequence identity with a nucleotide sequence selected from SEQ ID NOs: 56, 57, 59 and 65.

[0805] Clause 182 The circular RNA of any one of clauses 175-181, wherein the first retention loop-forming element and the second retention loop-forming element each comprise

[0806] SEQ ID NO: 13 and SEQ ID NO: 56; or

[0807] SEQ ID NO:31 and SEQ ID NO:65; or

[0808] SEQ ID NO:30 and SEQ ID NO:65; or

[0809] SEQ ID NO: 13 and SEQ ID NO: 59; or

[0810] SEQ ID NO: 16 and SEQ ID NO: 56; or

[0811] SEQ ID NO:13 and SEQ ID NO:57.

[0812] Clause 183 A pharmaceutical composition comprising the nucleic acid vector of any one of clauses 1 to 174 and / or the circular RNA of any one of clauses 175 to 182, and a pharmaceutically acceptable carrier. Example

[0813] The following examples further illustrate the invention described herein and show embodiments of the present invention. It will be appreciated by those skilled in the art that the techniques disclosed in the following examples represent techniques discovered by the inventors that have worked well in the practice of the present invention and can therefore be considered as constitutive modes of its practice. However, based on the disclosure of the present invention, it will be appreciated by those skilled in the art that changes may be made to the disclosed specific embodiments and similar results can still be obtained within the scope of the present invention.

[0814] Example 1: Circular RNA Formation Method

[0815] This example illustrates the in vitro circularization of various circular RNAs ( Figure 1 ),include:

[0816] 1) Using a ligase, such as RNA ligase or DNA ligase, the 3'-OH end and the 5'-phosphate end of the in vitro transcribed linear RNA are linked by a phosphodiester bond to form a circular RNA ( Figure 2 ).

[0817] 2) DNA or RNA splints are used to complement the terminal bases of the linear RNA produced by in vitro transcription. Under the catalysis of a ligase (such as RNA ligase, DNA ligase, etc.), the 3'-OH end and the 5'-phosphate end of the linear RNA are linked by a phosphodiester bond to form a circular RNA ( Figure 3 ).

[0818] 3) Through self-splicing ribozymes, for example, based on class I introns, class II introns, etc., shearing and ligation reactions occur to form circular RNA. The basic principle is to connect the exon E1 and E2 sequences end to end through molecular cloning to form a continuous circular plasmid. The intron is sheared and broken by restriction endonucleases to obtain a linear plasmid. Then, in vitro transcription is performed through the promoter upstream of the inverted 3' intron to obtain a linear RNA containing a 3' intron-E2-E1-5' intron structure. The specific splicing site conserved sequence of exon E1 is broken by the nucleophilic attack of the free guanosine 3' hydroxyl, and exon E1 produces a naked 3' hydroxyl, while guanosine binds to the broken 5' intron. Subsequently, the exposed 3' hydroxyl group of exon E1 attacks the conserved sequence between the 3' intron and exon E2, excising the 3' intron, while exon E2 and E1 undergo a circularization reaction to obtain a circular E1-E2 RNA ( Figure 4 ,5).

[0819] 4) Through the combined action of self-cleaving ribozymes (such as HDV, HHR, Twister, etc.) and ligases (such as RtcB, etc.), the ends of linear RNA are connected to form circular RNA. The basic principle is to place the 5' and 3' self-cleaving ribozyme sequences at the ends of the linear plasmid respectively through molecular cloning. After initiating in vitro transcription, the ends of the linear RNA precursors produced will be automatically cleaved by the 5' and 3' end ribozymes to form 5'-OH and 2', 3'-cyclic phosphates, respectively. Subsequently, under the action of ligases (RtcB, etc.), the ends are linked by phosphodiester bonds to form circular RNA ( Figure 6 ).

[0820] Example 2: Introduction of class I intron retention looping elements leads to immunogenicity of circular RNA

[0821] The circular RNA synthesized in vitro mainly consists of two elements: 1) the retained circular element, that is, the additional sequence introduced into the final product of the circular RNA during the circularization reaction; 2) the sequence of interest (Cargo) ( Figure 7). The retained circular element is an additional sequence retained on the circular RNA introduced by an in vitro circularization method (mainly by ribozyme circularization). Taking the self-splicing circularization of the pre-tRNAI intron of Anabaena (Wesselhoeft AR et al., (2018) Engineering circular RNA for potent and stable translation in eukaryotic cells.) as an example, 176 nucleotide sequences will be additionally introduced and retained in the successfully prepared circular RNA final product. This example illustrates that the retention of additional unnecessary nucleotide sequences in the circular RNA final product will have a negative impact on the corresponding circular RNA final product, at least including the possibility of interfering with the insertion of the target sequence of interest, or potentially leading to a certain degree of natural immune response in the cell.

[0822] 1. Circular RNA Synthesis and Purification

[0823] Three methods ( Figure 2 , 4 5) Preparation and purification of circular RNA circPOLR2A in vitro:

[0824] Method 1: Circular RNA was successfully prepared by RNA in vitro transcription and intramolecular ligation with T4 RNA ligase, and then purified in vitro by denaturing polyacrylamide gel electrophoresis (denaturing PAGE) to obtain high-purity circPOLR2A ( Figure 2 ).

[0825] Method 2: Circular RNA was successfully prepared by RNA in vitro transcription and td I intron self-cleavage (Chen GY et al., (2017) Sensing Self and Foreign Circular RNAs by Intron Identity; Wesselhoeft AR et al., (2018) Engineering circular RNA for potent and stable translation ineukaryotic cells.), and then purified in vitro by denaturing PAGE to obtain high-purity circPOLR2A ( Figure 4 ).

[0826] Method 3: Circular RNA was successfully prepared by RNA in vitro transcription and Anabaena class I intron cyclization (Wesselhoeft AR et al., (2018) Engineering circular RNA for potent and stable translation ineukaryotic cells.), and then purified in vitro by denaturing PAGE to obtain high-purity circPOLR2A ( Figure 5 ).

[0827] 2. Comparison of the immunogenicity of circPOLR2A obtained by three different methods at the cellular level

[0828] Circular RNA was successfully prepared by the above three cyclization methods, and high-purity circPOLR2A was purified in vitro by denaturing PAGE purification. Then, circPOLR2A (200 ng / well) was introduced into human A549 cells in 12-well plates by liposome transfection. After 1 hour or 6 hours of transfection, the cells were collected and RT-qPCR was performed to detect the expression levels of cytokines IFNβ, TNFα, IL6 and RIG-I.

[0829] The results showed that circPOLR2A prepared and purified by method 1 did not lead to increased expression levels of cytokines IFNβ, TNFα, IL6 and RIG-I compared with double-stranded RNA Poly(I:C), unpurified RNA and linear POLR2A. These data fully demonstrate that circPOLR2A prepared and purified in vitro by method 1 does not cause significant immune response. In contrast, circPOLR2A prepared and purified in vitro by methods 2 and 3 led to increased expression levels of cytokines IFNβ, TNFα, IL6 and RIG-I. These data fully demonstrate that circPOLR2A prepared by methods 2 and 3 will cause enhanced immune response.

[0830] 3. Potential Mechanistic Explanation

[0831] The secondary structures of circular RNA prepared by three methods were predicted. Fig. 9 As shown, the cyclic RNA prepared by method 2 and method 3 retains the additional nucleotide sequence introduced by the cyclization method, and the additionally introduced sequence forms a stable double-stranded stem-loop structure ( Fig. 9 The in-frame part of the sequence is inferred to form a stable double-stranded stem-loop structure. The double-stranded stem-loop structure induces a natural immune response in cells.

[0832] Example 3: Improved class I intron retention looping element

[0833] As mentioned above, 176 nucleotides were additionally introduced and retained in the final circular RNA product by in vitro transcription and self-splicing cyclization of the class I intron of Anabaena pre-tRNA (Wesselhoeft et al., 2018A.R., et al., (2018) Engineering circular RNA for potent and stable translation ineukaryotic cells.). We assume that the potential adverse factors caused by the additional introduction of sequences, especially leading to a certain degree of natural immune response in cells. This embodiment has carried out a series of improved explorations on the self-splicing cyclization of the class I intron of the class I incubator of Anabaena pre-tRNA (named Ana3.0) in Wesselhoeft et al., 2018.

[0834] Shortening the sequence of the retained circular element generated by the Anabaena group I intron in circular RNA maintains efficient circularization efficiency

[0835] The preliminary RNA secondary structure prediction of the retained extra nucleotide sequence by RNAstructure (https: / / rna.urmc.rochester.edu / RNAstructureWeb / index.html) showed that the retained extra nucleotide sequence tended to form a relatively long stem-loop structure. Without changing the overall stem-loop structure, the retained sequence was truncated in a series of ways based on the distance from the splicing site from far to near. Fig.10 ) and detected the effect of truncation on the circularization efficiency of Anabaena class I introns. The truncated versions of the retention sequence retained 99 nucleotides (Ana1.0), 66 nucleotides (Ana0.9), and 27 nucleotides (AnaX). Taking the circular mCherry produced in vitro as an example, the Northern Blot results showed that the circularization efficiency of retaining 27 nucleotides or more was basically the same as that of the original version Ana3.0 ( Fig.10 ). Among them, RNase R is used as a tool enzyme to verify the circular structure of circular RNA. It can effectively degrade linear RNA with exposed ends, but cannot degrade circular RNA.

[0836] 2. Shortened circular RNAs generated by Anabaena group I introns retain low immunity at the cellular level Originality

[0837] To compare the immunogenicity of a series of truncated circular RNAs synthesized by self-splicing of group I introns of Anabaena, circular mCherry with different truncated versions of group I introns of Anabaena was synthesized in vitro, and the purity of the different truncated versions was detected by Northern Blot ( Fig.10). Different truncated versions of circular mCherry RNA and linear mCherry mRNA of the same mass (200ng) were transfected into A549 cells. Six hours after transfection, the cells were collected and Trizol reagent was added to extract the total RNA of the cells according to the instructions, and RT-qPCR was performed to detect the mRNA expression levels of cytokines IFNβ, TNF, IL6 and RIG-I. The results showed that the circular mCherry produced by retaining 27 additional nucleotides of AnaX had lower immunogenicity than other truncated versions of class I introns of Anabaena. In addition, the immunogenicity of different truncated versions of circular mCherry was lower than that of linear mCherry mRNA, which is consistent with the conclusion that circular RNA has lower immunogenicity than linear RNA in Implementation Plan 2. At the same time, the circular mCherry formed by T4 ligase has the lowest immunogenicity ( Fig.10 ). Among them, IFNβ, TNFα, IL6 and RIG-I are commonly used marker genes for intracellular immunogenicity detection, and the positive control Poly(I:C) is a commonly used cellular level long double-stranded RNA virus stimulation analog.

[0838] 3AnaX-circular RNA has a higher translation efficiency than mRNA

[0839] To detect translation efficiency, Lipofectamine MessengerMAX TM (Thermo Fisher) 200ng of linear mCherry mRNA and different amounts (6.25ng-200ng) of circular mCherry RNA containing the retention ring element produced by the AnaX circularization method were introduced into human HEK293FT cells. The red fluorescence signal of the translation product mCherry was detected at different time points using a fluorescence microscope ( Fig.11 ).like Fig.11 As shown, 24 hours after the introduction, the red fluorescence signal of the cells introduced with 200 ng mRNA was similar to that of the cells introduced with 50 ng mCherry ( Fig.11 , red fluorescence quantitative statistical results), indicating that compared with linear mCherry mRNA, AnaX synthesizes circular mCherry with higher intracellular translation efficiency.

[0840] 4AnaX-circular RNA is less immunogenic than mRNA

[0841] To detect the innate immune response induced by linear mRNA transfection into cells, Lipofectamine MessengerMAX TM(Thermo Fisher) 200ng of linear mCherry mRNA and different amounts (6.25ng-200ng) of circular mCherry RNA containing retained circular elements produced by the AnaX circularization method were introduced into human A549 cells. Six hours after transfection, the cells were collected and Trizol reagent was added to extract the total RNA of the cells for RT-qPCR to detect the mRNA expression levels of cytokines IFNβ, TNFα, IL6 and RIG-I. The results showed that the expression levels of the corresponding cytokines in A549 cells transfected with 200ng of linear mCherry mRNA were higher than those in A549 cells transfected with circular RNA produced by AnaX ( Fig.12 ). Moreover, under the premise of basically the same translation efficiency, A549 cells transfected with circular mCherry had almost no increase in the corresponding cytokine levels, indicating that under the same translation efficiency, the circular mCherry produced by AnaX has lower immunogenicity than the linear mCherry mRNA ( Fig.12 ). Among them, IFNβ, TNFα, IL6 and RIG-I are commonly used marker genes for intracellular immunogenicity detection, and the positive control Poly(I:C) is a commonly used long double-stranded RNA virus mimic.

[0842] Example 4: Circularization of RNAs of different lengths using the AnaX system

[0843] To examine the circularization of RNA with different lengths of interest sequences (cargo), various circular RNAs, including EGF, FGF1, RBD, G6PC, PAH, Luciferase, and HGF, were generated in vitro using the AnaX circularization method, and the circularization efficiency was measured on denaturing PAGE gels ( Fig.13 ). The results showed that RNAs of different lengths can be efficiently circularized by the AnaX system. However, as the cargo length increases, the circularization efficiency decreases. RNase R is a tool enzyme for verifying the circular structure of circular RNA. It can effectively degrade linear RNA with exposed ends, but cannot degrade circular RNA.

[0844] To compare the immunogenicity of circular RNAs with different cargo lengths generated by AnaX, 200 ng of the above-produced RNA was transfected into A549 cells, and the same amount of mRNA with the same coding sequence was used as a control. Six hours after transfection, the cells were collected and Trizol reagent was added to extract total RNA from the cells for RT-qPCR to detect the mRNA expression levels of cytokines IFNβ, TNFα, IL6, and RIG-I. Fig.14As shown, circular RNA causes lower immunogenicity than its corresponding linear mRNA with the same coding sequence, which is consistent with the data and conclusions in Example 2. IFNβ, TNFα, IL6 and RIG-I are commonly used marker genes for intracellular immunogenicity detection, and the positive control Poly(I:C) is a commonly used long double-stranded RNA virus stimulus.

[0845] To detect the efficiency of circular RNA and linear RNA in protein translation in cells, Lipofectamine MessengerMAX TM The circular RBD and circular Luciferase synthesized by AnaX and their corresponding mRNAs with the same coding sequence were transfected into HEK293FT cells using RNA transfection reagent (Thermo Fisher). Total cell protein was collected 24 hours later and the protein level of the translated protein was detected by Western Blot. The results showed that the translation efficiency of the circular RNA produced by AnaX was higher than that of the corresponding linear mRNA with the same coding sequence ( Fig.15 ).

[0846] In summary, this series of embodiments demonstrates that the circular RNA produced by AnaX has higher translation efficiency and lower immunogenicity than its corresponding linear RNA. More importantly, compared with the circular RNA produced by Ana3.0 (Wesselhoeft AR et al., (2018) Engineering circular RNA for potent and stable translation ineukaryotic cells.), the circular RNA produced by AnaX retains fewer retained nucleotides and has lower immunogenicity.

[0847] Example 5: Further Improvement of the Retention Circular Element Sequence in the Circular RNA Produced by the AnaX System

[0848] It is pointed out in the literature that the stem-loop pairing region of the exon anticodon region of the natural Anabaena tRNA-Leu class I intron is necessary for the self-splicing reaction of the class I intron (Zaug, AJ et al., (1993). Self-splicing of the group I intron from Anabaena pre-tRNA: requirement for base-pairing of the exons in the anticodon stem. Biochemistry 32(31):7946-7953.). The stem-loop structure formed by the AnaX retention loop element is close to the stem-loop structure of the natural anticodon region of the natural tRNA-Leu, and a reasonable design is generated based on the principle that this structure plays an important role in the self-splicing reaction.

[0849] 1. Interference with the pairing of the stem in the stem-loop structure of the retained looping element can lead to a decrease in the looping efficiency

[0850] There are 5 base pairs (5bp) in the stem-loop structure of the AnaX retention loop element. The mutant AnaXD1 introduced a GA single base mutation in the middle of the pairing region of the first retention loop element at the 3' end, and its corresponding complementing mutant AnaXRD1 introduced a CT mutation at the corresponding position of the second retention loop element at the 5' end; in order to destroy the pairing region of the stem, the 5 bases ACGGA in the pairing region of the first retention loop element at the 3' end were mutated to the complementary UGCCU in AnaXD2; in order to destroy the pairing region of the stem, the 5 bases UCCGU in the pairing region of the second retention loop element at the 5' end were mutated to the complementary AGGCA in AnaXD3. The complementing mutant AnaXD2 also has a complementary mutation to form a paired stem again in the stem-loop structure. According to preliminary RNA secondary structure predictions, the mutations carried by AnaXD1 and AnaXD2 completely destroyed the stem-loop structure of the characteristic element, while AnaXD3 disrupted the original pairing (5 base pairs) to produce a weaker structure with 3 base pairs. The complement mutants AnaXRD1 and AnaXRD2 can restore the stem-loop structure of the retained loop element ( Fig.16A ).

[0851] Taking the cyclization of POLR2A as an example, the precursor RNA was produced by in vitro transcription under buffer conditions with low magnesium ion concentration (5mM MgCl2), and then in self-splicing reaction buffer (50mM Tris-HCl, 10mM MgCl2, 1mM DTT, pH7.5). After incubation at 55°C for a certain period of time, RNA denaturation loading buffer was added to terminate the reaction. Denaturing PAGE shows the change trend of precursors and generated circular RNAs in the self-splicing reaction over time. The circular RNA generated by AnaXD1 and AnaXD3 mutants within 8 minutes of the cyclization reaction was reduced to less than 30% of the AnaX version. AnaXD2 produced almost no circular RNA, while the circular RNA generation efficiency in AnaXRD1 and AnaXRD2 mutants was restored to varying degrees compared with the above three mutants ( Fig.17 ).

[0852] In summary, base pairing of AnaX retention in the stem-loop structure region of the ring-forming element is a necessary condition for the ring-forming reaction to produce circular RNA.

[0853] 2Increasing the number of base pairings in the stem-loop structure of the retained looping element can lead to enhanced looping efficiency

[0854] Mutant AnaXE1 introduced a single base mutation at the side of the first retained loop-forming element at the 3' end away from the splicing site, increasing the base pairing in the stem of the stem-loop structure from 5 to 7 pairs; mutant AnaXE2 introduced a single base mutation at the side of the second retained loop-forming element at the 5' end away from the splicing site, increasing the base pairing in the stem of the stem-loop structure from 5 to 7 pairs; mutant AnaXE3 introduced the above two mutations, increasing the base pairing in the stem of the stem-loop structure to 9 pairs; mutant AnaXE4 introduced two additional nucleotide insertions at the side of the second retained loop-forming element at the 5' end away from the splicing site based on mutant AnaXE1, increasing the base pairing in the stem of the stem-loop structure to 9 pairs; mutant AnaXE5 introduced four additional nucleotide insertions at the side of the second retained loop-forming element at the 5' end away from the splicing site based on mutant AnaXE1, increasing the base pairing in the stem of the stem-loop structure to 11 pairs. AnaXE1, AnaXE4, and AnaXE5 maintained the pairing between the first retained loop element near the splice site and the intron while enhancing the pairing, while AnaXE2 and AnaXE3 disrupted this pairing ( Fig. 16B ).

[0855] Taking the cyclization of POLR2A as an example, the precursor RNA was produced by in vitro transcription under buffer conditions with low magnesium ion concentration (5mM MgCl2), and then in self-splicing reaction buffer (50mM Tris-HCl, 10mM MgCl2, 1mM DTT, pH 7.5). After incubation at 55°C for a certain period of time, RNA denaturation loading buffer was added to terminate the reaction. The results of denaturing PAGE showed the dynamic change trend of the precursor and the generated circular RNA over time in the self-splicing reaction. The circular RNA generation rate of AnaXE1, AnaXE4, and AnaXE5 was significantly higher than that of AnaX, while the circular RNA generation rate of AnaXE2 and AnaXE3 was significantly reduced ( Fig.17 ).

[0856] To further verify that increasing the number of base pairs on the side of the retained looping element away from the splicing site can lead to enhanced looping efficiency, firefly Luciferase RNA with retained looping elements AnaX, AnaXE1 and AnaXE4 was generated by in vitro transcription and further used for looping reactions. The looping efficiency was compared among these retained looping elements. The results of denaturing PAGE gel showed that under the same reaction conditions and the same reaction time, the circular RNA products of AnaXE1 and AnaXE4 were more than those of AnaX ( Fig.19 A, B).

[0857] In summary, increasing the number of complementary base pairs in the stem of the stem-loop structure of the retained loop-forming element can lead to enhanced loop-forming efficiency.

[0858] 3. Replace the paired base sequence of the stem-loop structure of the retained loop element with an artificially designed sequence to enhance the looping efficiency

[0859] The stem stability of the stem-loop structure of the retained loop element may be enhanced by increasing the G / C ratio in the stem of the stem-loop structure. The stem of the AnaXAU mutant contains a large number of AU pairs, and the minimum number of paired bases must be at least 7 to achieve a lower free energy than AnaX ( Fig.18 ). The paired bases in the stem region of mutants AnaXCGv1, AnaXCGv2, and AnaXCGv3 were changed to GC base pairs. AnaXCGv1 has 5 GC base pairs, and AnaXCGv2 and AnaXCGv3 have 7 GC base pairs. The first 3' end retention loop element of AnaXCGv2 is all G, and the first 3' end retention loop element of AnaXCGv1 and AnaXCGv3 is all C ( Fig.18 ).

[0860] Taking the cyclization of Luciferase RNA as an example, the self-splicing reaction was performed after in vitro transcription of the precursor RNA. The results of denaturing PAGE gel showed that the amount of circular RNA product generated by AnaXCGv3 was more than that of AnaX after 2 minutes and 8 minutes of reaction. The amount of circular RNA product generated by AnaXAU was close to that of AnaX. On the denaturing PAGE gel, the amount of circular RNA product generated by AnaXAU and AnaXCGv2 was less than that of AnaX ( Fig.19 A, C). AnaXCGv1 and AnaXCGv3 produced more circular RNA than AnaX, indicating that they led to increased circularization efficiency, while AnaXAU and AnaXCGv2 produced less circular RNA than AnaX, indicating that they led to decreased circularization efficiency ( Fig. 20 ). These data are consistent with the above results.

[0861] The above rational design of the retention ring-forming element was also applied to produce circular mCherry RNA. The results of denaturing PAGE gel showed that the ring-forming efficiency of AnaXAU, AnaXCGv1 and AnaXCGv3 was higher than that of AnaX, while the ring-forming efficiency of AnaXCGv2 was lower than that of AnaX( Fig. 20 ), indicating that the base pair composition of the loop structure of the retention loop element has a significant effect on the looping efficiency. The looping efficiency can also be affected by the length and base composition of the sequence of interest (cargo), but all the data still support that AnaXCGv1 and AnaXCGv3 enhance the looping efficiency.

[0862] In summary, the pairing sequence of the stem of the stem-loop structure of the AnaX retention loop element can be replaced by an artificially designed pairing sequence, and AnaXCGv1 and AnaXCGv3, in which the stem region of the stem-loop structure is entirely G / C paired, lead to enhanced looping efficiency of RNA carrying cargos of different base compositions and lengths.

[0863] Effects of mutated AnaX retention loop elements on the immunogenicity of circular RNA

[0864] To compare the immunogenicity of AnaX and mutants, Luciferase RNA containing AnaX, AnaXE1, AnaXE4, AnaXAU, AnaXCGv1, AnaXCGv2 and AnaXCGv3 were generated by in vitro transcription and circularization. The same mass (100ng) of circular Luciferase containing various retention circularization elements was transfected into human A549 cells. Six hours after transfection, the cells were collected separately, and Trizol reagent was added to extract the total RNA of the cells for RT-qPCR to detect the mRNA expression levels of cytokines IFNβ, TNFα, IL6 and RIG-I. The results showed that the circular Luciferase containing AnaX, AnaXE4 and AnaXCGv3 had lower immunogenicity, causing an average increase in the expression of IFNβ mRNA within 25 times, and an average increase in the expression of RIG-I mRNA within 7 times. The levels of TNFα and IL6 remained at a very low level, without significant changes ( Fig.21 ). IFNβ, TNFα, IL6 and RIG-I are commonly used marker genes for intracellular immunogenicity detection, and the positive control Poly(I:C) is a commonly used long double-stranded RNA virus stimulus.

[0865] Effects of mutations in the AnaX retention ring-forming element on circular RNA translation efficiency

[0866] To compare the translation efficiency of in vitro synthesized circular RNAs with AnaX retention ring-forming elements or mutated AnaX retention ring-forming elements, Luciferase RNA was generated by in vitro transcription and further subjected to ring-forming reactions. The translation of circular Luciferase RNAs with AnaX, AnaXE1, AnaXE4, AnaXAU, AnaXCGv1, AnaXCGv2, and AnaXCGv3 retention ring-forming elements was detected in HEK293FT cells. The same mass (200 ng) of in vitro circularized circular Luciferase was transfected into human 293FT cells. After 24 hours, the cells were collected and total protein samples were extracted. Western Blot results showed that the expression level of Luciferase protein of AnaXCGv1 was lower than that of AnaX, the expression levels of Luciferase protein of AnaXCGv2 and AnaXCGv3 were higher than that of AnaX, and the expression levels of Luciferase protein of AnaXE1, AnaXE4, and AnaXAU were close to that of AnaX ( Fig. 22A). Actin protein was used as an internal reference for Western Blot. In addition, the luciferase activity was measured by adding the corresponding substrate to generate a luminescent signal. The luminescent signal reflects the expression level of luciferase in the cell. The results showed that the luminescent signals of the circular Luciferase containing AnaXE4 and AnaX retention ring elements were similar. The luminescent signal intensity of AnaXCGv3 circular Luciferase was higher than that of AnaX, and the luminescent signal intensity of other constructs was significantly lower than that of AnaX ( Fig. 22 B).

[0867] In summary, the neck loop structure formed by the retained looping elements of circular RNA, namely AnaX and mutations, are crucial for high cyclization efficiency. Preserving the conformation of the loop structure, increasing the number of stem base pairings or strengthening the stem base pairing (i.e., G / C base pairs relative to A / T base pairs) can significantly improve the cyclization efficiency. In addition, these retained looping elements also lead to increased translation efficiency and reduced cellular immunogenicity.

[0868] 6 Changing the specific sequence of the loop in the stem-loop structure of the retention loop element can inhibit loop formation

[0869] The first retention loop element of the Anabaena group I intron, three nucleotides adjacent to the splice site, and the internal guide sequence (IGS) form the P1 double-stranded region of the ribozyme and determine the 5' splice site. The second retention loop element and several bases adjacent to the splice site participate in the formation of the P10 double-stranded region of the ribozyme and determine the 3' splice site. These two parts of the sequence form the loop region in the stem-loop structure of the retention loop element. In order to explore the effect of the loop region in the stem-loop structure of the retention loop element on RNA looping, different mutants (AnaXD5-AnaXD14) were designed for the loop region to determine the effect on the looping efficiency. Mutant AnaXD 5 changes AAAA to UUUU in the loop region of the stem-loop structure of the second retention loop-forming element; mutant AnaXD 6 changes CUU to CAA in the loop region of the stem-loop structure of the first retention loop-forming element; mutant AnaXD 7 truncates AAAA to AA in the loop region of the second retention loop-forming element; mutant AnaXD 8 completely removes AAAA in the loop region of the second retention loop-forming element; mutant AnaXD 9 changes AAAA to GAAA in the loop region of the second retention loop-forming element; mutant AnaXD 10 changes AAAA to UAAA in the loop region of the second retention loop-forming element; mutant AnaXD 11 changes AAAA to CAAA in the loop region of the second retention loop-forming element; mutant AnaXD 12 changes CUU to CUC in the loop region of the first retention loop-forming element; mutant AnaXD 13 is to change CUU to CUA in the first characteristic element loop region; mutant AnaXD 14 is to change CUU to CUG in the first retention loop element loop region ( Fig.23 A).

[0870] Taking the cyclization of POLR2A as an example, if the loop of the stem-loop structure in the AnaX P1 region is destroyed in mutants AnaXD 6, AnaXD 13 and AnaXD14, the RNA cannot form a loop. In mutant AnaXD12, the CUU in the loop region of the first retained looping element is changed to CUC, so that the GU pairing at the stem-loop of the AnaX system P1 is converted to GC pairing, thus maintaining the original conformation and not affecting the looping. Mutants AnaXD 5, AnaXD 7, AnaXD9, AnaXD10 and AnaXD11 respectively change or truncate the bases in the loop region of the second retained looping element, and still retain the looping efficiency. However, completely removing all bases in the loop region of the second retained looping element (mutant AnaXD8) can significantly reduce the looping efficiency ( Fig.23 B, C).

[0871] In summary, the P1 structure destroyed by mutation in the loop region of the first retained looping element will lead to the loss of RNA looping ability. The nucleotides in the loop region of the second retained looping element act as linkers. Mutation or truncation does not affect looping, but the nucleotides in the loop region cannot be completely deleted.

[0872] Example 6: Effect of the stem length of the AnaX retention loop element on loop formation

[0873] This example explores the minimum number of base pairing required for the AnaX retention loop element stem-loop structure stem region to form a loop. The loop structure of the stem-loop region near the splice site retains a series of truncations that change the retention loop element to 17, 15, 13 and 11 nucleotides and the stem base pairs to 5, 4, 3, and 2 base pairs. The truncations are named AnaXv1, AnaXv2, AnaXv3, and AnaXv4. Taking the cyclization of mCherry RNA as an example, the above truncated versions all retain the ability to form a loop ( Fig.24 ). It is worth noting that the 5' and 3' ends of the sequence of interest form a structure with 3 base pairs, which may compensate for the truncation of the stem of the retained loop element. The above results indicate that retaining the loop conformation in the stem-loop structure and minimizing the number of base pairs in the stem can still retain the loop-forming ability of AnaX.

[0874] Example 7: Modification of the homology arm sequence outside the self-splicing intron fragment of the AnaX system

[0875] like Fig.25As shown in the figure, as the length of the sequence of interest (cargo) increases, the looping efficiency of the AnaX system decreases. In order to improve the looping efficiency of larger RNA cargo, we modified the homology arm sequence outside the intron fragment of the AnaX system, including 1) increasing the length of the homology arm sequence; 2) replacing the random sequence of the homology arm with an AU base pairing sequence; 3) replacing the random sequence of the homology arm with a UA base pairing sequence; 4) replacing the random sequence of the homology arm with an AU base pairing sequence and increasing the number of base pairs; 5) replacing the random sequence of the homology arm with a UA base pairing sequence and increasing the number of base pairs; 6) replacing the random sequence of the homology arm with a CG base pairing sequence; 7) replacing the random sequence of the homology arm with a GC base pairing sequence and increasing the number of base pairs; 8) replacing the random sequence of the homology arm with a CG base pairing sequence and increasing the number of base pairs; 9) removing the homology arm sequence ( Fig.25 ).

[0876] In order to detect the effect of the modified homology arm sequence outside the intron fragment on the circularization efficiency of the AnaX system, the circularization of luciferase RNA was taken as an example, and the circularization efficiency was detected using denaturing PAGE gel. The results showed that increasing the length of the random base pairing sequence of the homology arm significantly improved the circularization efficiency of RNA. However, when the homology arm sequence was changed to AU / UA pairing, there was no obvious effect on the RNA circularization efficiency. On the contrary, increasing the number of AU / UA pairings will reduce the RNA circularization efficiency. When the homology arm sequence was changed to GC / CG pairing, it would affect the in vitro transcription efficiency and also significantly inhibit the RNA circularization efficiency ( Fig.26 ).

[0877] In summary, increasing the length of the homology arm sequence outside the intron fragment can significantly improve the efficiency of AnaX-catalyzed intron circularization. However, the homology arm sequence outside is paired with poly-GC, which will seriously affect the in vitro transcription efficiency and thus reduce the amount of circular RNA produced.

[0878] Example 8: Improvement of the looping efficiency and retention of looping elements in Azoarcus class I introns

[0879] To further verify the importance of the stem-loop in the retained loop-forming element for the circularization of class I introns, we tested the circularization efficiency of another wild-type Azoarcus class I intron. The sequence of the retained loop-forming element was mutated to verify the effect on its circularization efficiency. Taking circular POLR2A as an example, the results of denaturing PAGE gel showed that the wild-type Azoarcus class I intron can form a loop and produce circular RNA, but its circularization efficiency is lower than that of the improved AnaX. However, changing the nucleotides in the stem region of the stem-loop of the Azoarcus class I intron retained loop-forming element, that is, changing the original AU pairing to GC pairing, enhances the stability of the stem structure and significantly improves the circularization efficiency of the Azoarcus class I intron ( Fig. 27 The above results indicate that the stem-loop structure in class I intron retention looping elements plays an important role in its looping, and improving the stability of the stem structure can promote the looping efficiency.

[0880] Example 9: In the AnaX system, IRES can be located downstream of the protein coding sequence

[0881] To detect the effect of IRES downstream of protein coding sequences on circular RNA protein translation, taking Luciferase as an example, we placed IRES (CVB3) upstream or downstream of the Luciferase coding sequence in the AnaX, Ana0.9, Ana1.0 and Ana3.0 systems, respectively. Denaturing PAGE gel results showed that IRES could form a circle with similar efficiency whether it was upstream or downstream of the protein coding region. Subsequently, circular Luciferases from different Azoarcus class I introns were purified by denaturing PAGE gel excision. Using Lipofectamine MessengerMAX TM RNA transfection reagent was used to introduce an equal amount (200 ng) of circular Luciferase RNA into human HEK293FT cells. The intensity of the reaction between luciferase protein and substrate was used to reflect the expression level of luciferase protein, that is, the translation efficiency. The results showed that in the AnaX, Ana0.9 and Ana1.0 systems, IRES did not affect protein translation upstream or downstream of the protein coding region. However, for Ana3.0, IRES downstream of the protein coding sequence can significantly affect protein translation. It may be that the strong structure formed by the retained ring element in Ana3.0 hinders the rate of ribosome movement ( Fig.28 ), thus, leading to low protein translation efficiency.

[0882] Example 10: Improvement of the circular RNA preparation method

[0883] This example demonstrates that the improved circular RNA preparation method can effectively synthesize circular RNA mCherry in vitro through in vitro transcription and subsequent AnaX self-splicing method, and the circular RNA prepared by this method can be correctly translated into protein ( Fig.29 ).

[0884] Taking in vitro synthesized circular RNA mCherry as an example, circular mCherry is prepared by in vitro transcription and AnaX self-splicing. The improved circular RNA preparation method specifically includes the following steps:

[0885] 1. Plasmid construction and in vitro transcription: The circular RNA mCherry template was obtained by PCR. The linear full sequence with T7 promoter at the 5' end was inserted into the pUT7 vector through the multiple cloning site, and the recombinant plasmid was verified by Sanger sequencing.

[0886] 2. Take 1 μg of the PCR-amplified linear template sequence with a T7 promoter at the 5' end, and incubate it with 2 μl of T7 RNA polymerase (Promega), rATP, rCTP, rUTP, rGTP (1 mM each) and a buffer containing 20 mM Mg2+ at 37°C for 3.5 hours to obtain a linear precursor RNA containing a class I intron self-splicing sequence of Anabaena at the 5' and 3' ends and a mixed initial RNA product of circular mCherry after self-splicing.

[0887] 3. After analyzing the circular RNA, purify it by denaturing PAGE gel.

[0888] To detect the cyclization efficiency of the improved circular RNA preparation method, taking mCherry RNA as an example, we used denaturing PAGE gel to analyze the mCherry RNA primary product obtained by the improved circular RNA preparation method or the mCherry RNA primary product obtained by the original cyclization method. The results showed that the cyclization efficiency of the circular RNA obtained by the improved circular RNA preparation method (25.5%) was basically the same as that of the original method (27.9%).

[0889] To further test the translation efficiency of circular RNA prepared by the improved method described above, Lipofectamine MessengerMAX TM (Thermo Fisher) RNA transfection reagent was used to introduce 200 ng of circular mCherry prepared by the improved method into human HEK293FT cells. The red fluorescence signal of mCherry protein was detected by fluorescence imaging microscopy ( Fig.29), confirming the translation level of the circular mCherry prepared by the improved method. The results showed that the circular mCherry prepared by the improved method can translate red fluorescent protein in cells, and the efficiency of translating red fluorescent protein is similar to that of the original method.

[0890] In summary, the improved circular RNA preparation method is more convenient than the original method while maintaining the same circularization efficiency. The improved method has obvious application prospects in large-scale preparation of circular RNA.

[0891] Example 11: Improved in vitro transcription conditions effectively improve circularization efficiency

[0892] This example demonstrates that improving in vitro transcription conditions can effectively increase total RNA yield and RNA circularization efficiency.

[0893] 1. Increasing magnesium ion concentration can promote in vitro transcription efficiency and looping ability

[0894] To further optimize the circularization efficiency, taking the circular mCherry produced by the AnaX system as an example, after incubation at 37°C for 3.5 hours in vitro transcription (IVT), a gradient of Mg was added to the IVT product. 2+ (0-500 mM) and incubated at 37°C for 0.5 h. The total RNA yield and RNA circularization efficiency were analyzed by native agarose gel and denaturing PAGE. The results showed that the total RNA yield was related to the additional addition of Mg. 2+ The concentration is positively correlated ( Fig.30 In addition, the circular mCherry and the corresponding linear precursor RNA also increased significantly ( Fig.30 In addition, two other circular RNAs with different sequences, circular HGF and EGF, produced the same results and confirmed that in Mg 2+ As the concentration gradually increased, the total RNA yield, circular RNA yield and circularization efficiency increased significantly.

[0895] In summary, by increasing Mg 2+ The concentration not only increased the total RNA yield, but also increased the circular RNA formation efficiency.

[0896] 2. Monovalent metal cations can promote in vitro transcription efficiency and increase the total yield of circular RNA

[0897] To further optimize the efficiency of in vitro transcription and circularization, taking the circular Luciferase RNA produced by AnaX as an example, additional sodium ions (Na + ) or potassium ion (K +), and the effect on RNA in vitro transcription and circularization efficiency was detected using natural agarose gel. The results showed that as Na + As the concentration increases, the total RNA yield of in vitro transcription gradually increases. + When the concentration reached 15 mM, the total RNA yield reached a plateau. + The increase in concentration did not affect the circularization efficiency of Luciferase RNA, but the total yield of circular Luciferase RNA increased significantly ( Fig.32 ). with Na + Same, add extra K + It can promote in vitro transcription efficiency without affecting RNA circularization. + When the concentration reaches 90mM, the in vitro transcription efficiency reaches a plateau ( Fig.33 ). The above results show that monovalent metal cations, such as Na + and K + It can promote in vitro transcription efficiency without affecting RNA circularization, thereby increasing the total yield of circular RNA.

[0898] 3. Monovalent anions can promote in vitro transcription efficiency and increase the total yield of circular RNA

[0899] To further optimize the efficiency of in vitro transcription and circularization, taking the circular Luciferase RNA produced by AnaX as an example, additional chloride ions (Cl - ) or acetate ion (OAc - ), and the effect on in vitro transcription and circularization efficiency was detected using natural agarose gel. The results showed that with the increase of Cl - As the concentration increases, the total RNA yield of in vitro transcription gradually increases. - When the concentration reached 90 mM, the total RNA yield reached a plateau. - The increase in concentration did not affect the circularization efficiency of Luciferase RNA, but the total yield of circular Luciferase RNA increased significantly ( Fig.33 ). - Same, add extra OAc - Can promote in vitro transcription efficiency without affecting RNA circularization ( Fig.33 and Fig.34 ). The above results show that monovalent anions, such as Cl - and OAc - It can promote in vitro transcription efficiency without affecting RNA circularization, thereby increasing the total yield of circular RNA.

[0900] 4. Effect of in vitro transcription temperature on RNA transcription and circularization

[0901] Literature reports that 55°C is a suitable temperature for RNA circularization. Therefore, in order to further simplify the RNA circularization step, we explored whether increasing the temperature of RNA in vitro transcription has a positive effect on improving the circularization efficiency. Taking the circular Luciferase RNA produced by AnaX as an example, we used the thermostable T7 polymerase to perform in vitro transcription and subsequent circularization reactions at different temperatures, and used natural agarose gel to detect the total RNA yield and circularization efficiency of the Luciferase RNA produced by in vitro transcription. The results showed that compared with the universal temperature of 37°C, in vitro transcription can be performed at high temperatures of 50°C and 55°C, but the transcription efficiency is significantly reduced, and it does not play a role in promoting the RNA circularization efficiency ( Fig.35 ). The above results indicate that performing in vitro transcription and cyclization reaction at a temperature suitable for RNA cyclization does not improve the RNA cyclization efficiency, but inhibits the RNA in vitro transcription efficiency.

[0902] 5. Effect of in vitro transcription time on RNA transcription and circularization

[0903] In order to detect the effect of in vitro transcription time on in vitro transcription and cyclization efficiency, circular Luciferase and circular IL2 RNA were used as examples to compare the in vitro transcription efficiency and cyclization efficiency at different time points using native agarose gel electrophoresis. The results showed that as the in vitro transcription time increased, the cyclization efficiency of circular Luciferase and circular IL2 was proportional to the in vitro transcription time, but the transcription yield of circular Luciferase and circular IL2 was optimal at 5-7.5 hours ( Fig.36 ). Too long a transcription may cause RNA degradation and result in a significant decrease in RNA transcription yield. The above results show that extending the in vitro transcription time to a certain extent can promote RNA cyclization and obtain high-yield RNA, but too long in vitro transcription may cause RNA degradation and reduce the total RNA yield.

[0904] 6. Effect of in vitro transcription buffer on RNA transcription and circularization

[0905] In order to detect the effects of different buffers on in vitro transcription and circularization efficiency, the circular Luciferase RNA produced by AnaX was taken as an example. During the in vitro transcription process, HEPES and Tris-HCl buffers were used for in vitro transcription and subsequent circularization reactions, respectively. The effects of different buffers on in vitro transcription and circularization efficiency were compared using natural agarose gel. The results showed that the HEPES and Tris-HCl buffer systems had the same in vitro transcription efficiency. However, during the in vitro transcription process, the circular Luciferase could achieve a higher circularization rate in the HEPES buffer system compared with the Tris-HCl buffer. The above results show that the HEPES and Tris-HCl buffer systems do not affect the in vitro transcription efficiency, but the HEPES buffer is more conducive to circularization during in vitro transcription ( Fig.37 ).

[0906] Example 12: Improved cyclization conditions effectively improve cyclization efficiency

[0907] This example demonstrates that improving the cyclization conditions during the preparation of circular RNA can improve the cyclization efficiency.

[0908] 1. Divalent metal ions can promote cyclization efficiency

[0909] To further optimize the circularization efficiency, taking the circular Luciferase RNA produced by AnaX as an example, in the circularization step, the manganese ion (Mn) with a gradient concentration (0-50 mM) was detected. 2+ ) and incubated for 15 min to detect the efficiency of RNA products obtained by the "one-step method". The corresponding circularization efficiency was analyzed by native agarose gel. The results are shown in Fig.38 As shown in the figure, increasing the manganese ion concentration within a certain range can effectively improve the RNA cyclization efficiency. 2+ The best effect was achieved at a concentration of 20 mM. When the concentration exceeded 20 mM, the cyclization efficiency could not be further improved. 2+ It can promote the splicing of class I introns and improve the efficiency of circularization. 2+ The optimal concentration is 20 mM.

[0910] 2. Effect of reaction temperature and reaction time on cyclization efficiency

[0911] To explore the effect of reaction temperature and time on cyclization efficiency, the circular Luciferase RNA produced by AnaX was used as an example. Different temperatures (35°C-60°C) and times (15-60 min) were tested in the cyclization step. The corresponding cyclization efficiency was analyzed by native agarose gel. The results are shown in Figure 2. Fig.39As shown in the figure, as the temperature increases, the cyclization efficiency gradually increases and begins to reach a plateau at 50°C. When the temperature reaches 60°C, the cyclization efficiency begins to decrease. Different reaction times do not show significant differences in the cyclization efficiency, that is, 15-30 minutes is enough for the cyclization reaction to occur completely. The above results show that 50°C-60°C is the optimal temperature for the cyclization reaction, and the reaction time is not the main factor affecting the cyclization efficiency.

[0912] 3. Effects of buffer and pH on cyclization efficiency

[0913] In order to detect the effects of different buffers and pH on the cyclization efficiency, taking circular OTC RNA as an example, HEPES and MES buffers with different pH (5.5-7.5) were tested during the cyclization process. The effects of different buffers and different pH on the cyclization efficiency were analyzed using natural agarose gel and denaturing PAGE gel. The results showed that the HEPES and MES buffer systems had similar in vitro transcription efficiencies above pH 6.0, but at pH 5.5, the cyclization efficiency was significantly reduced. The above results show that under conditions above pH 6.0, both HEPES and MES buffers are suitable for in vitro cyclization, but low pH is not suitable for cyclization ( Fig.40 ).

[0914] Example 13: A novel circular RNA purification method can effectively enrich circular RNA

[0915] This example demonstrates that the novel circular RNA purification method can effectively remove linear precursor RNA and intron-spliced ​​RNA, and enrich and purify circular RNA synthesized in vitro by class I self-splicing introns.

[0916] Taking circular mCherry RNA as an example, circular mCherry is prepared by in vitro transcription and further circularization using an AnaX self-splicing intron with 27 nucleotides as a retention ring element. The RNA primary product prepared by this circularization method contains circular mCherry in the process of self-splicing and circularization as well as a series of linear precursor RNAs and intron-cleaved RNAs. In order to effectively enrich and purify circular mCherry from the RNA primary product, the linear precursor RNA and intron-cleaved RNA are removed, and a base-complementary paired DNA probe is designed to remove the linear precursor RNA and intron-cleaved RNA. The strategy of this purification method is different from the purification strategy of the prior art. This method uses a complementary paired DNA probe that specifically binds only to linear precursor RNA and intron-cleaved RNA, and uses streptavidin magnetic beads to bind the DNA probe to specifically remove linear precursor RNA and intron-cleaved RNA. Subsequently, the base-complementary paired DNA probe that specifically targets the retention ring element of circular RNA is co-incubated with the RNA sample and enriched with streptavidin magnetic beads. Finally, the circular RNA is eluted with an elution buffer to achieve the purpose of enriching and purifying the circular RNA.

[0917] DNA probes with complementary base pairing were designed for the introns in the linear precursor RNA and the retained looping elements in the circular RNA, respectively, and were named Ligand-Intron (SEQ ID NO: 94) and Ligand-Feature (SEQ ID NO: 95). The probes were synthesized by Shanghai Sangon Biotech Co., Ltd. and modified with biotin. 20 μg of the initial circular mCherry RNA product was added to a 1.5 ml centrifuge tube without RNase, and 5 μL (100 mM) of the above biotin-modified Ligand-Intron probe (the molar ratio of DNA probe to target RNA was 10 0 ~10 5:1), incubate at 68°C for 10 minutes, then cool naturally at room temperature (~25°C) to anneal, so that the biotin-modified DNA probe can effectively bind to the target precursor RNA and the RNA sheared from the intron. Take 200 μL of streptavidin magnetic beads (1 mg of magnetic beads can bind 200 pmol of biotin-modified DNA probe) and add them to the above mixture, place it on a rotating shaker at room temperature (~25°C) and incubate for 15 minutes. After the incubation is completed, collect the supernatant. The supernatant is then placed in a new RNase-free centrifuge tube and collected as the flow-through component. The streptavidin magnetic beads were washed three times with BW buffer (5 mM Tris-HCl, 0.5 mM EDTA, 1 M NaCl, 0.01% Tween-20), 100 μL of RNase-free double-distilled water was added to the tube, and then the tube was placed in a 68°C water bath for 2 minutes to elute and collect the eluate (the three eluates were named E1, E2 and E3, respectively).

[0918] After using the Ligand-Intron probe to remove the precursor RNA and intron-cleaved RNA, take the flow-through component collected above to further enrich and purify the circular RNA. Add 5μL (100mM) of biotin-modified Ligand-Feature probe to the flow-through component above, incubate at 68°C for 10 minutes, and then cool naturally at room temperature (~25°C) to allow the biotin-modified DNA probe to effectively bind to the target circular RNA. Take 200μL of streptavidin magnetic beads and add them to the mixed solution, place on a rotating shaker and incubate at room temperature (~25°C) for 15 minutes. After incubation, collect the supernatant and place it in a new RNase-free centrifuge tube as the flow-through component. The streptavidin magnetic beads were washed three times with BW buffer (5 mM Tris-HCl, 0.5 mM EDTA, 1 M NaCl, 0.01% Tween-20), 100 μL of RNase-free double distilled water was added to the tube, and then the tube was placed in a 68° C. water bath for 2 minutes to collect the eluate as the elution fraction (the two eluates were named E1 and E2, respectively).

[0919] In order to detect the purification efficiency of the new circular RNA purification method, the initial product (Input) of the circular RNA preparation, as well as the flow-through fraction and elution fraction after different probe enrichment and elution were collected and analyzed using denaturing PAGE gel. Fig.41As shown, the Ligand-Intron probe can effectively bind to and remove the linear precursor RNA and intron-cleaved RNA in the initial product of circular RNA, thereby improving the efficiency of the Ligand-Feature probe in specifically enriching and purifying circular mCherry.

[0920] In summary, the novel circular RNA purification method described above can effectively remove linear precursor RNA and intron-cleaved RNA, thereby achieving the enrichment and purification of circular RNA.

[0921] Example 14: Effect of probes of different lengths on circular RNA purification efficiency

[0922] As mentioned above, the Ligand-Intron probe can effectively bind to and remove the linear precursor RNA and intron-cut RNA mixed in the initial product of circular RNA, while the Ligand-Feature probe can specifically enrich and purify circular RNA. In order to further explore the length of probes that effectively purify circular RNA, probes of different lengths containing biotin tags for purifying circular RNA were designed and synthesized (Ligand-F10, SEQ ID NO: 96; Ligand-F20, SEQ ID NO: 97; Ligand-F23, SEQ ID NO: 98; Ligand-F25, SEQ ID NO: 99; Ligand-F27, SEQ ID NO: 100; Ligand-F29, SEQID NO: 101). Using the aforementioned probes of different lengths, taking circular mCherry as an example, the efficiency of these probes in purifying circular RNA was tested.

[0923] First, the effects of three probes (Ligand-F10, Ligand-F20, and Ligand-F27) on circular RNA enrichment were detected. The experimental procedure is as follows: 20 μg of the initial circular mCherry product was added to an RNase-free 1.5 ml centrifuge tube, and 5 μL (100 mM) of the above biotin-modified DNA probe was added. After the tube was heated to 68°C and incubated for 10 minutes, it was placed at room temperature (~25°C) and cooled naturally to allow the biotin-modified DNA probe to effectively bind to the target circular RNA. 200 μL of streptavidin magnetic beads were added to the above mixture and placed on a rotating shaker at room temperature (~25°C) for incubation for 15 minutes. After incubation, the supernatant was collected and transferred to a new RNase-free centrifuge tube as the flow-through component. The streptavidin magnetic beads were washed three times with BW buffer (5mM Tris-HCl, 0.5mM EDTA, 1M NaCl, 0.01% Tween-20), 100μL of RNase-free double distilled water was added to the mixture, and then the tube was placed in a 68°C water bath for 2 minutes to collect the elution fractions (the two eluates were named E1 and E2, respectively). The collected circular RNA was used to prepare the initial product (Input), flow-through fraction, and elution fraction, and analyzed by denaturing PAGE gel electrophoresis. The results are shown in Figure 2. Fig.42 As shown in the figure, the two probes Ligand-F-20 and Ligand-F-27 can specifically enrich and purify circular mCherry, but the shorter Ligand-F-10 cannot effectively enrich circular RNA. In addition, Ligand-F-27 has a stronger efficiency in enriching circular RNA than Ligand-F-20, but its enriched and purified products also contain a certain amount of linear precursor RNA and sheared RNA.

[0924] The efficiency of circular RNA purification by probe length (Ligand-F23, Ligand-F25, Ligand-F27 and Ligand-F29) was further tested. T...

Claims

1. A circular RNA precursor comprising the following elements arranged in the following order from 5' to 3' direction: a) 3' self-splicing intron fragment; b) a first retention loop element; c) a nucleotide sequence of interest; d) a second retention loop-forming element; and e) 5' self-splicing intron fragment; wherein the circular RNA precursor is capable of generating a circular RNA comprising the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element by self-splicing thereof, The total length of the first retention loop-forming element and the second retention loop-forming element is about 5 to about 100 nucleotides.

2. The circular RNA precursor of claim 1, wherein the self-splicing intron is selected from a class I intron and a class II intron, for example, the self-splicing intron is a class I intron.

3. The circular RNA precursor of claim 1 or 2, wherein the self-splicing intron is selected from the IC3 subclass of class I introns.

4. The circular RNA precursor of any one of claims 1 to 3, wherein the self-splicing intron is selected from the group I introns of the cyanobacteria Anabaena, the group I introns of T4 phage, or the group I introns of Azoarcus sp. BH72, for example, the self-splicing intron is the group I intron of the cyanobacteria Anabaena.

5. The circular RNA precursor of any one of claims 1 to 4, wherein the self-splicing intron is selected from the group consisting of the class I intron of the Anabaena pre-tRNA-Leu gene, the class I intron of the T4 phage td gene, or the class I intron of the Azoarcus sp. BH72 pre-tRNA-Leu gene, for example, the self-splicing intron is the class I intron of the Anabaena pre-tRNA-Leu gene.

6. The circular RNA precursor of any one of claims 1 to 5, wherein the 3' self-splicing intron fragment is derived from the 3' end portion of a natural self-splicing intron, i.e., the portion from the internal division site to the 3' end of the natural self-splicing intron, and wherein the 5' self-splicing intron fragment is derived from the 5' end portion of a natural self-splicing intron, i.e., the portion from the internal division site to the 5' end of the natural self-splicing intron, and the combination of the 3' self-splicing intron fragment and the 5' self-splicing intron fragment retains the self-splicing activity of the natural self-splicing intron.

7. The circular RNA precursor of claim 6, wherein the internal segmentation site is located in the P6, P2, P5, P8 or P9 region of a class I intron, or the D4 region of a class II intron, preferably, the internal segmentation site is located in the P6 region of a class I intron.

8. The circular RNA precursor of claim 6 or 7, wherein the 3' self-splicing intron fragment has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity with the 3' end portion of a natural self-splicing intron, and the 5' self-splicing intron fragment has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity with the 5' end portion of a natural self-splicing intron.

9. The circular RNA precursor of any one of claims 1 to 8, wherein the self-splicing intron is a class I intron of an Anabaena pre-tRNA-Leu gene, and the 3' self-splicing intron fragment comprises, or consists of, the nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 100% identical to SEQ ID NO: 1; and the 5' self-splicing intron fragment comprises, or consists of the nucleotide sequence of SEQ ID NO: 2, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 100% identical to SEQ ID NO:

2.

10. The circular RNA precursor of any one of claims 1 to 8, wherein the self-splicing intron is a class I intron of the T4 phage td gene, and the 3' self-splicing intron fragment comprises, or consists of, the nucleotide sequence of SEQ ID NO:5, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO:5; and the 5' self-splicing intron fragment comprises, or consists of the nucleotide sequence of SEQ ID NO:6, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO:

6.

11. The circular RNA precursor of any one of claims 1 to 8, wherein the self-splicing intron is a class I intron of the Azoarcus sp. BH72 pre-tRNA-Leu gene, and the 3' self-splicing intron fragment comprises, or consists of, the nucleotide sequence of SEQ ID NO: 3, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 3; and the 5' self-splicing intron fragment comprises, or consists of the nucleotide sequence of SEQ ID NO: 4, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO:

4.

12. The circular RNA precursor of any one of claims 1 to 11, wherein the first retention loop-forming element and the second retention loop-forming element cause the circular RNA comprising them to have reduced immunogenicity relative to a control RNA, such as a control circular RNA comprising loop-forming elements of SEQ ID NO: 29 and SEQ ID NO: 64, or a control linear RNA comprising the same nucleotide sequence of interest.

13. The circular RNA precursor of any one of claims 1 to 12, wherein the first and second retention loop-forming elements cause the circular RNA or circular RNA precursor comprising them to have a comparable or increased looping efficiency relative to a control circular RNA or circular RNA precursor, such as a control circular RNA or circular RNA precursor comprising the first and second retention loop-forming elements of SEQ ID NO: 29 and SEQ ID NO: 64 (Ana3.0), respectively.

14. The circular RNA precursor of any one of claims 1-13, wherein the first retention loop-forming element and the second retention loop-forming element have a total length of about 20 to about 35 nucleotides.

15. The circular RNA precursor of any one of claims 1 to 14, wherein the first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure, for example, to achieve circularization after self-splicing.

16. The circular RNA precursor of claim 15, wherein the loop of the stem-loop structure comprises a splicing junction.

17. The circular RNA precursor of any one of claims 15-16, wherein the first retention loop-forming element comprises a sequence structure described in the following formula: 5'-first loop sequence-first paired sequence-first non-paired sequence-3'; and the second retention loop-forming element comprises a sequence structure described in the following formula: 5'-second non-paired sequence-second paired sequence-second loop sequence-3', wherein the first non-pairing sequence or the second non-pairing sequence may be present or absent independently, The first pairing sequence and the second pairing sequence can complementarily pair to form a stem of the stem-loop structure, wherein the first loop sequence and the second loop sequence can form a loop of the stem-loop structure, for example, by self-splicing to perform circularization.

18. The circular RNA precursor of claim 17, wherein the first loop sequence comprises or consists of one or more nucleotides that can pair with the P1 region corresponding to the self-splicing intron to form the P10 double-stranded region during cyclization.

19. The circular RNA precursor of claim 17 or 18, wherein the first loop sequence consists of a (N)n nucleotide sequence, wherein N represents any nucleotide (A, G, U or C), and n represents an integer between 1 and 20, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

20. The circular RNA precursor of any one of claims 17 to 19, wherein the first loop sequence comprises or consists of AAAA, AA, UUUU, CAAA or GAAA, preferably AAAA.

21. The circular RNA precursor of any one of claims 17 to 20, wherein the second loop sequence comprises or consists of one or more nucleotides that can pair with an internal guide sequence (IGS) corresponding to a self-splicing intron to form a P1 double-stranded region during cyclization.

22. The circular RNA precursor of any one of claims 17 to 21, wherein the second loop sequence comprises CUU or CUC, preferably CUU.

23. The circular RNA precursor of any one of claims 17 to 22, wherein the loop of the stem-loop structure has a CUUAAAA, CUUUUUU, CUUAA, CUUGAAA, CUUUAAA, CUUCAAA or CUCAAAA sequence, preferably CUUAAAA.

24. The circular RNA precursor of any one of claims 17-23, wherein the stem portion in the stem-loop structure comprises 2-15 or more consecutive base pairs. Preferably, the stem portion in the stem-loop structure comprises 5, 6 or 7 consecutive base pairs.

25. The circular RNA precursor of any one of claims 17-24, wherein the stem portion in the stem-loop structure comprises at most 2 base mismatches, or the stem portion comprises only 1 base mismatch, preferably, the stem portion does not comprise a base mismatch.

26. The circular RNA precursor of any one of claims 17-25, wherein the first pairing sequence comprises only G and the second pairing sequence comprises only C.

27. The circular RNA precursor of any one of claims 17-25, wherein the first pairing sequence comprises only C and the second pairing sequence comprises only G.

28. The circular RNA precursor of any one of claims 17-25, wherein the first pairing sequence comprises only A and the second pairing sequence comprises only U.

29. The circular RNA precursor of any one of claims 17 to 25, wherein the first paired sequence comprises or consists of any one of SEQ ID NOs: 42 to 55, and the second paired sequence comprises or consists of any one of SEQ ID NOs: 78 to 93.

30. The circular RNA precursor of any one of claims 15-29, wherein the predicted free energy of the stem-loop structure is less than about -1 kal / mol, less than about -2 kal / mol, less than about -3 kal / mol, less than about -4 kal / mol, less than about -5 kal / mol, less than about -6 kal / mol, less than about -7 kal / mol, less than about -8 kal / mol, less than about -9 kal / mol, less than about -10 kal / mol, or less.

31. The circular RNA precursor of any one of claims 1 to 30, wherein the first retention loop-forming element comprises, or consists of, a 3' exon region from the 5' to 3' direction and an optional first spacer; the second retention loop-forming element comprises, or consists of, a 5' exon region from the 3' to 5' direction and an optional second spacer.

32. The circular RNA precursor of claim 31, wherein the 3' exon region is derived from a natural 3' exon of a self-splicing intron, the 5' exon region is derived from a natural 5' exon of a self-splicing intron, and the 3' exon region and the 5' exon region can be recognized and / or spliced ​​by a self-splicing intron or a combination of a 3' self-splicing intron fragment and a 5' self-splicing intron fragment.

33. The circular RNA precursor of claim 32, wherein the 3' exon region is a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to a native 3' exon or a contiguous stretch of about 1 to about 50 nucleotides starting from the 5'-terminal nucleotide of a native 3' exon, The 5' exon region is a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with a native 5' exon or a continuous stretch of about 1 to about 50 nucleotides starting from the 3' terminal nucleotide of a native 5' exon.

34. The circular RNA precursor of any one of claims 1-33, wherein the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 13-55.

35. The circular RNA precursor of any one of claims 1-34, wherein the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 56-93.

36. The circular RNA precursor of any one of claims 1-35, wherein the first retention loop-forming element comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 13-55, and the second retention loop-forming element comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 56-93.

37. The circular RNA precursor of any one of claims 1 to 36, wherein 1) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and The second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 57; 2) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 58; 3) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 4) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60; 5) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 61; 6) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 62; 7) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 8) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 9) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 10) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 11) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 12) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67; 13) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 14) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 15) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 16) The first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:

63.

38. A circular RNA precursor comprising the following elements arranged in the following order from 5' to 3' direction: a) 3' self-splicing intron fragment; b) a first retention loop element; c) a nucleotide sequence of interest; d) a second retention loop-forming element; and e) 5' self-splicing intron fragment; wherein the circular RNA precursor is capable of generating a circular RNA comprising the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element by self-splicing thereof, wherein the total length of the first retention loop-forming element and the second retention loop-forming element is about 5 to about 100 nucleotides, wherein the self-splicing intron is selected from the class I intron of the Anabaena pre-tRNA-Leu gene, wherein the 3' self-splicing intron fragment comprises the nucleotide sequence of SEQ ID NO: 1, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 1, or consists thereof; and the 5' self-splicing intron fragment comprises the nucleotide sequence of SEQ ID NO: 2, or a nucleotide sequence that is at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to SEQ ID NO: 2, or consists thereof, wherein the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 13-55, and The second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 56-93.

39. The circular RNA precursor of claim 38, wherein the 3' self-splicing intron fragment comprises or consists of the nucleotide sequence of SEQ ID NO: 1, and the 5' self-splicing intron fragment comprises or consists of the nucleotide sequence of SEQ ID NO:

2.

40. The circular RNA precursor of claim 38 or 39, wherein 1) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and The second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 57; 2) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 58; 3) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 4) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60; 5) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 61; 6) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 62; 7) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 8) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 9) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 10) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 11) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 12) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67; 13) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 14) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 15) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 16) The first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:

63.

41. The circular RNA precursor of any one of claims 1-40, wherein the circular RNA precursor further comprises a 5' homology arm sequence and a 3' homology arm sequence that can complementarily pair to form a homology arm double-stranded region.

42. The circular RNA precursor of claim 41, wherein the 5' homology arm sequence is upstream of the 3' self-splicing intron fragment, and the 3' homology arm sequence is downstream of the 5' self-splicing intron fragment.

43. The circular RNA precursor of any one of claims 1-42, wherein the homology arms are about 5-50 nucleotides in length, preferably about 40 nucleotides in length.

44. The circular RNA precursor of any one of claims 41-43, wherein the two homology arm sequences can be polyA and polyT, respectively, or polyG and polyC, respectively.

45. The circular RNA precursor of any one of claims 41-44, wherein one of the homology arm sequences may have any of the nucleotide sequences in SEQ ID NOs: 151-162 or a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% sequence identity with any of SEQ ID NOs: 151-162, and the other homology arm sequence may have a corresponding complementary sequence.

46. ​​The circular RNA precursor of any one of claims 1-45, wherein the nucleotide sequence of interest comprises at least one protein coding sequence and a translation initiation element such as an internal ribosome entry site (IRES) operably linked thereto.

47. The circular RNA precursor of claim 46, wherein the translation initiation element, such as an IRES, is located upstream of the 5' end of at least one protein coding sequence.

48. The circular RNA precursor of claim 46, wherein the translation initiation element, such as an IRES, is located downstream of the 3' end of at least one protein coding sequence.

49. The circular RNA precursor of any one of claims 46-48, wherein the protein coding sequence encodes a protein of eukaryotic, prokaryotic or viral origin, e.g., any protein for therapeutic or diagnostic use.

50. The circular RNA precursor of any one of claims 46-49, wherein the translation initiation element is an internal ribosome entry site (IRES), and the IRES sequence can be selected from but is not limited to the following IRES sequences: Taura syndrome virus, blood-sucking assassin bug virus, Theilerian encephalomyelitis virus, simian virus 40, fire ant virus 1, aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immune Epidemiology: Epidemics defect virus type 1, lizard leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea geometrid-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FGF2, human SFTPA1, human AML l / RUNXl, Drosophila antennae, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, human UNR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip shrivelled disease virus, aptamer of eIF4G, Coxsackievirus B3 (CVB3) or Coxsackievirus A (CVA1 / 2), preferably, the IRES is CVB3, BRAV-1_L, PV1_L, CAV2_L, BRAV-1, PV1 or CAV2.

51. The circular RNA precursor of any one of claims 46-50, wherein the IRES comprises the nucleotide sequence shown in one of SEQ ID NOs: 105-135, or comprises a nucleotide sequence having at least 75%, e.g., at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to one of SEQ ID NOs: 105-135.

52. The circular RNA precursor of any one of claims 1-45, wherein the nucleotide sequence of interest is a non-protein coding sequence, for example, the non-protein coding sequence is selected from antisense RNA, aptamer, guide RNA, or a non-protein coding RNA naturally present in an organism.

53. The circular RNA precursor of any one of claims 1-52, wherein the nucleotide sequence of interest is about 10 to about 20,000 nucleotides in length.

54. The circular RNA precursor of any one of claims 1-53, wherein the circular RNA precursor does not comprise nucleotide chemical modifications.

55. A nucleic acid vector for producing a circular RNA molecule, the vector comprising a coding sequence for the circular RNA precursor of any one of claims 1-54.

56. The nucleic acid vector of claim 55, further comprising an RNA polymerase promoter sequence operably linked to the circular RNA precursor coding sequence.

57. The nucleic acid vector of claim 56, wherein the promoter is a T7 RNA polymerase promoter, a T6 viral RNA polymerase promoter, an SP6 viral RNA polymerase promoter, a T3 viral RNA polymerase promoter, or a T4 viral RNA polymerase promoter, preferably a T7 RNA polymerase promoter.

58. A circular RNA prepared from the circular RNA precursor of any one of claims 1 to 54 or prepared from the nucleic acid vector of any one of claims 55 to 57.

59. A circular RNA comprising a first retention loop-forming element, a nucleotide sequence of interest, and a second retention loop-forming element, wherein the first retention loop-forming element, the nucleotide sequence of interest, and the second retention loop-forming element are defined by any one of claims 1-54.

60. A circular RNA comprising a first retention loop-forming element, a nucleotide sequence of interest, and a second retention loop-forming element, The total length of the first retention loop-forming element and the second retention loop-forming element is about 5 to about 100 nucleotides.

61. The circular RNA of claim 60, wherein the first and second retention loop-forming elements participate in RNA circularization via a self-splicing intron, such as a class I intron, preferably a class I intron of an Anabaena pre-tRNA-Leu gene.

62. The circular RNA of claim 60 or 61, wherein the first retention loop-forming element and the second retention loop-forming element are covalently linked, for example, the 5' end of the first retention loop-forming element and the 3' end of the second retention loop-forming element are covalently linked.

63. The circular RNA of any one of claims 60-62, wherein the first and second retention loop-forming elements cause the circular RNA comprising them to have reduced immunogenicity relative to a control RNA, such as a control circular RNA comprising the retention loop-forming elements of SEQ ID NO: 29 and SEQ ID NO: 64, or a control linear RNA comprising the same nucleotide sequence of interest.

64. The circular RNA of any one of claims 60-63, wherein the first and second retention loop-forming elements cause the circular RNA comprising them to have comparable or increased looping efficiency relative to a control circular RNA, such as a control circular RNA comprising the retention loop-forming elements of SEQ ID NO: 29 and SEQ ID NO: 64 (Ana3.0).

65. The circular RNA of any one of claims 60-64, wherein the total length of the first retention loop-forming element and the second retention loop-forming element is about 20 to about 35 nucleotides.

66. The circular RNA of any one of claims 60-65, wherein the first retention loop-forming element and the second retention loop-forming element are configured to form a stem-loop structure.

67. The circular RNA of claim 66, wherein the loop of the stem-loop structure comprises a splice site between the first retention loop-forming element and the second retention loop-forming element.

68. The circular RNA of any one of claims 60-67, wherein the first retention loop-forming element comprises a sequence structure described in the following formula: 5'-first loop sequence-first paired sequence-first non-paired sequence-3'; and the second retention loop-forming element comprises a sequence structure described in the following formula: 5'-second non-paired sequence-second paired sequence-second loop sequence-3', wherein the first non-pairing sequence or the second non-pairing sequence may be present or absent independently, The first pairing sequence and the second pairing sequence can complementarily pair to form a stem of the stem-loop structure, wherein the first loop sequence and the second loop sequence can form a loop of the stem-loop structure.

69. The circular RNA of claim 68, wherein the first loop sequence comprises or consists of one or more nucleotides that can pair with the P1 region corresponding to the self-splicing intron during cyclization to form a P10 double-stranded region.

70. The circular RNA of claim 68 or 69, wherein the first loop sequence comprises or consists of a (N)n nucleotide sequence, wherein N represents any nucleotide (A, G, U or C) and n represents an integer between 1-20, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.

71. The circular RNA of any one of claims 68-70, wherein the first loop sequence comprises or consists of AAAA, AA, UUUU, CAAA or GAAA, preferably AAAA.

72. The circular RNA of any one of claims 68-71, wherein the second loop sequence comprises or consists of one or more nucleotides that can pair with an internal guide sequence (IGS) corresponding to a self-splicing intron to form a P1 double-stranded region during circularization.

73. The circular RNA of any one of claims 68-72, wherein the second loop sequence comprises CUU or CUC, preferably CUU.

74. The circular RNA of any one of claims 68-73, wherein the loop of the stem-loop structure has a CUUAAAA, CUUUUUU, CUUAA, CUUGAAA, CUUUAAA, CUUCAAA or CUCAAAA sequence, preferably CUUAAAA.

75. The circular RNA of any one of claims 68-74, wherein the stem portion in the stem-loop structure comprises 2-15 or more consecutive base pairs, preferably, the stem portion in the stem-loop structure comprises 5, 6 or 7 consecutive base pairs.

76. The circular RNA of any one of claims 68-75, wherein the stem portion in the stem-loop structure comprises at most 2 base mismatches, or the stem portion comprises only 1 base mismatch, preferably, the stem portion does not comprise a base mismatch.

77. The circular RNA of any one of claims 68-76, wherein the first pairing sequence comprises only Gs and the second pairing sequence comprises only Cs.

78. The circular RNA of any one of claims 68-76, wherein the first mate sequence comprises only C and the second mate sequence comprises only G.

79. The circular RNA of any one of claims 68-76, wherein the first pairing sequence comprises only A and the second pairing sequence comprises only U.

80. The circular RNA of any one of claims 68-76, wherein the first pairing sequence comprises or consists of any one of SEQ ID NOs: 42-55, and the second pairing sequence comprises or consists of any one of SEQ ID NOs: 78-93.

81. The circular RNA of any one of claims 67-80, wherein the predicted free energy of the stem-loop structure is less than about -1 kal / mol, less than about -2 kal / mol, less than about -3 kal / mol, less than about -4 kal / mol, less than about -5 kal / mol, less than about -6 kal / mol, less than about -7 kal / mol, less than about -8 kal / mol, less than about -9 kal / mol, less than about -10 kal / mol, or less.

82. The circular RNA of any one of claims 60-81, wherein the first retention loop-forming element comprises, or consists of, a 3' exon region from the 5' to 3' direction and an optional first spacer; and the second retention loop-forming element comprises, or consists of, a 5' exon region from the 3' to 5' direction and an optional second spacer.

83. The circular RNA of claim 82, wherein the 3' exon region is derived from a natural 3' exon of a self-splicing intron, the 5' exon region is derived from a natural 5' exon of a self-splicing intron, and the 3' exon region and the 5' exon region can be recognized and / or spliced ​​by a self-splicing intron or a combination of a 3' self-splicing intron fragment and a 5' self-splicing intron fragment.

84. The circular RNA of claim 83, wherein the 3' exon region is a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to a native 3' exon or a contiguous stretch of about 1 to about 50 nucleotides starting from the 5' terminal nucleotide of a native 3' exon, The 5' exon region is a sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with a native 5' exon or a continuous stretch of about 1 to about 50 nucleotides starting from the 3' terminal nucleotide of a native 5' exon.

85. The circular RNA of any one of claims 60-84, wherein the first retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 13-55.

86. The circular RNA of any one of claims 60-85, wherein the second retention loop-forming element comprises or consists of a nucleotide sequence having at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 56-93.

87. The circular RNA of any one of claims 60-86, wherein the first retention loop-forming element comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 13-55, and the second retention loop-forming element comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 56-93.

88. The circular RNA of any one of claims 60-87, wherein 1) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 15, and The second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 57; 2) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 14, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 58; 3) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 18, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 4) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 19, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 60; 5) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 20, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 61; 6) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 21, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 62; 7) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 23, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 8) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 24, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 9) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 26, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 10) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 27, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 11) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 28, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 12) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 67; 13) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 14) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 13, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 56; 15) the first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 17, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO: 59; 16) The first retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:22, and the second retention loop-forming element comprises or consists of the nucleotide sequence of SEQ ID NO:

63.

89. The circular RNA of any one of claims 60-88, wherein the nucleotide sequence of interest comprises at least one protein coding sequence and a translation initiation element such as an internal ribosome entry site (IRES) operably linked thereto.

90. The circular RNA of claim 89, wherein the translation initiation element, such as an IRES, is located upstream of the 5' end of at least one protein coding sequence.

91. The circular RNA of claim 89, wherein the translation initiation element, such as an IRES, is located downstream of the 3' end of at least one protein coding sequence.

92. The circular RNA of any one of claims 89-91, wherein the protein coding sequence encodes a protein of eukaryotic, prokaryotic or viral origin, e.g., a protein for therapeutic or diagnostic use.

93. The circular RNA of any one of claims 89-92, wherein the translation initiation element is an internal ribosome entry site (IRES), and the IRES sequence can be selected from, but is not limited to, the following IRES sequences: Taura syndrome virus, blood-sucking assassin bug virus, Theilerian encephalomyelitis virus, simian virus 40, fire ant virus 1, aphid virus, reticuloendotheliosis virus, Forman polio virus 1, soybean looper virus, Kashmir bee virus, human rhinovirus 2, glass leafhopper virus-1, human immunodeficiency virus 2, Trapped virus type 1, glass leafhopper virus-1, lice P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea geometrid-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus, acute bee paralysis virus, hibiscus yellow ringspot virus, swine fever virus, human FGF2, human SFTPA1, human AML1 / RUNXl, Drosophila antennae, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, human U NR, mouse UtrA, human VEGF-A, human XIAP, Drosophila hairless, Saccharomyces cerevisiae TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, turnip shrivell disease virus, aptamer of eIF4G, Coxsackievirus B3 (CVB3) or Coxsackievirus A (CVA1 / 2), preferably, the IRES is CVB3, BRAV-1_L, PV1_L, CAV2_L, BRAV-1, PV1 or CAV2.

94. The circular RNA of any one of claims 89-93, wherein the IRES comprises the nucleotide sequence shown in one of SEQ ID NOs: 105-135, or comprises a nucleotide sequence having at least 75%, e.g., at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% sequence identity to one of SEQ ID NOs: 105-135.

95. The circular RNA of any one of claims 60-88, wherein the nucleotide sequence of interest is a non-protein coding sequence, for example, the non-protein coding sequence is selected from antisense RNA, aptamer, guide RNA, or a non-protein coding RNA naturally present in an organism.

96. The circular RNA of any one of claims 60-95, wherein the nucleotide sequence of interest is about 10 to about 20,000 nucleotides in length.

97. The circular RNA of any one of claims 60-96, wherein the circular RNA does not comprise nucleotide chemical modifications.

98. Use of the circular RNA precursor of any one of claims 1 to 54 and / or the circular RNA of any one of claims 58 to 97 as an expression vector.

99. A pharmaceutical composition comprising the circular RNA precursor of any one of claims 1 to 54 and / or the nucleic acid vector of any one of claims 55 to 57 and / or the circular RNA of any one of claims 58 to 97, and a pharmaceutically acceptable carrier.

100. The pharmaceutical composition of claim 99, for use in treating a disease in an individual.

101. A method for preparing circular RNA, the method comprising: 1) Providing a circular RNA precursor according to any one of claims 1 to 54 or obtaining a circular RNA precursor by transcribing from a nucleic acid vector according to any one of claims 55 to 57; 2) incubating the circular RNA precursor in the presence of a divalent metal cation at a temperature at which RNA circularization occurs; and 3) Harvesting the circular RNA obtained in step 2).

102. The method of claim 101, wherein the divalent metal cation is Mg 2+ and / or Mn 2+ .

103. The method of claim 101 or 102, wherein the concentration of the divalent metal cation is about 5 mM to about 550 mM.

104. A method for preparing circular RNA, the method comprising a) providing a nucleic acid vector comprising a self-splicing intron-based RNA circularization element as a transcription template; and b) incubating the nucleic acid vector in an in vitro transcription system comprising a divalent metal cation and an RNA polymerase for a first period of time, during which the linear RNA produced by in vitro transcription self-circularizes under the action of the RNA cyclization element to produce a circular RNA.

105. The method of claim 104, wherein the nucleic acid vector is the nucleic acid vector of any one of claims 55-57.

106. The method of claim 104 or 105, wherein the divalent metal cation in the in vitro transcription system is Mg2 + .

107. The method of any one of claims 104-106, wherein the in vitro transcription system further comprises a monovalent metal cation and / or a monovalent anion.

108. The method of claim 107, wherein the monovalent metal cation is Na + or K + .

109. The method of claim 107, wherein the monovalent metal anion is Cl - or CH3COO - (OAc).

110. The method of any one of claims 104-109, wherein the concentration of the divalent metal cation in the system during the first period of time is about 5 mM to about 50 mM.

111. The method of any one of claims 107-110, wherein the concentration of the monovalent metal cation in the system during the first time period is about 5 mM to about 100 mM.

112. The method of any one of claims 107-111, wherein the concentration of the monovalent anion in the system during the first period of time is about 5 mM to about 150 mM.

113. The method of any one of claims 107-112, wherein the method does not include a step of isolating and / or purifying linear RNA produced by in vitro transcription.

114. The method according to any one of claims 107-113, wherein the buffer of the in vitro transcription system is selected from Tris hydrochloric acid buffer, or HEPES buffer, or MES buffer, or citric acid buffer, or phosphate buffer, preferably, the buffer of the in vitro transcription system is HEPES buffer.

115. The method of any one of claims 107-114, wherein the pH range of the in vitro transcription system is about 5 to about 8, preferably, the pH of the in vitro transcription system is about 7.

5.

116. The method of any one of claims 107-115, wherein the RNA polymerase is selected from T7 RNA polymerase, T6 viral RNA polymerase, SP6 viral RNA polymerase, T3 viral RNA polymerase or T4 viral RNA polymerase, preferably, the RNA polymerase is T7 RNA polymerase.

117. The method of any one of claims 107-116, wherein the first period of time is about 0.5 hours to about 24 hours, preferably, the first period of time is 3 hours.

118. The method of any one of claims 107-117, wherein the first period of reaction is carried out at about 16°C to about 60°C, preferably, the first period of reaction is carried out at about 37°C.

119. The method of any one of claims 107-118, wherein after the first period of reaction in step b), the method further comprises step c): adding an additional amount of metal cations to the in vitro transcription system and reacting for a second period of time; or The system's buffer is changed, metal cations are added and reacted for a second period of time.

120. The method of claim 119, wherein the metal cation added for the second time period reaction is a divalent metal cation, such as Mg 2+ or Mn 2+ .

121. The method of claim 119 or 120, wherein during the second period of time, the metal cation is added to a final concentration of about 5 mM to about 550 mM.

122. The method of claim 119 or 121, wherein during the second time period, the buffer of the system is changed to Tris hydrochloric acid buffer, or HEPES buffer, or MES buffer, or citric acid buffer, or phosphate buffer.

123. The method of claim 119 or 122, wherein the pH range of the reaction system during the second time period is 5-8.

124. The method of claim 119 or 123, wherein the second period of time is from about 5 minutes to about 2 hours.

125. The method of claim 119 or 124, wherein the second period of reacting is conducted at about 25°C to about 75°C.

126. The method of claim 104 or 125, wherein the method further comprises a step of recovering or purifying the produced circular RNA.

127. A method for purifying circular RNA, the method comprising: a) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a circular RNA-specific probe under conditions that allow the circular RNA-specific probe to specifically bind to the circular RNA and form a complex; b) separating the complex from one or more components in the mixture that are not bound to the circular RNA-specific probe; and c) releasing the circular RNA from the complex.

128. The method of claim 127, wherein the circular RNA is prepared by circularizing a linear circular RNA precursor.

129. The method of claim 127 or 128, wherein the circular RNA is prepared by ligating both ends of a linear circular RNA precursor using an RNA ligase, or by the self-splicing ribozyme activity of a self-splicing intron-based circularization element contained in the linear circular RNA precursor.

130. The method of any one of claims 127-129, wherein the circular RNA-specific probe is a single-stranded DNA or RNA probe.

131. The method of any one of claims 127-130, wherein the circular RNA-specific probe specifically hybridizes to regions on both sides of the circularization junction of the circular RNA.

132. The method of any one of claims 127-131, wherein the circular RNA-specific probe is about 10 nucleotides to about 35 nucleotides in length or longer.

133. The method of any one of claims 127-132, wherein the circular RNA-specific probe is immobilized on a support, such as a solid support, for example, the circular RNA-specific probe is immobilized on a support after binding to the circular RNA, or the circular RNA-specific probe is pre-immobilized on a support.

134. The method of any one of claims 127-133, wherein the conditions in step a) comprise denaturing the RNA at about 60°C to about 95°C for about 2 minutes to about 10 minutes, and then gradually reducing the temperature to below about 40°C to anneal the circular RNA to the circular RNA-specific probe.

135. The method of claim 134, wherein step c) releases the circular RNA by increasing the temperature to about 60°C to about 95°C (e.g., about 60°C, about 62°C, about 64°C, about 66°C, about 68°C, about 70°C, about 75°C, about 80°C, about 85°C, about 90°C, about 95°C).

136. The method of any one of claims 127-133, wherein the conditions in step a) comprise high salt at a concentration ranging from 0.25M to 2M.

137. The method of claim 136, wherein the salt is NaCl or a guanidine salt.

138. The method of claim 136 or 137, wherein step c) releases the circular RNA by eluting with an elution buffer, such as a low salt buffer.

139. The method of claim 138, wherein the elution buffer is Tris-EDTA buffer (TE buffer) or water.

140. The method of any one of claims 127-139, wherein step b) removes the one or more components by washing the complex with a wash buffer.

141. The method of any one of claims 127-140, wherein the method further comprises the steps of: i) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a linear circular RNA precursor-specific probe under conditions that allow the linear circular RNA precursor-specific probe to specifically bind to the linear circular RNA precursor and form a complex; ii) removing the complex formed by the linear circular RNA precursor-specific probe and the linear circular RNA precursor from the mixture, and iii) collecting the mixture containing circular RNA obtained in step ii).

142. The method of claim 141, wherein steps i)-iii) are performed before step a), for example, steps i)-iii) are performed multiple times before step a), for example, 2 times, 3 times, 4 times or more.

143. The method of claim 141, wherein steps i)-iii) are performed simultaneously with steps a)-c).

144. A method for purifying circular RNA, the method comprising: i) contacting a mixture comprising circular RNA and uncircularized linear circular RNA precursor with a linear circular RNA precursor-specific probe under conditions that allow the linear circular RNA precursor-specific probe to specifically bind to the linear circular RNA precursor and form a complex; and ii) removing the complex formed by the linear circular RNA precursor-specific probe and the linear circular RNA precursor from the mixture, iii) collecting the mixture containing circular RNA obtained in step ii), and Optionally, steps i)-iii) are performed multiple times, such as 2 times, 3 times, 4 times or more.

145. The method of claim 144, wherein the linear circular RNA precursor-specific probe specifically binds to the linear circular RNA precursor and does not substantially bind to the circular RNA.

146. The method of claim 144 or 145, wherein the linear circular RNA precursor-specific probe is immobilized on a support, such as a solid support, for example, the linear circular RNA precursor-specific probe is immobilized on the support after binding to the linear circular RNA precursor, or the linear circular RNA precursor-specific probe is pre-immobilized on the support.

147. The method of any one of claims 127-146, wherein the linear circular RNA precursor comprises the following elements arranged in the following order from 5' to 3' direction: a) 3' self-splicing intron fragment; b) a first retention loop element; c) a nucleotide sequence of interest; d) a second retention loop-forming element; and e) 5' self-splicing intron fragment; The linear circular RNA precursor is capable of removing the 3' self-splicing intron fragment and the 5' self-splicing intron fragment by self-splicing to generate a circular RNA comprising the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element.

148. The method of claim 147, wherein the circular RNA-specific probe specifically hybridizes to at least a portion of the first retention loop-forming element and a portion of the second retention loop-forming element.

149. The method of claim 147 or 148, wherein the linear precursor RNA-specific probe hybridizes to a portion of the linear circular RNA precursor excluding the first retention loop-forming element, the nucleotide sequence of interest, and the second retention loop-forming element.

150. The method of any one of claims 147-149, wherein the linear precursor RNA-specific probe hybridizes to the 3' self-splicing intron fragment or a portion thereof or its 5' flanking sequence, or the 5' self-splicing intron fragment or a portion thereof or its 3' flanking sequence.

151. The method of any one of claims 147-150, wherein the linear circular RNA precursor comprises a sequence selected from SEQ ID NOs: 96-101 or a complementary sequence thereof, preferably SEQ ID NO: 100 or a complementary sequence thereof, which is outside the first retention loop-forming element, the nucleotide sequence of interest and the second retention loop-forming element, and the linear precursor RNA-specific probe specifically hybridizes to it.

152. The method of any one of claims 147-151, wherein the molar ratio of the probe to the RNA molecules in the mixture is about 1:1 to about 100,000:

1.

153. A method for purifying circular RNA, the method comprising: i) adding a linear RNA-specific tag to the linear RNA in a mixture comprising circular RNA and linear RNA; ii) contacting the mixture comprising circular RNA and linear RNA with a linear RNA probe that specifically binds to the tag under conditions that allow the probe to specifically bind to the linear RNA and form a complex; and iii) removing the complex formed by the linear RNA probe and the linear RNA from the mixture, iv) collecting the mixture containing circular RNA obtained in step ii), Optionally, steps ii)-iv) are performed multiple times, such as 2 times, 3 times, 4 times or more.

154. The method of claim 153, wherein the tag comprises a polyA, polyG, polyU, or polyC sequence.

155. The method of claim 153 or 154, wherein the tag is about 10-200 nt in length or the probe is about 10-200 nt in length.

156. The method of any one of claims 153-155, wherein the tag is added to the linear RNA by adding PolyA / T / C / G polymerase or ligase to the mixture.

157. The method of any one of claims 153-156, wherein the linear RNA probe specifically binds to the added tag and does not substantially bind to the circular RNA.

158. The method of any one of claims 153-157, wherein the linear RNA probe is a single-stranded DNA probe, or a single-stranded RNA probe.

159. The method of any one of claims 153-158, wherein the linear RNA probe is immobilized on a support, such as a solid support, for example, the linear RNA probe is immobilized on a support after binding to the linear RNA, or the linear RNA probe is pre-immobilized on a support.

Citation Information

Patent Citations

  • Circular RNA compositions and methods

    WO2021236855A1